The effects of vitamin D3 (1α,25-dihydroxyvitamin D3) on the haematopoietic differentiation of stem cells in murine in vitro studies and human in vivo studies by Al Qaisi, Mayada
  
 
The Effects of Vitamin D3 (1α,25-Dihydroxyvitamin D3) 
on the Haematopoietic Differentiation of Stem Cells 
in Murine in vitro Studies and Human in vivo Studies 
 
 
Mayada Al Qaisi 
 
 
A thesis submitted in partial fulfilment of the requirements 
of the Manchester Metropolitan University for the degree 
of Doctor of Philosophy 
 
 
Director of Study 
Prof. Bill Gilmore 
 
 
Healthcare Science Research Institute 
The Manchester Metropolitan University 
 
 
2015 
 2 
Abstract … 
Previous research using cancer cells has demonstrated that 1α,25-dihydroxyvitamin D3 
(VD3) can suppress cell proliferation and promote cell differentiation. The research 
reported in this research ascertains that VD3 plays a similar role in haematopoiesis. This 
was investigated using the E14/ OP9 co-culture as it has previously been shown to be a 
good setting for studying haematopiesis. The effects of VD3 on E14 and OP9 were tested 
separately with different VD3 levels to demonstrate that sufficient levels of VD3 were 
crucial in promoting differentiation and suppressing proliferation of both cell lines. The 
effective dosage of VD3 was 100 nmol/L. This dosage was then used to test the effect of 
VD3 on cell proliferation and differentiation in haematopoiesis in the E14 / OP9 co-
culture system through analyses of growth factors, cluster of differentiation (CD) 
markers, colony-forming cell (CFC) counts, haematopoiesis-specific genes and cytokine 
expression. VD3 was shown to promote differentiation thereby accelerating the early 
appearance of differentiated cells in the co-culture system. The in vitro study was 
followed by an in vivo pilot study, in which blood samples were taken monthly from a 
group of adult volunteers over a three-month period for analysis of VD levels, CD34 
expression and blood cell counts. In the in vivo pilot study, it was found that there were 
significant non-random temporal variations in the measurements and there were 
statistically significant positive correlations between each of 25-hydroxyvitamin D 
(25(OH)D) level, white blood cell count, platelet count, CD34+ progenitor cell count and 
VD3 level. Overall, the research reported in this thesis demonstrated for the first time an 
anabolic effect of VD3 in haematopoiesis on murine E14 and OP9 cells in vitro. In 
addition, the pilot study on human volunteers demonstrated that a comparable effect takes 
place on human cells in vivo and these results could be used to inform future studies.  
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Some of the contributions of this thesis have been published in one journal paper1 and 
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Chapter 1 Introduction 
 
1.1 Literature Review 
1.1.1 Embryonic stem cells 
Embryonic stem cells (ESCs), derived from the inner cell mass of the blastocyst-stage of 
early mammalian embryos, have the potential to undergo unlimited self-renewal by 
placing them in specific culture conditions, either in vitro or in vivo (Evans and Kaufman 
1981), as shown in Figure 1. Once the cells are released from these conditions and placed 
into a differentiation-promoting environment (in vitro or in vivo), the cells differentiate 
into derivatives of all three primary germs: ectoderm, mesoderm, endoderm and then into 
many different cell types in the body (Nishikawa et al., 2007). Thus, ESCs have unveiled 
widespread application potentials in the fields of biomedical research and regenerative 
medicine (Yu et al., 2007; Keller, 2005). 
 
Figure 1. Embryonic stem cells (ESCs) derived from the inner cell mass of the blastocyst-
stage of embryo 
(Source: personal communitation) 
The majority of recent studies into embryonic stem cells suggest that ESCs could be used 
to cure many cellular deficiency diseases, such as heart failure, stroke, and haematological 
disorders resulting from the absence of one or more critical populations of cells, and so if 
cell populations could be regenerated, tissue repair could be realised (Murry and Keller, 
2008). 
Embryonic stem cells
Inner cell mass
Derived from the inner cell 
mass of pre-implantation 
blastocysts
Undifferentiated 
embryonic stem 
cells in culture
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Patient-specific ESC equivalents (Park et al., 2008; Takahashi et al., 2007; Yu et al., 
2007) would provide new tools to evade the immune system, thus giving insight into 
fundamental disease mechanisms and providing drug-discovery screens. The most 
important potential application of ESCs is the generation of cells that could be used for 
cell-based therapies, such as transplanting haematopoietic stem cells (HSCs) in leukaemia 
treatment (Brustle et al., 1999; Tian, et al., 2008), which entails the use of high-quality 
sources of tissue-matched bone marrow, mobilised peripheral blood or umbilical cord 
blood. Appropriate bone marrow is often in short supply, whilst cord blood, though 
bankable, contains fewer HSCs, which makes it less suitable for adult transplantation. 
Directed differentiation of ESCs towards HSCs offers a potentially attractive alternative 
to these conventional sources (Ledran et al., 2008). 
The pluripotency of ESCs makes them difficult to control, but to enable differentiation of 
ESCs, three methods have been employed: (1) forming three-dimensional aggregates, 
known as embryoid bodies (EBs); (2) making ESC cultures as monolayers on 
extracellular matrix proteins; (3) directly placing ESC cultures on supportive stromal 
layers, so that differentiation could take place in contact with these cells (Keller 2005; 
Nishikawa et al., 2007). These will be described in more details in Section 1.1.5 with 
Figure 6.  
Although it is not clear which method is the most efficient one, each method promotes 
ESCs to differentiate into many different cell types in culture. In early studies, remarkable 
differentiation has been found using foetal calf serum (FCS) in the protocol, but these 
protocols were difficult to repeat because of the poorly defined mixture of factors in 
serum and the variability between different serum lots, and most were not well optimised 
for any particular lineage. Studies were successful using serum-free medium with specific 
inducers for differentiation (Kubo et al., 2004; Ng et al., 2005; Yasunaga et al., 2005) 
and for reporter ESCs to observe and have access to early differentiation stages (Fehling 
et al., 2003; Gadue et al., 2006; Ng et al., 2005; Tada et al., 2005). These techniques have 
aided understanding of ESC differentiation through developmental biology by 
recognising the main phenomena in ESC cultures that facilitate early lineage commitment 
in the embryo, enabling efficient and reproducible generation in highly differentiated cell 
populations. The cellular mechanism and target cell affected by microenvironments in 
augmenting haematopoietic specification from pluripotent embryonic stem cells (ESCs) 
has yet to be evaluated (Junfeng et al., 2008). This study goes on to focus on the 
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development and differentiation of haematopoietic lineages, as access to such cell 
population may provide new therapies for some of the world’s most devastating diseases. 
This is particularly important for the study of human development because the availability 
and accessibility of normal cells from human embryos is limited. 
1.1.2 Embryogenesis in mice 
In embryogenesis, gastrulation is the formation of three primary layers: ectoderm, 
mesoderm and endoderm, as shown in Figure 2. Gastrulation in the mouse begins with 
the appearance in the epiblast region of the primitive streak (PS), which will go on to 
form the posterior part of the embryo (Tam and Behringer, 1997). Gastrulation involves 
uncommitted epiblast cells from the PS becoming either mesoderm or endoderm. 
 
Figure 2. Embryonic stem cells differentiate into derivatives of all three primary germs – 
ectoderm, mesoderm, endoderm – during the process of gastrulation 
(Source: personal communication) 
Gene expression and developmental potential have been found to vary according to the 
regions (posterior, mid, and anterior) of the PS. Different genes have been expressed: 
Brachyury (T) (Kispert and Hermann, 1994) and Mixl1 (Hart et al., 2002; Ng et al., 2005) 
are expressed throughout the PS; Foxea2 and Goosecoid are typically in the anterior part 
(Kinder et al., 2001; Seilies et al., 2006); HoxB1 , Evx1 are in the posterior part and early 
sequential expression of mouse Hox genes is essential for their later function (Forlani et 
al., 2003). 
Specification of mesoderm and endoderm subpopulations is not random in time and 
space. The first mobilised epiblast cells cross the posterior PS, forming the extra-
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embryonic mesoderm, which in turn specialises to form different tissue cells such as 
haematopoietic and endothelial cells of the yolk sac (Kinder, 1999). With further 
gastrulation, cells moving through the anterior of the PS give rise to different types of 
mesoderm, such as cardiac mesoderm, as well as paraxial and axial mesoderm at a later 
stage. Definitive endoderm comes from epiblast cells that have crossed the anterior part 
of the PS, whilst epiblast cells that do not enter the PS form the ectoderm (Keller 2008; 
Tam et al., 1997). 
Specific lineages seem to be induced by spatial and temporal factors during gastrulation 
in and around the PS. The transforming growth factor-beta (TGFß) family are essential 
for PS formation and germ layer induction.  This includes the bone morphogenic protein 
(BMP4) family (Hogan, 1996), the nodal growth differentiation factor (Nodal) (Shier, 
2003) family and the wingless-type mouse mammary tumour virus (MMTV) integration 
site (Wnt) family (Yamaguchi, 2001). Gadue et al. (2005) confirmed that TGF-βs, BMP4, 
Wnt, Nodal and fibroblast growth factor (Fgf) pathways are essential for the 
differentiation of ESCs in culture. These genes are required for gastrulation and germ 
layer induction in the embryo. A combination of different levels of expression of agonists 
of the pathways and of regionalised expression of inhibitors leads to the formation of 
signalling domains, which regulate germ layer induction and specification (Gadue et al., 
2005). Thus, germ layer development is a dynamic process that is controlled partially by 
coordinated activation and regional inhibition of the Wnt, Nodal and BMP-signalling 
pathways. 
1.1.3 Translating embryology to ESCs 
Some properties of ESC cultures, through the manipulation of BMP, Wnt and Nodal 
pathways (which are involved in the systematisation of germ layer development in vitro), 
have been studied in the immediate vicinity of the PS. It has been proved that Brachyury 
is found to control the construction of the PS region and the onset of mesoderm population 
(Lerchner et al., 2000; Murry 2008). In the absence of serum in the culture of ESCs, 
BMP4 was found to induce the forming of a Brachyury-positive population and 
subsequently the development of foetal liver kinase 1 (FLK1)-expressing (FLK1+) 
mesoderm (Ng et al., 2005; Nostro et al., 2008). Hence, BMP4 is crucial for the formation 
of FLK1+ mesodermal cells (Sarah et al., 2001). Disruption of the basic stem cell 
leukaemia (SCL) gene expression causes a block early in the hematopoietic program, 
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leading to defects in all hematopoietic lineages. SCL expression is induced by BMP4, and 
a dominant negative BMP4 receptor inhibits SCL expression in the central region of the 
embryo (Paul et al., 1998).These findings agree with previous work demonstrating that 
BMP4 is needed for the generation of FLK1+ and SCL+ cells mesoderm (Park et al., 2004; 
Vidricaire et al., 1994).  
Furthermore, it was found that the activin and Wnt pathways are required for the 
formation of cells expressing Brachyury and mesoderm development. Blocking Wnt 
signalling at an early phase of differentiation in serum-stimulated cultures stopped the 
establishment of cells expressing Brachyury and mesoderm expansion, indicating that this 
pathway is required for the generation of the PS (Naito et al., 2006; Ueno et al., 2007). 
Conversely, adding Wnt to serum-containing cultures at the onset of differentiation 
accelerates the formation of PS population and enhances mesoderm development.  
It was also found that the activation of the Nodal pathway by the addition of Activin A 
(activin) could induce a PS population and subsequent mesoderm formation (Vidricaire 
et al., 1994; Kubo et al., 2004). It has also been demonstrated that haematopoiesis from 
the mesoderm occurs via BMP4-mediated signals and that expansion and/or 
differentiation of such progenitors is achieved by the interplay of the TGFβ1 family and 
the Activin A signalling (Park et al., 2004). From these investigations, a partial 
understanding of signalling pathways in early ESC differentiation can be derived. 
The regulation of ESC differentiation is through direct and indirect effects, and the 
differentiation pathway is intricate. Gadue et al. (2006) designed a reporter mouse-ESC 
cell line to model PS establishment in vitro. It contained the green fluorescent protein 
(GFP) cDNA targeted PS gene Brachyury (T) and CD4 cDNA targeted anterior PS gene 
Foxa2. The GFP was only activated or reported when cells were undifferentiated and 
were turned off once they differentiated. Thus, the investigation revealed that Wnt and 
Nodal signalling are simultaneously required for the development of the GFP-T+CD4-
Foxa2+ PS cell population. However, Wnt and activin/Nodal individually showed distinct 
inducing properties. It was also found that BMP4 signalling was not required for PS 
generation (Nostro et al., 2008), but BMP4 alone does promote the development of the 
PS and the mesoderm (Ng et al., 2005; Park et al., 2004), an indirect effect mediated by 
the induction of Wnt and Nodal, as shown in Figure 3 below. Thus, BMP4, Wnt and 
activin/Nodal signalling pathways that regulate the PS development and the onset of 
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mesoderm in the early embryo have also been found to be required in vitro. These are 
summarised in Figure 3 below.  
 
Figure 3. ESC differentiation pathways, showing the roles of BMP4, Wnt and activin 
(Source: www.sciencedirect.com/science/article) 
 
1.1.4 Cytokines and growth factors  
Cytokines and growth factors are cell signalling proteins and glycoproteins, each of 
which has a matching cell-surface receptor that transmits the signal through subsequent 
intracellular signalling cascades to alter a function or to cause a response from the 
cell. Almost all cytokines are pleiotropic, and many cytokines often have overlapping 
activities so that a single cell can respond to several cytokines in the same manner. In 
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addition, it is quite often to have a cellular function that is encouraged by a collection of 
cytokines and growth factors. The same cytokine can play different roles with different 
types of cells, partly because there are different receptors for the same cytokine for 
different functions.  
 
Figure 4. Deviation of haematopoietic cells showing sites of activity of CSFs and ILs 
(Rodak, Fritsma and Doig, 2008) 
Many cytokines have been shown to be important to hematopoietic development, such as 
erythropoietin (Epo) (Iscove and Sieber, 1975), granulocyte colony-stimulating factor (G-
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CSF) (Nicola et al., 1983), macrophage-CSF (M-CSF or CSF-1) (Stanley and Heard, 
1977), granulocyte / macrophage-CSF (GM-CSF) (Metcalf et al., 1980), interleukin 1 
(IL-1) (Mochizuki et al., 1987), IL-3 (Iscove and Roitsch, 1985), IL-4 (Paul and Ohara, 
1987), and IL-6 (Wong et al., 1988). Some of these factors are lineage specific, such as 
Epo and CSF-1, whilst others act on multiple lineages, such as IL-3 and GM-CSF. Steel 
factor (SLF) (Anderson et al., 1990; Zsebo et al., 1990) and its receptor, c-kit (Chabot 
et al., 1988; Geissler et al., 1988), are critical to hematopoietic, germ cell, and melanocyte 
development. However, their precise functions during development are not clear (Russell, 
1979; Silvers, 1979). 
1.1.5 Differentiation of ESCs in culture 
Given suitable conditions and free of the factors keeping them as stem cell, ESCs will 
undergo differentiation, yielding progeny made up of the derivatives of the three 
embryonic germ layers, namely mesoderm, endoderm and ectoderm (Keller, 1995; Smith, 
2001). However, there is no differentiation in culture of wild-type ESCs into 
trophectoderm. Instead, the ESCs form the inner cell mass, which is the foundation of the 
embryonic population. This is represented in Figure 5 below.  
 
Figure 5. Scheme of early cell populations in relation to primary germ layers in early mouse 
development  
(Source: http://genesdev.cshlp.org/content/19/10/1129.full) 
 
ESC differentiation may be initiated through three general approaches, as shown in Figure 
6 below. The first method allows the aggregation of ESCs to form three-dimensional 
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colonies called embryoid bodies (EBs) (Doetschman et al., 1985; Keller 1995). With the 
second method, there is direct culturing of ESCs on stromal cells, where differentiation 
of the former occurs in contact with the latter (Nakano et al., 1994). The most frequently 
used stromal cell line in this second method is OP9, isolated originally from CSF-1-
deficient op/op mice cells (Yoshida et al., 1990). In the third method, extracellular matrix 
proteins are used, on which an ESC monolayer differentiates (Nishikawa et al., 1998). 
 
Figure 6. Three different methods for ESC differentiation.  
(Source: http://genesdev.cshlp.org/content/19/10/1129.full) 
ESCs of a wide variety of cell types have been generated from the three aforementioned 
differentiation methods (Keller, 1995; Smith, 2001). Detailed study of lineages have 
shown that these methods have proved to be efficient for differentiation to occur, whereby 
the events sequence in culture was shown to be a faithful recapitulation of what happens 
in the early stages of an embryo.   
There are particular advantages and limitations to each of the three approaches to ESC 
differentiation. The three-dimensional structure of EBs is advantageous in that it is 
favourable to cell-cell interactions that may be significant for some programs of 
development (Keller, 1995). EBs are complex because of the generation of cytokines and 
the inducing factors in the structures themselves. These complexities can make it difficult 
to interpret the results of experiments aiming to gain understanding of the signalling 
pathways of lineage commitment.  
The growth of a particular cell line is promoted in co-culture with stromal cells. The 
drawback is that stromal cells may produce certain factors whose effects are to influence 
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the differentiation of ESCs to unwanted cell types. Another disadvantage of this method 
is that it may be difficult to separate the ESC-derived cells from the stromal cells (Gadue 
et al., 2005). 
Differentiation in monolayers is a simple method, in which the aforementioned complex 
effects of neighbouring cells and supporting stromal cells can be minimised. However, 
this method is dependent on the matrix proteins used, as particular proteins may be critical 
in whether the developing cell types are generated and survive.    
There are three criteria to consider in choosing the appropriate ESC model for lineage-
specific differentiation (Smith, 2001). First, it is necessary to set up protocols in which 
the particular cell type may be developed efficiently and reproducibly. It is desirable to 
combine selection strategies with schemes of optimal differentiation in order that highly 
enriched cell populations can be isolated. Secondly, the program of development that sets 
up the lineage of the early embryo should be recapitulated in lineage from ESCs. Thirdly, 
whether in culture or subsequently transplanted to an animal model, the mature cell 
populations that have developed in these cultures must exhibit appropriate functional 
properties. However, the third criterion remains unfulfilled (Keller, 2005). 
1.1.6 Mesoderm induction 
The surface glycophosphoprotein CD34 is expressed on committed and primitive 
haematopoietic stem cells (Krause et al., 1996).  About 1 to 5% of bone marrow cells and 
0.1% of peripheral blood cells express CD34+ in normal individuals (Krause et al., 1996). 
Therefore, the detection of changes in haematopoietic stem cells can be done by analysing 
CD34+ cells. Physiological levels of vitamin D were found to promote differentiation of 
CD34+ hematopoietic progenitors, indicated by all the monomacrophagic imuno-
phenotypic and morphological markers in a liquid culture model being induced (Grande 
et al., 2002).   
The development of haematopoiesis is from subpopulations of mesoderm induced 
temporally in a defined pattern. The FLK1 and platelet-derived growth factor (PDGFR) 
receptors are largely expressed on subpopulations of this lineage, whereby the early stages 
of mesoderm induction from the PS can be monitored by the up-regulation of these 
receptors. Thus, FLK1 and PDGFR expression marks progenitors with broad mesodermal 
potential (Ema et al., 2006). The ESC-derived CD34+ cells are highly enriched in cells 
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expressing haematopoiesis associated genes FLK1, GATA1, GATA2, and SCL/TAL1 
(Maxim et al., 2005).  
GATA-binding factor 1 (GATA1) and GATA-binding factor 2 (GATA2) belong to the 
GATA transcription factor family that binds to a DNA region with GATA sequence, and 
are involved in cell growth and cancer (Ko and Engel, 1993). GATA1 is essential for 
erythroid and megakaryocytic development and is expressed at high levels in erythroid 
cells, mast cells, and megakaryocytes. It regulates the switch of foetal haemoglobin to 
adult haemoglobin (Ohneda and Yamamoto, 2003). GATA2 is expressed in 
hematopoietic progenitors, including early erythroid cells, mast cells, and 
megakaryocytes, as well as in non-haematopoietic ESCs (Dorfman et al., 1992; Ohneda 
and Yamamoto, 2003). 
Although most studies have not distinguished PS formation from mesoderm induction, 
several have provided insights into the signalling pathways that regulate this step. It is 
known that the BMP signalling is necessary to induce FLK1+ haematopoietic mesoderm 
from Brachyury-expressing populations, which indicates that this pathway is at the level 
of mesoderm induction (Park et al., 2004). This finding is in agreement with other studies 
demonstrating that ventral mesoderm can be generated by treating ESCs with a 
combination of cytokines and bone morphogenetic protein 4 (BMP4) during the 
development of embryoid bodies (EB) (Chadwick et al., 2003). 
It was found that haematopoietic mesoderm generation from a Brachyury-GPF tagged PS 
population depends on a combination of Wnt, activin/Nodal, and BMP signalling, and 
that the up-regulation of FLK1 correlates with mesoderm fate (Hidaka et al., 1999; Nostro 
et al., 2008). These findings confirm previous studies demonstrating clearly that FLK1 
gene is essential for early stages of haematopoietic development (Maxim et al., 2005).  
With these findings, it is established that subpopulations of mesoderm can be generated 
in mouse ESC cultures with various concentrations of BMP4, or a combination of BMP4 
and activin, and with manipulation of different signalling pathways at relevant 
developmental stages (Era et al., 2007). 
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1.1.7 ESCs and haematopoietic lineages 
Haematopoiesis has been extensively studied, since many of the first ESC studies 
concentrated on blood cell development (Keller, 2005; Olsen et al., 2006). The aim of 
such investigations has often been that of inducing the formation of transplantable HSCs 
from ESCs. The relationship of various cells related to haematopoiesis is depicted in 
Figure 7. 
 
Figure 7. Haematopoiesis maturation and differentiation chart 
(Source: http://www.dentalarticles.com/images/hematopoiesis.png) 
Although it is comparatively easy to generate blood cell lineages from ESCs, the 
development of HSCs from genetically unmodified ESCs is another matter, possibly due 
to the complexity of embryonic haematopoietic development, which occurs at different 
times and at different embryonic sites. 
In the early mouse embryo, haematopoiesis commences independently at two different 
sites, namely the yolk sac and the para-aortic splanchnopleura (P-Sp). The P-Sp is an 
intra-embryonic region in the caudal part of the embryo where aorta, gonads and 
mesonephros are subsequently developed (AGM) (Cumano and Godin, 2007).  
The yolk sac and the P-Sp show significantly different haematopoietic potential. The yolk 
sac generates primitive erythrocytes and a subset of other haematopoietic populations 
including macrophages and progenitors of the definitive erythroid, megakaryocyte, and 
mast cell lineages, but pre-circulation yolk sac manifests little or no lymphoid or HSCs 
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potential. On the other hand, the P-Sp-derived haematopoietic population generates both 
HSCs and multi-potential progenitors that yield myeloid, lymphoid, and definite erythroid 
lineages in vitro. In human embryos, haematopoietic expansion follows a similar model 
(Keller et al., 2005; Chen et al., 2003). Given these differences, it will be necessary to 
recapitulate these developmental stages in vitro and to identify the equivalent of P-Sp-
derived haematopoiesis in order to isolate HSCs from ESCs (Murry et al., 2008). This, in 
turn, allows for further studies into the basic biology and therapeutic potential of this 
progenitor. 
1.1.8 Factors crucial to the maintenance of ESCs 
There is an on-going revision of the main methods and techniques employed for the 
maintenance of ESCs in undifferentiated proliferative states, even years after the initial 
discovery of the derivation of ESC lines. Currently, researches indicate that there are a 
number of variables contributing to growth and differentiation in vitro. 
ESCs are initially established and maintained in co-culture with mouse embryonic feeder 
cells (Evans and Kaufman, 1981; Martin, 1981). The leukaemia inhibitory factor (LIF) 
was identified in later studies as a feeder-cell-derived molecule playing a key part in 
maintaining these cells (Smith et al., 1988; Williams et al., 1988; Stewart et al., 1992). 
With recombinant LIF, feeder cell function can be replaced and the growth of 
undifferentiated ESCs can be supported, given the presence of appropriate batches of FCS 
(Smith et al., 1988; Williams et al., 1988). BMP4 was found to play a role in ES cell 
growth and it can replace the need for serum in the presence of LIF (Ying et al., 2003). 
Therefore, ESCs can be grown with defined factors without serum or feeder cells. LIF 
acts through the LIFR/gp130 receptor and activates signal transducer and activator of 
transcription 3 (STAT3), an important regulator of mouse embryonic stem cell self-
renewal. STAT3 is known to inhibit differentiation into both mesoderm and endoderm 
lineages by preventing the activation of lineage-specific differentiation programs (Niwa 
et al., 1998; Matsuda et al., 1999; Graf et al., 2011), whereas yhe activation of the mothers 
against decapentaplegic homolog (SMAD) (a transcription factor) and the subsequent 
induction of the helix-loop-helix Id factors (an inhibitor of differentiation) mediate the 
effect of BMP4 on undifferentiated ESCs (Katherine et al., 2010). The treatment of ESCs 
during EB development with a combination of cytokines and BMP4, a ventral mesoderm 
inducer, strongly promotes hematopoietic differentiation. Addition of BMP4 had no 
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statistically significant effect on hematopoietic differentiation, but it enables significant 
enhancement in progenitor self-renewal (Chadwick et al., 2003). Apart from STAT3 and 
Id, three other transcription factors and enzymes were found to be essential in the 
maintenance of the undifferentiated state of ESCs. These are Oct3/4 (Niwa et al., 2000) 
and Nanog (Chambers et al., 2003; Mitsui et al., 2003; Loh et al., 2006). It has been 
shown that Oct4, Nanog and Sox2 harmoniously work in a combinatorial complex to 
regulate ESC pluripotency and cellular differentiation (Kashyap et al., 2009; Nishikawa 
et al., 2007). In the absence of Oct4, pluripotent cells return to trophoblast both in vivo 
and in vitro, identifying Oct4 to be an important regulatory molecule in the initial cell fate 
decisions during mammalian development. Nanog was identified as a factor that can 
sustain pluripotency in ESCs even in the absence of leukaemia inhibitory factor (LIF) 
(Loh et al., 2006).  
Although stem cells from different origins require different growth conditions for 
maintenance and display different cell surface markers, the undifferentiated state of ESCs 
can be characterised by a high level of alkaline phosphatase (AP) expression, which, 
along with the expression of surface markers including stage-specific embryonic antigens 
(SSEA-1, -3 and -4), and the transcription factors Oct4, Nanog, and Sox2 indicates a 
subset of cells with self-renewal potential (Chunhui et al., 2001; O’Connor et al., 2008). 
The AP enzyme is considered to be the most recognisable stem-cell marker (Chen et al., 
2011). This enzyme is capable of catalysing reactions to give a coloured product that is 
easily detectable by light microscopy. 
1.1.9 Recapitulating haematopoiesis in mouse ESC cultures 
Whether cultured with serum or serum-free supplemented with inducers, mouse ESCs 
show rapid and synchronous differentiation to the haematopoietic lineages (Keller, 2005; 
Murry et al., 2008). It was found that differentiation in these cultures closely parallels 
that in the early embryo: PS to FLK1+; FLT3 mesoderm to yolk-sac-like haematopoietic 
program. The haemangioblast has been identified as a progenitor that manifests 
haematopoietic and vascular potential and defines the start of haematopoiesis (Choi et al., 
2009). Another progenitor has been identified in the posterior PS region of the early 
mouse embryo that may signify the yolk sac haemangioblast. Thus, haemangioblast 
commitment is initiated in the primitive streak of the mouse embryo (Huber et al., 2004). 
In ESC cultures, primitive erythroid progenitors develop after the appearance of the 
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haemangioblast, bringing about the primitive erythropoiesis stage of haematopoiesis 
(Kitajima et al., 2003; Maxim et al., 2005; Murry et al., 2008). 
It has been observed in the differentiation cultures that, besides primitive erythrocytes, 
other progenitors such as those of the macrophage, definitive erythroid, megakaryocyte 
and mast cell lineages develop with a kinetic model parallel to the yolk sac (Murry et al., 
2008). In this early stage of haematopoiesis, HSCs and progenitors of the lymphoid 
lineage are not generated. The equivalent of yolk sac haematopoiesis is represented in the 
first haematopoietic population to be developed from the ESCs, as suggested by these 
patterns of lineage development. It seems that this in vitro system recapitulates what is 
found in vivo, given that yolk sac haematopoietic development in ESC cultures and the 
early embryo are markedly similar. 
Although the yolk sac stage is well characterised in mouse ESC cultures, specification 
and development is relatively unexplored for P-Sp haematopoiesis. A characteristic 
defining the P-Sp is lymphoid potential, and mouse ESCs can generate these lineages, 
given the suitable conditions. 
CD34+ populations, obtained by differentiation of ESCs in co-culture with OP9 stromal 
cells in the presence of a combination of growth factors, are enriched in cells with features 
of lymphohaematopoietic potential (Vodyanik et al., 2005). Moreover, mouse ESCs will 
yield cells of B lymphoid potential when co-cultured with monolayer MS-5 stromal cells 
and three cytokines, namely stem cells factor (SCF), interleukins 3 (IL-3) and IL-7 
(Taguchi et al., 2007). B cells potential was demonstrated in the co-culture of ESCs with 
OP9 stromal cells in media containing lymphoid cytokines (Nakano et al., 1994). Holmes 
and Carlos (2009) demonstrated that differentiation of mouse ESCs into T-lymphocytes 
can be achieved in vitro with the support of OP9-DL1. This is OP9 that ectopically 
expresses the notch ligand delta-like 1 (DLL1) and the DLL1 gene plays a role in 
mediating cell fate decisions during haematopoiesis. 
Several gene targeting studies demonstrated the role of specific transcription factors 
including Scl/tal-1 (Begley et al., 1989), Runx1 (Wang and Speck, 1992), GATA1 and 
GATA2 (Orkin, 1992) in the establishment of the haematopoietic system. Each of these 
transcription factors functions at definitive stages of blood cell differentiation (Keller, 
2005). 
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In ESCs co-cultured with OP9 stromal cells, GATA1 and GATA2 were detected on days 
2 and 3 of ESC differentiation, coinciding with the appearance of CD34+ cells, whilst 
SCL expression was detected a day later and then gradually decreased, while GATA1 
expression gradually increased up to day 10 (Maxim et al., 2005). This confirms earlier 
studies demonstrating that GATA1 and GATA2 transcription factors seem to regulate the 
proliferation and differentiation of blood cells lineage (Suwabe et al., 1998). 
From these observations, it appears that in these cultures a population equivalent to the 
P-Sp region is generated. Collectively, these observations indicate that the haematopoietic 
system commences with the production of a limited number of specialised lineages in the 
yolk sac and matures over time into a full multi-lineage system with the switch to the P-
Sp region (Keller, 2005). 
Although it has been successful attempt to obtain HSCs differentiated from ESCs in 
serum-stimulated cultures (Burt et al., 2004), routine isolation of HSCs by these method 
is still not achieved. This means that long-term engraftment in host animals of mouse 
HSCs differentiated from could depend on a particular batch of serum. It is found that, in 
order to achieve the development, survival and expansion of HSCs derived from mouse 
ESCs, the expression of HoxB4 and the caudal-related homeobox-containing factor Cdx4 
in mouse ESC-derived haematopoietic had to be activated prior to transplantation (Daley 
et al.,; Kyba et al., 2002; Wang et al., 2005b). The expression of Cdx4 in mouse ESC 
cultures promotes haematopoiesis (Davidson et al., 2003), whilst the expression of 
HoxB4 induces extensive self-renewal, with expansion of bone marrow-derived HSCs 
and multi-lineage repopulation in recipient animals (Sauvageau et al., 1995). 
Earlier studies investigating the effect of stromal cells and their microenvironments that 
promote haematopoietic differentiation of ESCs have shown that osteoblastic cells 
regulate the haematopoietic stem cell niche (Calvi et al., 2003). Moreover, cytokines and 
BMP4 secreted from stromal cells promote haematopoietic differentiation of human 
embryonic stem cells (hESCs) (Chadwick et al., 2003). Ralph et al. (2000) found that a 
number of cytokines play a role in the differentiation of blood cells, and the pathway of 
differentiation is determined by the balance of these cytokines within the 
microenvironment of the pluripotent stem cell and its subsequent lineage. 
Though the earliest stages of haematopoietic development in human embryos are not 
accessible for research, it is found that the in vitro hESCs/OP-9 co-culture system can be 
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used to recapitulate it (Lanza et al., 2009) as well as supporting both haemogenic 
precursors and their primitive haematopoietic progeny (Ji et al., 2008). Enhanced 
characterisation of haematopoietic progeny using the ES/OP-9 system has been achieved 
in recent studies (Maureen et al., 2011). An understanding of the embryonic origin of 
HSC and the factors regulating their generation and expansion in vivo will provide 
important information for the manipulation of these cells ex vivo (Timothy et al., 2004). 
To date, characterisation of specific factors capable of influencing haematopoietic cell 
fate from ESCs remains elusive. There are no protocols for the efficiency of HSCs from 
ESCs because the factors regulating their specification have not been defined. Moreover, 
it is still a challenge to isolate the lymphoid progenitors and to identify the signalling 
pathways involved because the ESCs were differentiated in complex cultures with 
stromal cells in serum-based medium. 
It seems that the complex process of haematopoiesis is regulated locally by the interaction 
of hematopoietic cells with cytokines secreted by adjacent stromal cells. It is suggested 
by several lines of evidence that some aspects of normal haematopoiesis can also be 
regulated by some vitamins such as VD3, compounds that are biochemically distinct from 
cytokines, and hematopoietic growth factors might have also been involved (Grande et 
al., 2002). These compounds are capable of exerting their biological effects through the 
interaction with specific nuclear receptors of the steroid receptor superfamily (Kumar et 
al., 1999). 
1.1.10 The benefit of using the E14/OP6 co-culture 
ESCs derived from the inner cell mass of the blastocyst-stage of early mammalian 
embryos have the potential to undergo unlimited self-renewal in specific culture 
conditions either in vitro or in vivo (Lanza and Klimanskaya, 2009). Interestingly, once 
released from these conditions and placed into a differentiation-promoting environment 
in vitro or in vivo, the cells differentiate into derivatives of all three primary germs: 
ectoderm, mesoderm, endoderm and then into many different cell types in the body 
(Nishikawa et al., 2007; Thomas et al., 2009; Lanza et al., 2009).  
It has been shown that ESCs have the potential to differentiate into haematopoietic lineage 
(Vodyanik et al., 2006). ESCs differentiate into endothelial cells with haemangioblastic 
properties and colony-forming cells (CFCs) when the embryoid body differentiates or 
placed in S17 bone marrow stromal cell line co-culture (Kaufman et al., 2001; Zhan et 
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al., 2004). During the development of the embryoid body, if both cytokines and BMP4 
are added, ESCs haematopoietic differentiation is markedly promoted (Chadwick et al., 
2003). It is demonstrable from these results that ESCs as an alternative source of 
haematopoietic precursors, most useful in studies of haematopoietic ontogeny and 
haematopoietic cell transplantation. For this purpose, HSCs has to be produced in great 
quantity from ESCs, and the methods used must be re-producible.  
Alternatively, ESCs can be induced in vitro to differentiate into myeloid, lymphoid, 
erythroid, and megakaryocytic lineage cells by the macrophage colony-stimulating factor 
(M-CSF)-deficient stromal cell line OP9 (Nakano et al., 1994). It is found that, when 
cultured on OP9 stromal cells, ES cells differentiate into FLK1+ haemangioblasts, 
hematopoietic progenitors, and finally mature, terminally differentiated lineages 
(Maureen et. al., 2001). Hence the in vitro ESC/OP9 co-culture system can be used to 
recapitulate the early stages of hematopoietic development and support both haemogenic 
precursors and their primitive haematopoietic progeny (Vodyanik, 2005). It was 
originally designed to produce hematopoietic progeny without the over production of 
macrophages, as the OP9 stromal cell line is derived from the calvaria of osteopetrosis 
mutant mice that lack functional M-CSF.  
The study of Vodyanik et al. (2006) confirms other studies that it was possible to observe 
the haematopoietic differentiation of ESCs, CD34+ cells and CFCs in OP9 co-culture. 
This shows that the CD34+ cells that the OP9 system generated brought about B, natural 
killer (NK) and myeloid cell lineages, which indicated that ESCs could yield cells with 
definitive haematopoietic potential. It was also found that another benefit of OP9 co-
culture was that CD34+ cells could be generated in large quantity without the addition of 
cytokines.  
Thus, the use of ESCs/OP9 co-culture may be an excellent in vitro model to analyse 
haematopoietic development in its earliest stages. These include the study of cell 
populations and charactering the earliest genes involved. There is no need for external 
cytokines with this model, and its use does not incur the technical and ethical difficulties 
of experimenting on human embryos.  
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1.1.11 The pluripotency transcription factors Nanog, Oct4 
and Sox2 and ESC differentiation 
Three transcription factors are crucial in the regulation of the pluripotency of mouse 
ESCs, and these are octamer-binding transcription factor 4 (Oct4), Nanog homeobox 
(Nanog) and sex-determining region Y (SRY)-related high mobility group (HMG) box 2 
(Sox2) (Chambers et al., 2008; Niwa et al., 2008; Masui et al., 2008). During cell 
differentiation, the maintenance of ESCs’ pluripotency is reduced due to the down-
regulation effect of the Oct4 protein (Masui et al., 2008).  
Homeodomain protein Nanog mainly expresses itself in pluripotent cells and is crucial 
for the development of the early embryo (Chambers et al., 2008). Evidence from some 
studies indicates that Nanog maintains the self-renewal capability of ESCs and suppresses 
their differentiation, though it is not necessary for establishing pluripotency (Takahashi 
et al., 2006; Chambers et al., 2008). Over-expression of Nanog enables mouse ES cells 
to propagate in an environment free of leukaemia inhibitory factor (Chambers et al., 
2008). In contrast, when Nanog is absent or lacking, ESC differentiation occurs (Zaehres 
et al., 2008; Liang et al., 2008).  
Both Nanog (Liang et al., 2008) and Oct4 (Liu 1996) form specific transcriptional re- 
repressive complexes. However, research has found that Nanog has two powerful 
transcriptional activating domains (Avillion et al., 2003), suggesting that, as with Oct4 
(Ben-shushan et al., 2008), Nanog can be a transcriptional activator.  
The Sox2 transcription factor belongs to the SRY-related HMG box (Sox) transcription 
factor family (Masui et al., 2008; Avillion et al., 2003). Its expression is found in 
pluripotent cells and multi-potent embryonic and extra-embryonic cells. Whilst Sox2 is 
still less well characterised than either Oct4 or Nanog (Chambers et al., 2008; Niwa et 
al., 2008; Masui et al., 2008), it is known to be expressed in pluripotent and multi-potent 
embryonic and extra-embryonic cells and is of major importance  in regulating the fate 
of cells (Huangfu et al., 2008).  
In conclusion, Oct4, Nanog and Sox2 activate and maintain the expression of genes 
involved in self-renewal, while simultaneously repressing genes that mediate 
differentiation (Wu et al., 2008; Yang et al., 2009). This is schematically summarised in 
Figure 8. Thus, the undifferentiated state of ESCs can be characterised by the expression 
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of Oct4, Nanog, and Sox2, whilst the differentiated state loses the expression of these 
transcriptional factors. 
 
Figure 8. The function of Oct4, Nanog and Sox2 in regulating pluripotency and differentiation 
(Source: 
http://openi.nlm.nih.gov/imgs/512/3/3245296/3245296_pcbi.1002304.g009.png) 
1.1.12 CD34 marker of haematopoietic progenitor cells 
Haematopoietic activity seems to be mostly due to the cell population enriched in CD34+ 
from marrow or mobilised peripheral blood (Civin et al., 1984; Sutherland et al., 1989; 
Yabe et al., 1996). There is down-regulation of CD34 expression on primitive cells in 
their differentiation into mature cells (Sutherland et al., 1992). However, CD34 
expression is also detected on clonogenic progenitors and some lineage-committed cells 
(Andrew et al., 1989). While the exact role of CD34 remains to be defined, its pattern of 
expression is indicative of an important role in early haematopoiesis (Sutherland et al., 
1992). Therefore, CD34 has been regarded as the most crucial marker for HSCs and 
CD34+ cells can be analysed for detecting changes in HSCs. In fact, the current design of 
nearly all clinical and experimental protocols related to in vitro culture, gene therapy and 
HSC transplantation are for cell populations enriched for CD34+ cells. 
However, CD34 may not be the marker for the most primitive HSC, as it was shown that 
mouse HSCs could be CD34- (Osawa et al., 1996). Furthermore, in human CD34- cells 
low levels of engraftment and haematopoietic capacity were shown (Bhatis et al., 1998). 
Additionally, repopulating activity in a CD34- cell population in foetal sheep was 
demonstrated in transplantation studies (Zanjani et al., 1998).  It has been shown that 
mouse and human CD34+ cells may both proceed from CD34- cells (Nakamura et al., 
1999; Sato et al., 1999). This means HSCs may possibly be CD34+ or CD34-. Therefore, 
if the expression of CD34 marker is used as the only criterion for selecting primitive stem 
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cells, it might run the risk of excluding more primitive stem cells that do not express 
CD34.  
1.1.13 Structure and synthesis of 1α,25-dihydroxyvitamin D3 
(VD3) 
Vitamin D refers to a set of steroid molecules. The active form of vitamin D is 1α,25-
Dihydroxy-vitamin D3 (VD3), also known as cholecalciferol. Specifically, as shown in 
Figure 9, VD3 forms through the absorption ultra-violet (UV) B rays by a precursor 
molecule 7-dehydrocholesterol in the skin of animals (including human). Since adequate 
exposure to sunlight may be sufficient to satisfy an individual’s vitamin D requirement 
without need for dietary ingestion, it is not strictly speaking a vitamin. Dietary sources of 
vitamin D include egg yolk, fish oil and a number of plants. The plant form of vitamin D 
is called vitamin D2 (VD2), known also as ergosterol. Unfortunately, typical diets do not 
necessarily satisfy an individual’s vitamin D requirement. Therefore, exposures to 
sunlight and/or purposeful dietary supplementation are/is often necessary to prevent 
vitamin-D deficiency (How et al., 1994). 
VD3 synthesis in the skin is through conversion from 7-dehydrocholesterol, which is the 
chemical precursor of VD. Until the inactive form of VD3, cholecalciferal, is metabolised 
in the body to the hormonally-active form, known as 1,25-dihydroxycholecalciferol, 
vitamin D is not significantly biologically active. It is transformed in two steps. First, VD3 
is transferred by VD binding protein to the liver, where it is hydroxylated to 25-
hydroxycholecalciferol by the enzyme 25-hydroxylase. Then, after being transferred to 
the kidneys, 25-hydroxycholecalciferol acts as a substrate for 1-alpha-hydroxylase, 
resulting in 1,25-dihydroxycholecalciferol, which is the biologically active form 
(Brannon et al., 2008). This enzyme is also found in various extra-renal sites, such as 
osteoclasts, skin, colon, brain, and macrophages, and this may be a reason for the wide-
ranging effects of VD. The short half-life of VD in the liver is only about 3 weeks and 
therefore the body requires frequent replenishment of this vitamin (Teresa et al., 2009). 
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Figure 9. The synthesis and metabolism of Vitamin D 
(Source: http://www.mayoclinic.org/medicalprofs/endocrinology-vitamin-d-tests-
eu0603.html) 
 
VD2 and VD3 are hydrophobic, i.e., non-water-soluble, and so in order to be transported 
in blood, they are bound to carrier proteins. Vitamin D-binding protein is the major 
carrier. While the half-life of 25-hydroxycholecalciferol is in terms of weeks, that of 1,25-
dihydroxycholecalciferol is just hours. 
VD3 synthesised in skin exposed to UVB rays, and UVB rays are sufficiently present only 
when the sun is sufficiently high in the sky. Therefore, earlier and later in the day, and 
seasonally in higher latitudes, there may not be sufficient amount of UVB rays for the 
synthesis of adequate amount of VD3. Neither do UVB rays penetrate thick cloud. 
Consequently, the amount of VD3 synthesis is determined by the strength of the UVB 
rays, the length of exposure time to UVB rays and the pigmentation of the skin. Tanning 
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beds are not reliable means for acquiring VD3 as artificial tanning yields variable levels 
of UVA and UVB rays.  
1.1.14 Control of Vitamin D synthesis 
Hepatic synthesis of 25-hydroxycholecalciferol is only loosely regulated, and the level of 
this molecule in blood generally reflects the amount of vitamin D produced in the skin or 
ingested. In contrast, the activity of producing 1-alpha-hydroxylase in the kidney is tightly 
regulated. It is the kidney that serves as the major control point in the production of the 
active hormone 1,25-dihydroxycholecalciferol. The major inducer of 1-alpha-
hydroxylase is parathyroid hormone. 1-alpha-hydroxylase is also induced by low level of 
phosphate in blood. 
Different species differ in their abilities to synthesise vitamin D. Humans, cattle, horses, 
pigs, rats and sheep have sufficient 7-dehydrocholesterol in their skin to be efficiently 
converted to cholecalciferol. On the other hand, cats and dogs have much less 7-
dehydrocholesterol in their skin and its photochemical conversion to cholecalciferol is 
inefficient, so these animals rely more dietary intake of vitamin D than other species do 
(How et al., 1994). 
1.1.15 The effect of VD3 on functional cells 
Vitamin D has well-established effects in the regulation of calcium and phosphate 
homeostasis. VD3 is widely used for the treatment of metabolic bone diseases such as 
rickets / osteomalacia, renal osteodystrophy and osteoporosis (Deluca, 2004). Bone 
density is increased by the treatment with hydroxylated vitamin D (Papadimitropoulos et 
al., 2002). This is mainly achieved through an increase in calcium uptake in the intestine 
(Eastell et al., 1991). The differentiation of ESCs into osteoblasts in vitro is enhanced to 
60% when exposed to VD3 (Zurnieden et al., 2007).  
In addition to its classical function in the maintenance of calcium homeostasis and 
exerting a wider range of biological activities including the regulation of cellular 
differentiation and proliferation (Anderson et al., 2003), VD3 was demonstrated to be a 
powerful differentiation inducer for a large variety of neoplastic cells, including 
carcinoma cells of various origins and acute myeloid leukaemia (Grande et al., 2002). It 
has been shown to have pro-differentiation and anti-proliferative effects on keratinocytes 
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(Ludered et al., 2010) and prostate cancer cells (Chen et al., 2000), as well as stimulating 
granulocyte-monocyte committed stem cells into their clonal proliferation in vivo (Yetgin 
et al., 2004). 
Vitamin D metabolites may also be involved in immune-regulation and haematopoietic 
differentiation (Walters, 1992). It is found that VD3 strongly induces haematopoietic stem 
cells to differentiate along a myeloid pathway and give rise to CD14+ cells (Weeres et al., 
2014). Studies of vitamin-D deficient rickets cases were undertaken regarding the effect 
on bone remodelling and the haematopoietic system (Yetgin et al., 1982; Yetgin et al., 
1989). VD3 was found in vitro to inhibit the proliferation of colonogenic blast cells and 
induce the differentiation of acute myeloblastic leukaemia (AML) cell lines into 
macrophage-like cells (Koeffler et al., 1984; Mangelsdorf et al., 1984; Munker et al., 
1986). However, 1,25(OH)2D37 slightly stimulates normal human granulocyte-monocyte 
committed stem cells into their clonal proliferation. 
Vitamin D receptor (VDR) is a transcription factor that mediates the actions of its ligand, 
VD3, in the promotion of monocyte/macrophage differentiation and the inhibition of 
proliferation and cytokine production by activated T lymphocytes (O’Kelly et al., 2002). 
VDR is known to be expressed in various tissues including kidney, intestine, bone, 
macrophages, placenta and skin (Anderson et al., 2003). Expression of VDR has been 
detected in various normal and leukemic haematopoietic cells, including macrophages 
and activated T lymphocytes (O’Kelly et al., 2002). An intracellular VDR3 has been 
detected in numerous tissues and cultured cells ranging from mouse fibroblasts to human 
breast cancer cells. Therefore, it appears that vitamin D may have a much broader 
physiological impact in the body (Peehl et al., 1994). 
In the target cells, VD3 acts through binding to VDR as indicated in Figure 10. This 
combination of vitamin D and receptors then function as transcription factors to modulate 
gene expression (How et al., 1994) and indirectly activates a family of cell cycle control 
proteins called cyclin-dependent kinases (CDKs). However, their activity is regulated by 
another family of proteins called cyclins.  
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Figure 10. The mechanism of gene regulation by VD3 
(RXR: Thyroid hormone receptor) 
(Source: http://www.nature.com/ki/journal/v63/n85s/images/4493809f1.gif) 
So far, the effects of VD3 in different stages of differentiation of various types of cells 
were examined using in vitro techniques. Hiroshi et al. (2012) investigated the effect of 
VD3 in the proliferating, differentiating and differentiated phases of C2C12 myoblasts, 
and found that VD3 supplementation inhibited the proliferation of C2C12 myoblasts, 
significantly decreased the mRNA expression of neonatal myosin heavy chain (MHC) 
and increased gene expression of MHC isoforms in the differentiation of C2C12 
myoblasts for 8 days. 
Systemic or locally produced VD3 may play a role in modulating cell development 
processes such as haematopoiesis (Bunce et al., 1997). It has been reported that 
physiological levels of vitamin D promote a differentiation of CD34+ haematopoietic 
progenitors characterised by the induction of all the monomacrophagic 
immunophenotypic and morphological markers in a liquid culture model (Yetgin et al., 
2004). Patients receiving treatment for acute myeloid leukaemia (AML) or acute 
lymphoblastic leukaemia (ALL) may have limited exposure to sunlight and often 
experience gastrointestinal side effects that may decrease their ability to maintain an 
adequate vitamin D level (Sprota et al., 2011). These findings support the notion that 
vitamin D might be involved in cell growth regulation and cancer protection. This might 
be the reason why the risk of dying from colorectal cancer is the highest in areas with the 
least amount of sunlight (Tangpricha et al., 2001). 
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Macrophage differentiation of human normal and leukemic myeloid stem cells has been 
induced by VD3 and its fluorinated analogues (Koeffler et al., 1984). Enhancement of 
VD3 induced differentiation of human leukaemia HL-60 cells into monocytes by 
parthenolide via inhibition of the activity of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) (Kang et. al., 2002). The efficacy of VD3 in leukaemia therapy 
has been improved by the development of novel vitamin D analogues that have potent 
antiproliferative activity and low hypercalcemic side effects (Sonoko et al., 2006). The 
cyclin-dependent kinase inhibitor 1 (p21) is a cyclin-dependent kinase inhibitor (CKI) 
and is a regulator of cell cycle progression at G1 / S phase (Gartel and Radhakrishnan, 
2005). The cyclin inhibitory protein p27Kip1 (p27) plays a vital role in regulating cell 
proliferation in response to the extracellular growth environment. Active proliferation 
requires the suppression of p27 levels throughout the cell cycle (Sa et al., 2004). VD3 
increases the expression of the cell cycle-regulating genes p21 and p27, inducing a G0 / 
G1 phase arrest in squamous cell carcinoma cell lines (Hager et al., 2001). Thus, the 
effects of VD3 may vary according to the type of cell and stage of differentiation at which 
VD3 treatment is started. 
1.1.16 The effect of VD3 on the cell cycle  
In order for mitosis to start, specific signals are needed by cells so that they can proliferate 
and be committed to the cell cycle. The mechanism is shown in Error! Reference source 
ot found.. 
There is a family of cell cycle control proteins known as cyclin-dependent kinases 
(CDKs) whose concentration remains constant all through the cell cycle. The activity of 
CDKs is regulated by another family of proteins known as cyclins. Specific cyclins bind 
to specific CDKs, and CDKs cannot function without this specific binding. The cyclin-
CDK interactions maintain the cell cycle, whilst at the same time there are control 
mechanisms which inhibit the cyclin-CDK complexes. 
Cyclin kinase inhibitors (CKIs) keeps the cell cycle inactive before the start of a new 
cycle. The CKI-CDK-cyclin complex is formed when CDKs interact with CKIs. When a 
growth factor or an external signal binds to its binding site or its receptor, the CKI-CDK-
cyclin complex is modified, which permits interaction between a subgroup of cyclins and 
their appropriate CDKs. This is regulated by cell division cycle 25 (CDC25) phosphatase.  
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Figure 11. cyclins and their CDKs that control cell‐cycle progression  
(Source: Niehrs and Acebron, 2012) 
There is an important regulatory protein known as retinoblastoma (pRb) with which the 
cyclin D-CDK4 and the cyclin D-CDK6 complexes interact. When CDK4 interacts with 
cyclin D, the resulting cyclin D-CDK4 complex adds the phosphor group to the pRb. This 
process is known as phosphorylation. Phosphorylation has the effect of lessening the 
binding capacity of a transcription factor known as E2F-1, and once E2F-1s are released, 
E2F-1-dependent genes will be activated. The transcription of a range of genes, notably 
the gene-encoding cyclin E, is promoted by the release of E2F-1. The enzyme histone 
deacetylase (HDAC) is another protein bound to pRb. 
The mechanism of action of VD3 was suggested to be mediated via the increase and up-
regulation (Okuno et al., 2012) in the expression of p21 and p27 genes. The latter genes 
were thought to encode cyclin-dependent kinase (CDK) inhibitors (Kanatani et al., 1999) 
previously associated with the inhibition of G1-cyclin-dependent kinase (Harper et al., 
1993; Toyoshima and Hunter, 1994). Cyclins and their associations with CDKs and CDK 
inhibitors (CKIs) act to regulate cell cycle progression from the G1 to S phase. The 
production of CDK inhibitory proteins (cip/kip) by p21 and p27 and their subsequent 
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complex formation with CDKs may inhibit the phosphorylation of retinoblastoma (pRb) 
and blocks progression of the cell cycle from G1 to S phase (Kanatani et al., 1999; 
Coqueret, 2003; Aoyagi et al., 2013). With the suspension of phosphorylation, pRb 
becomes a docking station to prevent the binding of the transcription factor E2F-1 to its 
target gene, which in turn prevents the production of the cyclin E gene. When cyclin E 
production is compromised, the cell cycle cannot move along from the G1-phase to the 
S-phase, thereby causing cells to differentiate and not to proliferate. 
1.1.17 Vitamin D deficiency 
Vitamin D has been shown to be important for several reasons (Teresa et al., 2009). It 
controls calcium absorption in the small intestine (Granney et al., 2008). It works in 
tandem with parathyroid hormone to bring about skeletal mineralisation and maintain 
bloodstream calcium homeostasis. It has probable anti-inflammatory (Krishnan and 
Feldman, 2011) and immune-modulating effects (Prietl et al., 2013), and it also has 
possible effects on cytokine levels. Thus, it is beneficial to have sufficient amount of VD3, 
and insufficient amount of VD3 is linked to many health problems.  
Guidelines on daily vitamin D allowance and vitamin D deficiency  
The US Institute of Medicine Recommended Dietary Allowance of VD is currently 
400  IU per day for children younger than 1 year of age, 600  IU per day for children at 
least 1 year of age and adults up to 70 years, and 800  IU per day for older adults (IOM, 
2011). The US Endocrine Society’s Clinical Practice Guideline advised that 400-1000  IU 
per day may be needed for children aged less than 1 year, 600-1000  IU per day for 
children aged 1 year or more, and 1500-2000  IU per day for adults aged 19 years or more 
to maintain 25(OH)D above the optimal level of 30 ng/mL (Pramyothin and Holick, 
2012).  
The US Institute of Medicine established that serum 25(OH)D of 20  ng/mL or more will 
cover the requirements of 97.5% of the population (Pramyothin and Holick, 2012). 
Individuals with level lower than this threshold are considered VD deficient (Sandy at 
al., 2009).  
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Furthermore, the National Health Service (NHS) of the United Kingdom (UK) has 
published descriptions of vtamin D levels of the population related to different stages 
from VD sufficiency to VD insufficiency and VD depletion (Table 1).  
Table 1. Stages from vitamin D sufficiency to vitamin D insufficiency and vitamin depletion 
(Source: NHS) 
 
VD sufficiency  
 VD supply diminished by lack of dietary vitamin, malabsorption of dietary 
vitamin or decreased exposure to sunlight 
 Lowered concentration of plasma concentration of 25(OH)D and VD3 
 Decreased intestinal absorption of calcium 
 Increased synthesis and secretion of parathyroid hormone 
 Increased synthesis of VD3 corrects defective calcium absorption, gives 
normocalcaemia at the expense of parathyroid hormone 
 Further decrease in 25(OH)D through increased turnover and increased 
consumption 
VD insufficiency Insufficient 25(OH)D to form adequate VD3 
 Failure to absorb calcium; calcium resorbed from bone; bone unable to 
mineralise 
VD depletion Osteomalacia and rickets 
Several health problems associated with low VD level are described in this table. 
However, there are also other health problems that may be related to low VD levels. Some 
of the links between VD deficiency and health are discussed below.   
Vitamin D and mortality  
VD may be one of the factors in reducing the risk of mortality owing to its anti-
inflammatory and immune-regulatory roles. VD3 supplementation is associated with 
lowered risk of mortality among dialysis patients (Wolf et al., 2007), administered on 
secondary-hyperparathyroidism patients. There is a correlation between low VD levels in 
serum and risk of mortality among chronic kidney patients before dialysis (Inaguma et 
al., 2008). However, no randomised prospective trials of VD on kidney patients have been 
undertaken (Al-Aly, 2007; Melamed and Thadhani, 2012). In addition, an association 
between 25(OH)D deficiency and hospital mortality in Medical Intensive Care Unit 
(MICU) patients has also been demonstrated (Sindhaghstta et al., 2011).  
In terms of health effects in general, low VD levels are related to increased inflammation 
and oxidative load. Low VD amongst more than 3,000 patients due for coronary 
angiography showed both increased cardio-vascular deaths, as well as multi-cause 
mortality (Dobnig et al., 2008). A standardised mortality ratio of 1.26 (any figure above 
1.0 indicates a higher-than-expected mortality) in the lowest-quartile VD level was found 
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in a study of over 13,000 individuals (Melame et al., 2008). A meta-analysis4 (Zheng et 
al., 2013) of 42 randomised controlled trials between January 1960 and January 2013 
collected from several databases, including MEDLINE, Embase and The Cochrane 
Register of Controlled Tirals, showed that supplementation of VD is effective in 
preventing overall mortality in a long-term treatment that is longer than 3 years, though 
it failed to identify the efficacy of VD on the mortality of any specific disease.  
Vitamin D and cardiovascular disease 
The presence of VD receptors in vascular smooth muscle, endothelium, and 
cardiomyocytes may have an influence on cardiovascular disease. Low VD levels have 
been found to be related to hypertension, coronary-artery calcification, and existing 
cardiovascular disease (Stefan et al., 2013). More than 1,700 individuals underwent a 
cohort study of VD levels and cardiovascular events for a five-year period. It was found 
that individuals with lower 25-OH D levels had a higher probability of suffering a 
cardiovascular event, with a hazard ratio of 1.62, a relationship that was significant for 
hypertension sufferers only (Wang et al., 2008). 
Vitamin D and diabetes 
It seems that VD3 may be important in glucose-metabolism homeostasis and in 
connection with types 1 and 2 diabetes mellitus (DM). From epidemiological data, it has 
been suggested that there may be a connection between early-life VD3 exposure and type 
1 DM (Mathieu et al., 2005), and it is thought that increased VD3 intake in infancy may 
reduce the risk of this disease developing (Danescu et al., 2009). Type 1 DM is linked to 
VD3 receptor-gene polymorphisms (Matieu et al., 2004; Teresa et al., 2009). There is an 
association between VD3 and a number of factors contributing to type 2 DM, notably 
defective pancreatic-cell function, insulin sensitivity and systemic inflammation.  
                                                 
4 Meta-analysis is a statistical technique that combines the findings from independent studies by combining 
data from two or more randomised control trials. It is most often used to assess the clinical effectiveness of 
healthcare interventions. A good meta-analysis aims for complete coverage of all relevant studies, looks 
for the presence of heterogeneity, and explores the robustness of the main findings using sensitivity analysis 
(Krombie and Davis, 2009). 
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There have been different physiological explanations on the role of VD3, such as in insulin 
secretion, with calcium in insulin action, or in cytokine regulation (Mathieu et al., 2005; 
Palomer et al., 2008; Danescu et al., 2009).There is evidence in one study for a link 
between low VD3 level, calcium or dairy consumption and the occurrence of type 2 DM 
or metabolic incidence, with a 0.36 prevalence (the portion in the total population with 
this condition), which occurred most frequently in non-black participants with the lowest 
25-hydroxyvitamin D. The study also showed type 2 DM had greatest prevalence of 0.71 
in individuals with low dairy consumption. Another study (Dalgård et al., 2011) found 
that VD sufficiency may provide protection against type 2 DM in subjects aged 70-74. 
An inverse relationship was found between type 2 DM and metabolic syndrome 
incidences and the intake of vitamin D and calcium (Pitta et al., 2007).  
Vitamin D and osteoporosis 
The most frequently occurring metabolic bone disease is osteoporosis, and lack of vitamin 
D is linked to it. Specifically, insufficient serum vitamin D causes decreased active 
transcellular calcium absorption. It has been found that combined calcium-vitamin D 
supplementation is linked to increased bone mineral density (Schnabel et al., 2012) and 
decreased hip fractures (Rodriguez-Martinez and Garcia-Cohen 2002). It has been 
demonstrated that a daily vitamin D intake of greater than 700 IU in combination with 
calcium reduced bone loss in comparison to a placebo, but 300 to 400 IU without calcium 
had no effect in reducing fractures (Granney et al., 2008). Furthermore, a Cochrane 
review was unable to determine whether vitamin D supplementation alone reduced bone 
fractures, but recommended combined calcium-vitamin D supplementation for the frail 
and elderly nevertheless (Avenell et al., 2009), and a meta-analysis concurred that 
combined supplementation is necessary (Boonen et al., 2007). Bergman et al. (2010) 
found that the daily dose of 800 IU of VD3 reduces the incidence of osteoporotic non-
vertebral, hip, and non-vertebral-non-hip fractures in elderly women, and VD3 
supplement increases the benefit of calcium supplementation for non-vertebral and non-
vertebral-non-hip fractures.  
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Vitamin D and falls amongst the elderly 
Vitamin D is thought to be crucial for the wellbeing of the elderly. Its supplementation 
evidently reduces the risk of falls, possibly by improving muscle function (Bruyère et al., 
2014). 
A trial of women who had had at least one fall in a prior 12-month period found that 
recipients of 1000 IU daily of ergocalciferol (VD2, i.e., calcium and vitamin D) had a 
significantly lower risk of falls than those who had received a placebo (Prince et al., 
2008). Daily vitamin D doses below 800 IU did not significantly reduce the risk of falls 
compared to the placebo (Broe et al., 2007). Another study found a significant 22% 
reduction in fall risk amongst an elderly group in reception of vitamin D compared to 
other elderly receiving calcium only or a placebo (Bischoff-Ferrari et al., 2004). Daily 
supplementation of 800 to 1000 IU is recommended for fall prevention function (Bruyère 
et al., 2014). 
Vitamin D and cancer 
Vitamin D is thought to be beneficial in preventing and suppressing cancer, perhaps 
because of its role in regulating cell growth and differentiation (Osborne et al., 2002). It 
has been demonstrated in vitro that dietary levels of VD and VD3 exhibit equivalent 
anticancer activity in mouse xenograft models of breast and prostate cancer (Srilatha et 
al., 2012). In a cohort study analysing the risk factors in a followed-up group of some 
1,100 men who do not have a disease, an increment in 25(OH)D level of 25 nmol/L was 
linked to a 17% reduction in total cancer cases (Giovannucci et al., 2006). However, 
another study, of nearly 17,000 people, found no such link, but rather an inverse relation 
between vitamin D level and colorectal cancer, though serum 25(OH)D levels of 
80 nmol/L afforded a 72% lowering of colorectal cancer risk in comparison with levels 
below 50 nmol/L (Freedman et al., 2007). A meta-analysis of 63 studies was done, in 
which 20 of 30 studies showed a lower frequency or reduced mortality of colon cancer, 
whilst 9 out of 13 breast-cancer studies and 13 out of 26 prostate-cancer studies similarly 
showed reduced incidence or mortality (Garland et al., 2006). A meta-analysis of 5 
studies (Mohr et al., 2014) found that high serum 25(OH)D was associated with lower 
mortality from breast cancer and suggested that serum 25(OH)D in all patients with breast 
cancer should be restored to the normal range (30-80 ng/mL).  
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Deficiency in Vitamin D may be a cause of osteomalacia, bone pain, muscle weakness, 
fatigue, and may increase the risk of fracture. It may also precipitate or exacerbate 
osteopenia and osteoporosis. Patients being treated for acute myeloid leukaemia (AML) 
or acute lymphoblastic leukaemia (ALL) may have had little exposure to sunlight and 
frequently suffer gastrointestinal side effects that may reduce their capability of 
maintaining a sufficient level of VD (Lisa et al., 2011). 
It is suggested (Iguchi et al., 2005) that Vitamin K2 plus VD3 in combination may be 
effective for differentiation-based therapy for leukaemia, as well as for leukaemia and 
myelodysplastic syndrome (MDS) where the cytopenias are mediated though apoptosis.  
It has been shown that dietary VD administration has an effect on the innate immune 
parameters of a gilt-head sea bream. The immunostimulant effect was greater on the 
cellular innate immune parameters assayed, suggesting that similar receptors to those 
present in mammals are involved in the action of this vitamin in the fish immune system 
(Cerezuela et al., 2009). 
Projections indicate that by increasing the yearly serum 25(OH)D level to 40 to 60 ng/mL 
(100–150 nmol/L) would reduce about 58,000 new cases of breast cancer every year, and 
would also bring down the number of new cases of colorectal cancer by about 49,000 
annually. Similarly, three quarters of deaths from these diseases in the United States and 
Canada could be prevented, according to observational studies in combination with a 
randomised trial. Taking these quantities of the serum will probably halve the case-fatality 
rates in breast, colorectal and prostate cancer (Cedric et al., 2009). This could be the result 
of the anti-inflammatory effects of VD3. It reduces the gene activation in breast cancer 
cells by interfering with the transactivation potential of the p65 subunit of the nuclear 
factor kappa B (NF-κB) (Tse et al., 2010). In another study (Guan et al., 2013), it is shown 
that VD3 might have anti-proliferation effects on lung cancer cells by up-regulating the 
transcription of the hsa-let-7a-2 gene in the latter.   
The mechanism of the anticancer action of VD3 is summarised in Figure 12. 
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Figure 12. The mechanism of the anticancer action of VD3 
(Source: http://www.vitamindwiki.com/tiki-
download_wiki_attachment.php?attId=1783) 
 
1.1.18 Vitamin D and haematological diseases and disorders 
VD is a steroid hormone. VD signalling takes place through VDRs. VDR is a receptors 
in the family of steroid/thyroid hormone-activated transcription factors and is the 
mediator of VD activity. VD binds with VDR to form dimers. Those dimers can then 
binds to VD response elements (VDREs) in promoters of target genes. Thus, VD and 
VDRs bind to specific locations of the human genome, resulting in target gene 
transcription (Kim et al., 2012; Bogunia-Kubik et al., 2008; O’Kelly et al., 2002; Bunce 
et al., 1997). Through this mechanism, VD has influence on almost 3,000 genes out of 
the 25,000 human genes. Thus, it regulates more genes and bodily functions than any 
other hormone discovered so far, and is one of the most potent hormones in the human 
body. 
VDRs have been identified on hematopoietic and lymphoid cells, amongst other tissues. 
This indicates that VD may play some important role in blood cell development and 
immune system function.  
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In the haematopoietic system, VDR is expressed on various hematopoietic precursors as 
well as monocytes, some thymocytes, and activated B and T lymphocytes (Luong and 
Koeffler, 2005). Through these, VD stimulation can influence haematopoietic 
development. VD3 treatment of both normal haematopoietic stem cell lines and leukemic 
cell lines leads to increased monocyte/macrophage differentiation results in increased 
numbers of these mature cells (Bunce et al., 1997; Grande et al., 2002). This treatment 
might be primarily affecting cytokine signalling and the final steps in differentiation in 
these two cell types (Bunce et al., 1997).  
As to the effect of VD in immune modulation, it is crucial in the immune response, 
enabling the production of over 200 antimicrobial peptides that fight off infections. 
Furthermore, the presence of the VDR on activated lymphocytes suggests a role in 
immune modulation on differentiated cells. As VD and VDR affects cytokine expression, 
they not only modulate the Th1 cellular immune response (O’Kelly, 2002), but also 
favour the Th2 hormonal immune response over Th1 (Luong and Koeffler, 2005; O’Kelly 
et al., 2002) through their immune-modulatory effect is still unclear. Furthermore, VD 
and VDR seems to be crucial for proper development of invariant natural killer (iNK) 
cells, a subset of lymphoid cells involved in the most basic immune responses and also in 
restricting autoimmunity (Yu and Cantorna, 2011; Yu et al., 2011). Additionally, VD and 
VDR may also have a role in immune tolerance, the process by which autoimmunity is 
prevented, as it mediating the homing of lymphoid cells to specific tissues and in 
attenuating inflammation (Yu et al., 2008).  
There is significant interest in studying VD analogues as treatment for myeloid 
malignancies, such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia 
(AML), as VD promotes differentiation of normal hematopoietic precursors and 
malignant myeloblasts in vitro. Some form of MDS may change to AML, but the exact 
mechanism by which this change is induced by VDR activation is not fully understood 
(Hall and Juckett, 2013).  
There are concerns of hypercalcemia if supraphysiological doses of VD are needed to 
induce differentiation (Bunce, Brown and Hewison, 1997; Koeffler, Hirji and Itri, 1985), 
but it seems that it is more promising to induce differentiation with fractionated dosing 
that reduces each dosage to within physiological ranges (Grande et al., 2002).  
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Various approaches of VD therapy for MDS have been studied. Some studies focus on 
single agent VD therapy (Koeffler, Hirji and Itri, 1985; Harrison and Bershadskiy, 2012; 
Molnar et al., 2007; Mellibovsky et al., 1998; Motomura et al., 1991) and some use VD2 
analogues (Koeffler et al., 2005; Petrich et al., 2008), whilst some other try combining 
VD with other differentiation and cytotoxic agents (Siitonen et al., 2007) or using growth 
factors with differentiating agents (Ferrero et al., 2009), as well as looking at 
combinations of VD analogues as differentiating agents with cytotoxic chemotherapy 
(Ferrero et al., 1996).  
AML, unlike MDS, tends to be fatal over weeks or months without effective treatment. 
Therefore, therapeutic plans that include only differentiating agents such as VD have 
tended to be used only in patients with very treatment resistant disease or those at high 
risk for side effects of conventional cytotoxic chemotherapy (Harrison and Bershadskiy, 
2012). There are trials with low dose cytarabine regimens combined with VD analogue 
and another agent (Slapak et al., 1992; Ferrero et al., 2004). There is at least one trial 
combining VD analogue and chemotherapy with a control group (Hellstrom et al., 1990), 
but most studies do not have control group and are also limited by variable response 
criteria and unclear end points, so it is difficult to draw conclusions from these studies. 
As to VD therapy for non-myeloid haematological cancers, pre-clinical studies have 
shown that VD has an inhibitory effect on lymphoid neoplastic cells (Luong and Koeffler, 
2005), and activity of the VD analogue EB1089 in the myeloma H929 cell line (Park et 
al., 2002; Park et al., 2000; Puthier et al., 1996) appears to promote apoptosis and induce 
cell cycle arrest by down-regulation of cyclin dependent kinases (Park et al., 2002).  
In addition, VD analogues are well-established therapies for some autoimmune 
conditions such as psoriasis, likely due to the effects of VD on the signalling, tissue 
targeting, or immune regulation of activated T and B cells. VDR stimulation is also 
crucial to the activity of antigen presenting cells and thus is crucial to response to 
infections. VD and VDR can also be used in immune reconstitution and immune 
surveillance in patients of transplantation such as allogeneic hematopoietic stem cell 
transplantation (HSCT) to suppress side effects and improve success rates (Pakkala et al., 
2001).  
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Besides using in direct treatments, it is prudent to maintain normal level of patients 
particularly vulnerable to bone disease and mineral loss, such as patients after allogeneic 
stem cell transplant and patients with multiple myeloma. 
1.2 Research Motivation 
The capacity of ESCs to undergo unlimited self-renewal and differentiation into many 
different cell types in the body has huge potentials in the fields of biomedical research 
and regenerative medicine. ESCs have been used for therapeutic intervention in the 
treatment of a wide range of disease conditions. One of the most important potential 
applications of ESCs for this purpose is the generation of cells that could be used for cell-
based therapies, such as transplanting HSCs in leukaemia treatment. The conventional 
treatment involves the use of high-quality sources of tissue-matched bone marrow, 
mobilised peripheral blood or umbilical cord blood. However, appropriate bone marrow 
is often in short supply and cord blood, though bankable, is less suitable for adult 
transplantation because it contains fewer ESCs. Thus, direct differentiation of ESCs 
towards HSCs offers a potentially attractive alternative to these conventional sources.  
Additionally, it has been demonstrated that VD3 is a powerful differentiation inducer for 
a wide variety of neoplastic cells, so this active form of vitamin D may help to promote 
cell differentiation in other cases. Previous related researches had been conducted mainly 
using cancer cells. Thus it is worth finding out if this is true with haematopoiesis using 
non-cancer ESCs.  
The difficulty with such research on ESCs is that the earliest stages of haematopoietic 
development that are not accessible in human embryos. However, it has been shown in 
vitro that the ESCs / OP9 stromal cells co-culture system can be used to recapitulate the 
earliest stages of haematopoietic development and support both haemogenic precursors 
and their primitive haematopoietic progeny (Lynch et al., 2011; Vodyanik et al., 2005). 
This is due to two important properties of the OP9 stromal cells. First, it does not produce 
the macrophage colony-stimulating factor (M-CSF) due to mutation, so there would be 
no M-CSF that would inhibit the haematopoiesis process (Kitajina, 1998). Secondly, it 
produces various cytokines that could be used to successfully to induce mouse ES cell 
differentiation into myeloid, lymphoid, erythroid, and megakaryocytic lineage cells 
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(Lynch, 2011), so no exogenous cytokines would be needed (ATCC, LGC standards, 
UK).  
Furthermore, E14 was shown to be efficiently able to support full development 
(Wakayama, 1999), so it is useful in researches on haematopoiesis. Hence, the E14 and 
OP9 cell lines and the E14 / OP9 co-culture are selected as the subjects of the in vitro 
studies in this research.  
1.3 Aims, Objectives and Hypotheses 
Based on the research motivation, therefore, the aim of these studies is to elucidate the 
effect of VD3 on the mechanisms of ESC differentiation towards haematopoietic cells and 
then blood cells. The overall hypothesis is that VD3 enhances and accelerates 
haematopoiesis. The null hypothesis is that VD3 has no effect on the differentiation of 
ESCs into blood cells.  
More specifically, VD3 enhances the differentiation of ESCs in the vicinity of OP9 
stromal cells into blood cells of erythroid, myeloid and B cell lineages, even without the 
influence of exogenous growth factors or complex structures. The null hypothesis is that 
VD3 will not enhance the differentiation of ESCs into blood cells when co-cultured with 
OP9 stromal cells. 
Thus, the first objective of the research is to ascertain whether or not VD3 plays an 
important role in suppressing proliferation and promoting differentiation of cells in 
general. The first hypothesis is that VD3 is instrumental in promoting cell differentiation 
and suppressing cell proliferation. The null hypothesis is that VD3 has no effect in 
promoting cell differentiation and suppressing cell proliferation.  
Then, the second objective of the research is to ascertain if VD3 plays a significant role 
in haematopoiesis. The second hypothesis is that VD3 encourages haematopoietic 
development by suppressing proliferation and promoting differentiation of cells in 
haematopoiesis.  The null hypothesis is that VD3 has no effect on haematopoiesis.  
Once the effect of VD3 on haematopoiesis is investigated with controlled amounts of VD3, 
the next step in the study would be to ascertain the effect of the change in VD3 level on 
the variations in the products of haematopoiesis. Thus, the third objective of the research 
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is to establish the effect of variable VD3 level on the haematopoietic progenitor cell count 
and the total number of blood cells over time. The third hypothesis is that the number of 
haematopoietic progenitor cells and major types of blood cells increase or diminish as the 
VD3 level increases or diminishes, i.e. there is positive correlation between the number 
of cell counts and the level of VD3. The null hypothesis is that VD3 level has no effect on 
the number of haematopoietic progenitor cells and major types of blood cells.  
1.4 Overall Design of the Study 
To test the hypotheses, three parts of researches involving several sets of studies were 
designed and conducted. First, to ascertain whether VD3 is crucial in promoting 
differentiation and suppressing proliferation, in vitro studies using mouse cell line were 
conducted. Separate investigations were carried out to find out the effects of VD3 on the 
proliferation phase of the E14 cell line and on stromal OP9 cells, respectively, as these 
two types of cells would also be used in the next step of the study. In both cases, VD3-
treated cells were compared to untreated ones. The materials, principles, protocols and 
methods used in this part of the research, as well as the results and findings obtained from 
it, are presented in Chapter Two.  
Secondly, to ascertain whether VD3 accelerates and promotes haematopoiesis of ESCs in 
the presence of OP9 stromal cells, in vitro studies using mouse cell lines were done using 
the co-culture of ESCs and OP9 stromal cells, i.e., the E14 / OP9 co-culture, as this was 
shown to be a good setting for the study of haematopoiesis. The materials, principles, 
protocols and methods used in this part of the research, as well as the results and findings 
obtained, are presented in Chapter Three. 
Thirdly, to ascertain if and how variation in VD3 level affects haematopoiesis, a pilot 
study was done in vivo with human participants, where the VD3 level was monitored but 
not controlled by the designs or settings of the experiment. The materials, principles, 
protocols and methods used in this part of the research, as well as the results and findings 
obtained, are presented in Chapter Four. 
Finally, based on the findings of these experiments, an overall conclusion was drawn. The 
summary of findings, the novelty, the contributions and the limitations of the research, 
together with possible directions for further researches, are presented in Chapter Five. 
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Chapter 2 The Effects of VD3 on E14 and OP9 
Cells in Vitro  
 
2.1 Introduction 
The aim of this part of the study is to ascertain if VD3 plays a key role in suppressing 
proliferation and promoting differentiation of cells in culture. The hypothesis is that VD3 
is instrumental in promoting cell differentiation and suppressing cell proliferation. 
Hence, there are two kinds of effects of VD3 that are under investigation. First, the anti-
proliferation effect of VD3 has studied through cell proliferation assays by cell counting 
and alkaline phosphate staining. Secondly, the effect of VD3 on cell differentiation has 
studied through cell cycle examination by flow cytometric analysis. Both mouse ESC line 
E14 and mouse stromal feeder OP9 cells in the proliferation stage have been investigated 
separately in vitro with both sets of tests.  
The materials and equipment used for the studies, the methods and protocols adopted for 
experimental preparation and analyses, the results obtained from the experiments, and the 
discussion based on the results are presented in this chapter.    
2.2 Protocols and Methods 
2.2.1 Cell culture preparation 
The cell cultures used in the study were prepared from thawed frozen stock. These were 
grown to desired population by inducing cell proliferation. Afterwards, cells were taken 
from these proliferated populations and transferred or passed to different growth 
conditions designed for the experiments. Unused cell cultures can be preserved by 
cryopreservation to be resurrected in the future for later experiments. These procedures 
used in the preparation of cell cultures for the study are described below. 
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Inducing proliferation of OP9 and E14 cells 
The stromal cells used in the present study were of the OP9 cell line (ATCC, LGC 
standards, UK) established from the calvaria of new born op/op mice. This cell line was 
chosen due to the property that they do not produce macrophage colony-stimulating factor 
(M-CSF). Primarily, OP9 cells do not produce functional M-CSF due to an osteoporotic 
mutation in the gene encoding M-CSF, and the presence of M-CSF had inhibitory effects 
on the differentiation of ESCs into blood cells other than macrophages. In fact, it has been 
reported that M-CSF has some inhibitory effects on the process of haematopoiesis 
(Kitajima et al., 1998), and OP9 cells have been used to co-culture mouse ESCs to 
successfully induce the differentiation of ESCs into blood cells of erythroid, myeloid and 
B cell lineages. Furthermore, co-cultivation with OP9 did not require exogenous growth 
factors or complex embryoid structures (Kitajima et al., 1998). 
To prepare samples for the present study, OP9 cells were induced to proliferate and 
expand by thawed cell stock vials at room temperature and added to a gelatinised 25 mm 
culture dish or T75 flask, at a density of 5 × 105 cells per dish or 2 × 106 per flask, in an 
undifferentiated state in a fully humidified atmosphere with 5% CO2 at 37 ºC in GM 
composed of 385 mL alpha modification minimum essential medium (no nucleosides) 
(αMEM) with 2.2 g/L sodium bicarbonate at pH 7.2, 100 mL heat-inactivated HyClone™ 
Foetal Bovine Serum, 5 mL non-essential amino acid solution (NEAA), 5 mL L-
glutamine (200 mM final), 5 mL penicillin-streptomycin solution (10.000 units/mL 
penicillin and 10.000 µg/mL streptomycin), and 500 µL 2-Mercaptoethanol (50 mM 
final). The medium was changed every 2-3 days.  
OP9 cultures were never grown beyond 90% confluency as this would result in their 
differentiation into adipocytes. It is possible to generate stable cell lines because OP9 
differentiation is not diminished by maintenance in either high cell-density or long period 
in continuous culture (Wolins et al., 2005). It was found that it took 6 hours for OP9 cells 
to settle down. 
The ESCs used in the present study are the murine ESCs of E14 cell line passages 1-36. 
The first successfully derived murine ESC line was achieved by Martin Evans and 
Matthew Kaufman in 1981 (Lanza et al., 2009) and the ESC line E14 was derived from 
the inbred mouse strain 129/Ola by Dr. Hooper in Edinburgh in 1985 (Hooper et al., 
1985).  
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As samples for the current study, E14 cells were induced to proliferate and expand by 
thawed cell stock vials at room temperature and added to gelatinised 25 mm culture dishes 
or T75 flasks at a density of 5  105 cells per dish or 2  106 per flask. They were in an 
undifferentiated state in a fully humidified atmosphere with 5% CO2 at 37 ºC in growth 
medium (GM) composed of 450 mL Dulbecco’s Modified Eagle’s medium (DMEM) 
with 10% Knockout™ Serum Replacement, 5 mL non-essential amino acid solution 
(NEAA), 5 mL L-glutamine (200 mM final), 5 mL penicillin-streptomycin solution 
(10.000 units/mL penicillin and 10.000 µg/mL streptomycin), 50 µL leukaemia 
inhibitory factor (LIF), and 500 µL 2-Mercaptoethanol (50 mM final) until 90% 
confluence was attained. The medium was changed every 2-3 days. 
Passaging of cells 
Passaging of cells was performed by aspirating culture mediums, washing cells with PBS 
to remove any remaining serum, trypsinising with 0.25% 
trypsin/ethylenediaminetetraacetic acid (EDTA) for 3-5 minutes at 37 ºC to detach cells 
adhered to the substrate and re-suspending the cells in pre-warmed GM (in at least 1:1 
ratio of trypsin:GM to deactivate the action of the trypsin. E14 cells were centrifuged at 
750 rpm for 5 minutes at room temperature, whilst OP9 cells were centrifuged at 130 × g 
for 7 minutes at room temperature. The supernatant was discarded and cells were re-
suspended in fresh GM. For cell counting, cell suspension was prepared in a 1:1 dilution 
in trypan blue stain (Bio Whittaker, Wokingham, UK) and cells were counted with a 
Neubauer haemocytometer (Assistent, Sondheim, Germany). Viable cells excluded the 
trypan blue dye and only the dead cells were stained, confirming a disruption to 
membrane integrity. After cells were counted and the numbers adjusted for dilution and 
stock volumes, cells were seeded with GM in a dish or a multi-well dish, pre-coated with 
0.1% gelatine. Working volumes were normally 15 mL of mediums for a T75 flask, 2 mL 
of medium per well for a 6-well multi-dish and 5 mL of medium for a 25 mm culture dish. 
Cell cryopreservation and resurrection 
Optimal freezing of cells depends on minimising intracellular ice crystal formation and 
reducing damage from formation of foci of high-concentration solutes when intracellular 
water freezes. This is achieved by freezing slowly, allowing water to leave the cell, but 
not so slowly that ice crystal formation is encouraged, and thawing rapidly to minimise 
 61 
ice crystal growth and generation of solute gradients formed as the residual intracellular 
ice melts. 
For preparation of cell stocks, confluent cell monolayers were trypsinised and cells 
counted with a Neubauer haemocytometer. Cell numbers were diluted in GM to 5 × 105 
cells/mL. 10% for E14 and 5% for OP9 of dimethyl sulphoxide (DMSO) (BDH, Poole, 
UK) was added dropwise to the cell suspension and cells were transferred to 1 mL 
cryovials. DMSO partially solubilises and stabilises the cell membrane, making it less 
prone to puncture and irreversible damage. This is mainly because it interrupts the lattice 
structure of ice so that fewer ice crystals would be formed. It also draws water out of the 
cells, dehydrating them and protecting intracellular components from ice crystal damage. 
Subsequently, cryovials of E14 cells were placed into freezing chambers (Mr Frosty™ 
which contains isopropanol alcohol) purchased from Nalgene (Rochester, NY, USA). 
These chambers were placed into a box of ice for 15 minutes, then at -20 ºC for 3 hours, 
and then transferred for overnight storage at -80 ºC. This procedure allows gradual 
freezing of the cells at a rate of -1 ºC/min, which allows the reduction in metabolism of 
the cells as well as enhanced survival upon resuscitation. Following overnight incubation 
at -80 ºC, cryovials were transferred to liquid nitrogen for long-term storage. The growth 
of ice crystals is reduced in liquid nitrogen, thus enhancing cell survival during long-term 
storage. On the other hand, cryovials of OP9 cells were placed into a box of ice for 15 
minutes then the freezing chambers were transferred for long-term storage at -80 ºC.  
For restoring cell stocks from liquid nitrogen, cryovials were placed at room temperature 
in a cell culture safety cabinet until thawed and cell suspension quickly transferred to a 
0.1% gelatine pre-coated flasks or dishes containing warm GM. 
Prevention of Cross-Contamination of Cells 
It is important to prevent and detect cross-contamination as it will severely affect the 
outcome of the experiments and invalidate the findings. Hence, there are standard 
procedures to follow so as to prevent and detect cross-contamination. These are listed in 
Table 2 on page 62. In this table, cross-contamination is categorised into seven types 
according to the nature of the contaminants: bacteria (Gram+, Gram), yeast, fungus, 
virus, endotoxin, mycoplasma and cellular.  
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Generally, for the studies of this research, all standard procedures were followed, with 
special attention on the cellular type of contamination. These include working with only 
one cell line at a time, thoroughly clean before and after introducing a new cell line into 
the laminar flow hood, sterilising all equipment and follow all standard procedure in 
preparation of all materials, etc. More specifically, to remove or limit the chances of 
cross-contamination, disposable tools were used extensively, whilst non-disposable ones 
were exclusively designated for this research and were kept in a dedicated cabinet.  
Most importantly, alkaline phosphatase staining was used regularly to determine the 
purity of stem cell samples.  
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Table 2. Troubleshooting Cell Culture Contamination 
Common cell culture contaminants, their sources, detection and prevention. 
(Corning, 2013) 
Type Source Detection Prevention 
Bacteria 
(Gram +, 
Gram -) 
 Lab personnel 
 Unfiltered air 
 Humidified 
incubators 
 Purified water 
 Insects 
 Plants 
 Contaminated 
cell stock 
 Media 
 
 Microbial 
culture 
 Gram’s stain 
test 
 Visual 
turbidity 
 pH becomes 
acidic 
 
 Aseptic technique 
 Antibiotics 
 Filtration (< 0.22 μm) 
 Use sterile products 
 Disinfection of CO2 incubators 
 Daily cleaning of hood space with 70% 
alcohol as well as monthly cleaning with 
10% bleach.  
 Daily, or at minimum weekly emptying of 
used media traps. 
 Store cell line stocks in vapour phase of 
LN2,  not in liquid phase 
 
Yeast  Humidified 
incubators 
 Lab personnel 
 Unfiltered air 
 Contaminated 
cell stock 
 
 Microbial 
culture 
 Visual 
turbidity 
 
 Aseptic techniques 
 Antimycotics 
 Filtration (< 0.5 μm) 
 Use sterile products 
 Disinfection of CO2 incubators 
 Daily cleaning of hood space with 70% 
alcohol as well as monthly cleaning with 
10% bleach.  
 Daily, or at minimum weekly emptying of 
used media traps. 
 Store cell line stocks in vapour phase of 
LN2,  not in liquid phase 
 
Fungus  Fruit 
 Cellulose 
products 
(cardboard) 
 Plants 
 Unfiltered air 
 Lab personnel 
 Contaminated 
cell stock 
 
 Microbial 
culture 
 Visual 
particulates, 
visual mycelia 
 
 Aseptic technique 
 Antimycotics 
 Filtration (< 0.5 μm) 
 Use sterile products 
 Daily cleaning of hood space with 70% 
alcohol as well as monthly cleaning with 
10% bleach.  
 Daily, or at minimum weekly emptying of 
used media traps. 
 Store cell line stocks in vapour phase of 
LN2, not in liquid phase 
 
Virus  Original 
tissues 
 Serum 
 Cross-
contamination 
 Lab personnel 
 
 Co-cultivation 
 PCR 
 Electron 
microscopy 
 In vivo testing 
 Assays 
 
 Aseptic technique 
 Ultrafiltration 
 Chemical treatment 
 Gamma irradiation or GI serum 
 Avoid using animal-derived products 
 Store cell line stocks in vapour phase of 
LN2, not in liquid phase 
 
Endotoxin  Serum 
 Bacterial 
contamination 
 Contaminated 
or not properly 
maintained 
water supply 
 
 Limulus 
amoebocyte 
lysate (LAL) 
assay 
 
 Aseptic technique 
 Ultrafiltration (< 5,000 daltons) 
 Affinity chromatography 
 Avoid using animal-derived products 
 
Mycoplasma  Contaminated 
cell lines 
 Serum 
 Media 
 Lab personnel 
 
 Hoechst stain 
 Microbial 
culture 
 Specialized 
kits 
 PCR 
 
 Aseptic technique 
 Antibiotics 
 Ultrafiltration (< 0.04 μm) 
 Use sterile products 
 Avoid using animal-derived products 
 Store cell line stocks in vapour phase of 
LN2,  not in liquid phase 
 
Cellular  Cross-
contamination 
of cultures 
 Cross use or 
sharing of 
media from a 
different cell 
line. 
 
 Cell 
authentication 
to determine 
identity and 
species of 
cells 
 
 Work with only one cell line at a time 
 Thoroughly clean before and after 
introducing a new cell line into the laminar 
flow hood 
 Store cell line stocks in vapour phase of 
LN2,  not in liquid phase 
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2.2.2 Cell proliferation assay by cell counting  
Cell proliferation of OP9 stromal cells and ESCs (E14) was evaluated by both 
conventional haemocytometer cell counting and alkaline phosphatase staining. 
To prepare cell cultures for the experiment to assess the effects exerted by VD3 on cell 
proliferation of pluripotential OP9 and E14 cells by conventional haemocytometer cell 
counting, confluent cultures of OP9 and E14 cells were first formed in separated T75 
flasks following the procedures described above. 6-well plates were pre-coated with 2 mL 
of gelatine. Those prepared for OP9 cells were incubated overnight at 37 ºC, and those 
for E14 cells were incubated for 45 minutes at room temperature. Excess gelatine was 
then aspirated.  
For cell plating, adherent cells on the T75 flasks were collected following trypsinisation, 
and were counted using a haemocytometer in the presence of trypan blue dye. Cells were 
then seeded at 80 × 103 cells in 2 mL GM per well of six-well plates. These were divided 
into two sets containing separate samples of OP9 and E14 cells. For each set, VD3 was 
added to the media in different wells at the concentrations of 1 nM, 10 nM and 100 nM, 
respectively, for both OP9 and E14 samples. One set of samples were then incubated for 
48 hours, and the other set 72 hours, before cell counting was performed. 6-well plates 
were incubated in a fully humidified atmosphere with 5% CO2 at 37 ºC. The control 
samples were prepared in the same way but without the addition of VD3. 
After the respectively designated periods of incubation, the samples were processed for 
cell counting. First, culture medium of each confluent 6-well plates was aspirated and the 
medium was saved in separate 15 mL tube (Lynch et al., 2011). Cells were then washed 
with PBS to remove any remaining serum. The samples were trypsinised with 0.25% 
trypsin / EDTA for 3-5 minutes at 37 ºC to detach cells adhered to the substrate, and the 
cells were then re-suspending in pre-warmed GM (in at least 1:1 ratio of trypsin:GM) to 
deactivate the action of the trypsin. Each medium removed during aspiration was then 
added back to the same sample (ibid.). OP9 cell samples were then centrifuged at 130 × g 
for 7 minutes at room temperature, whilst E14 cells samples were spun at 750 rpm for 5 
minutes at room temperature. The supernatant was discarded and cells were re-suspended 
in a 1:1 dilution in trypan blue stain to stain the dead cells before being counted with a 
Neubauer haemocytometer to obtain the results.  
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2.2.3 Alkaline phosphatase staining for the determination 
of pluripotency  
Principle 
Alkaline phosphatase (AP) is a hydrolase enzyme responsible for dephosphorylating 
molecules such as proteins, nucleotides and alkaloids under alkaline pH condition. In 
general, alkaline is located at the cell surface and is linked to the cell membrane. Thus, it 
is widely used as a stem cell membrane marker. Elevated expression of this enzyme is 
associated with undifferentiated pluripotent cells and stem cells (Macgregor et al., 1995). 
Cultures used to effectively propagate undifferentiated ESCs contain cells that can form 
single-cell-derived colonies of AP+ cells. In addition, it was shown that decreased 
expression of alkaline phosphatase enzyme is associated with differentiated ESCs 
(O’Connor et al., 2008). There are various methods for detecting AP, such as methods 
based on enzymatic reaction following visualisation with fast red violet dye. The dye is a 
cell-permeable chromogenic substrate for alkaline phosphatase that is non-toxic to cells, 
diffusing out over the course of one hour. Undifferentiated cells appear red or purple, 
whereas differentiated cells appear colourless. This feature provides a simple, sensitive, 
and rapid assay for the visualisation of undifferentiated pluripotent cells and colonies. 
Method 
To assess the effect of VD3 on cell proliferation of OP9 stromal cells and ESCs, 6-well 
plates were used. Separate sets of plates containing OP9 and E14 cells respectively were 
used. For the samples of each cell, one set was to be incubated for 48 hours and the other 
72 hours. Each set contained samples with 1 nM, 10 nM and 100 nM of VD3, respectively, 
as well as controls that had no VD3 added. The experiment was triplicated.  
The wells on the 6-well plates were pre-coated with 2 mL of 0.1% gelatine. Those to be 
containing OP9 were incubated overnight at 37 ºC and those to be plated with ESCs were 
incubated for 45 minutes at room temperature. Excess gelatine was then aspirated.  
For cell plating, the confluent cultures of OP9 and E14 cells were first formed following 
the procedures described before. The adherent cells on the plates or in the flasks were 
collected following trypsinisation, and were counted using a haemocytometer in the 
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presence of trypan blue dye. Cells were then seeded at 80 × 103 cells in 2 mL GM per 
well with or without VD3. VD3 was added to the media at the concentrations of 1 nM, 10 
nM, and 100 nM, respectively. 6-well plates were then incubated for either 48 or 72 hours 
in a fully humidified atmosphere with 5% CO2 at 37 ºC. 
After designated periods of incubation, the medium was aspirated and the cells were 
washed twice with PBS and fixed with methanol for 10 minutes. Excess methanol was 
then aspirated. For cell staining, 0.0012 g of Napthol (Sigma, Steinheim, Germany) was 
added into 30 mL of Tris (pH 9.2), 1200 µL of Dimethylformamide (Sigma) was added 
to dissolve the Napthol and then 0.0012 g of Fast Red TR salt (Sigma) was added to the 
solution immediately before use. Sufficient staining solution was added to cover the plates 
(22.5 mL) for 30 minutes. The stain was aspirated, and the plates were washed with 
H2O. After drying, alkaline phosphatase colonies were counted. Undifferentiated cells 
appeared red or purple, whereas differentiated cells appeared colourless. The results were 
evaluated in conjunction with the control. Optimum staining was obtained by developing 
the substrate in the dark.  
2.2.4 Cell cycle examination by flow cytometric analysis 
Principle 
Flow cytometric analysis or flow cytometry (FCM) is useful in counting and examining 
the properties of cells. The instrument for performing flow cytometry is called a flow 
cytometer, and it consists of the fluidic, optics and electronic systems, as illustrated in 
Figure 13. 
 
 
Figure 13. A schematic representation of the mechanisms of flow cytometry  
(Source: http://www.bdcompany.com/) 
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As illustrated in the figure, cells are injected into a hydro-focused stream of liquid and 
passed under a spot hit by a laser beam. The laser beams scattered by the passing cells are 
then picked up by detectors pointing at the same spot. Forward scatter (FSc) is picked up 
by the detector situated directly opposite the laser source, and it is an indication of the 
size of the cell, whilst side scatter (SSc) is picked up by detectors aimed perpendicular to 
the incoming laser beam, and this provides information on the inner complexity of the 
cell. Furthermore, fluorescent detectors may also be used to collect information on 
fluorescent chemicals found in cells, including the ones added to cells as required. For 
instance, to use FCM for the examination of cells in different phases of the cell cycle, a 
fluorescent intercalating agent, propidium iodide (PI), is added to the sample. It binds to 
DNA between the bases, and its fluorescence is intensified. Thus the intensity of the 
fluorescence of the PI-treated sample observed using FCM can reveal information about 
its DNA contents, as well as its phase in the cell cycle.  
There are different phases in the cell cycle. In the G1 phase, cell division has not yet 
started. In the S-phase, there is DNA replication, so the cell has more DNA than in the 
G1 phase. In the G2 phase, the DNA is fully replicated, and in the M phase, mitosis is 
underway, so a cell in either one of these two phases has twice the DNA it has in the G1 
phase. In FCM with PI, the more DNA bases there are, the higher the intensity of 
fluorescence there will be (Moore et al., 2010). So, if a batch of cells has been induced to 
differentiate, cells in the G1 phase will accumulate, so their percentage will be higher 
than those in the other phases, and the intensity of fluorescence will be reduced.  
Method  
To analyse the effect of VD3 on the cell cycle distribution of OP9 stromal cells and ESCs 
(E14), respectively, in the proliferation phase, confluent cultures of separated OP9 and 
E14 cells were first formed in T75 flasks and monolayer were washed with PBS and cells 
were detached with trypsin, as described above. Cells were counted then seeded at 
500 × 103 cells in 5 mL GM in 25mm plates with or without VD3 and incubated for either 
48 hours or 72 hours. For the treatments, VD3 was added to the media at the 
concentrations of 1 nM, 10 nM, and 100 nM, respectively. Plates were incubated in a 
fully humidified atmosphere with 5% CO2 at 37 ºC.  
For cell cycle analysis, after designated periods of incubation, trypsinsation and 
neutralisation, cells were harvested in 15 mL centrifuge tubes and pelleted by 
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centrifugation for 7 minutes at 130 × g for OP9 cells and for 5 minutes at 750 rpm for 
E14 cells. The supernatant was removed, and cells were washed with PBS and 
centrifuged. After centrifugation, the PBS supernatant was removed and cells were fixed 
with 3 mL of 75% ethanol. This was added in a drop wise manner to the cell pellet while 
vortexing (ethanol facilitates PI to intercalate into double-standard DNA). Samples were 
stored at -20 ºC overnight before centrifugation and removal of the ethanol supernatant. 
Cells were washed twice with PBS and 1 mL of PBS was retained with the cell pellet to 
enable re-suspension. Cells were mixed and transferred to 3 mL BD Falcon flow 
cytometry tubes (BD Biosciences, San Jose, CA, USA). 50 μl of ribonuclease A (RNase) 
and 10 µL of PI were added to the cell solution. RNase treatment was necessary as PI is 
also able to bind to RNA molecules. After 30 minutes of incubation at room temperature, 
samples were stored at 4 ºC before flow cytometric analysis was performed. 
Analysis 
Flow cytometric analysis was performed using the Cell Quest Pro software. Cell cycle 
was analysed using ModfitTM software (Verity Software House, Topsham, ME, USA), 
which allows analysis of cells in the G1/S/G2/M phases of the cell cycle. 
2.2.5 Materials, general equipment and specialist software 
used 
The materials, general equipment and specialist software used in this study are 
summarised below.  
Chemicals, solvents and reagents 
Unless otherwise stated, all general equipment, chemicals and solvents (analytical 
‘AnalaR’ or molecular biology/tissue culture grade) were purchased from Sigma (Poole, 
U.K.), Fisher Scientific (Leicestershire, UK), BDH (Poole, UK) and BD Biosciences (San 
Jose, CA, USA). 
Cell culture 
All cell culture experiments were performed under a Class II microbiological safety 
cabinet (Labcaire SC-R Recirculating Class II, North Somerset, UK). All cell incubations 
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were performed in Triple Red Laboratory Technology Nuaire DH Autoflow CO2 Air 
Jacketed Incubator (Buckinghamshire, UK). Liquid, medium and supernatants were 
discarded using an IBS Integra Biosciences Vacusafe Comfort (Chur, Switzerland). All 
solutions used for cell culture were prepared with distilled water from Elgastat Option 4 
water purifier (Elga Ltd, High Wycombe, UK). 
Cell culture reagents 
Sterile cell culture medium and supplements were purchased as follows: 
Dulbecco’s modified Eagle’s medium (DMEM), Knockout Serum replacement, and Non-
essential amino acid solution (NEAA) were purchased from Invitrogen (Paisley, 
Scotland).  
Minimum Essential mediums (No Nucleosides), powder (α MEM) was purchased from 
Invitrogen. Defined Foetal Bovine Serum HyClone, Heat-inactivated, (FBS) was 
purchased from Thermo Fisher Scientific (UK). Foetal bovine serum was purchased from 
Invitrogen, 1,25-dihydroxyvitamin D3 and May-Grunwald Giemsa staining, Napthol, 
Dimethylformamide Fast Red (TR) salt, and RNase were purchased from Sigma-Aldrich 
(England). Human LIF was purchased from Millipore (UK). 
The supplements L-glutamine, penicillin streptomycin solution and trypsin/EDTA, 
gelatine type A porcine skin were purchased from Invitrogen, and phosphate buffered 
saline (PBS) from Oxoid Ltd. (Basingstoke, UK). All solutions were prepared non-sterile 
in distilled water and were sterilised by autoclaving at 121 ºC in a bench top autoclave 
from Prestige Medical (Birmingham, UK) before usage in cell culture.  
Plastic wares  
Tissue culture flasks (T25 and T75), 6-well Nunclon™ Δ surface multi-well dishes were 
purchased from Nunc Life Sciences, Thermo Fisher Scientific (Rockslide, Denmark). 
Cryogenic vials, 15 mL and 50 mL sterile centrifuge tubes, cell scrapers and pipette tips 
for tissue culture, biochemistry and flow cytometry were purchased from Fisher Scientific 
(Loughborough, UK). 1.5 mL tubes were purchased from Eppendorf (Hamburg, 
Germany) Syringes were purchased from Terumo (Leuven, Belgium) and syringe filters 
(0.22 µM) from Corning (Lowell, MA, USA). 
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3 mL BD Falcon flow cytometry tubes were purchased from BD Biosciences (San Jose, 
CA, USA). Flow Cytometry was performed on BD FACSCalibur™ (Becton Dickinson, 
Franklin Lakes, NJ, USA) with Cell Quest Pro Software (Becton Dickinson, Franklin 
Lakes, NJ, USA). Cell cycle analysis was performed using Modfit™ software (Verity 
Software House, Topsham, ME, USA). Reagents for Flow cytometry were purchased 
from BD (BD Biosciences, San Jose, California, USA). 
Haemocytometer 
Cell proliferation assay was performed using trypan blue from Life Technology, 
haemocytometers from Abcam plc and the Leica DMI6000B microscope.  
Live imaging microscopy 
Live imaging microscopy was performed using Leica DMI6000B microscope equipped 
with an autoflow incubator, CO2 controller, heating unit and temperature controller, thus 
allowing maintenance of a fully humidified atmosphere with 5% CO2 at 37 ºC. Videos 
were generated and exported using the Leica Application Suite software (Wetzlar, 
Germany).  
Flow cytometry 
Flow Cytometry was performed using a BD FACSCalibur™ (Becton Dickinson, Franklin 
Lakes, New Jersey, USA) with Cell Quest Pro Software (Becton Dickinson). Cell cycle 
analysis was performed using Modfit™ Software (Verity Software House, Topsham, 
Maine, USA). Reagents for flow cytometry were purchased from BD (BD Biosciences, 
San Jose, California, USA).  
2.2.6 Statistical Analyses 
Statistical analyses and significance of data were determined using GraphPad Prism 
version 5.00 (GraphPad Software, San Diego, California USA, www.graphpad.com). 
Statistical significance for the difference between two contrasting measurements was 
determined with a two-way ANOVA, where p<0.05 were considered significant. This 
was followed up by examining the statistical significance for interactions between more 
than two groups within the factor with Bonferroni post-hoc analysis. 
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2.3 Results 
2.3.1 Cell Proliferation assay by cell counting 
The effect of VD3 on OP9 cells in the proliferation phase 
The anti-proliferation effect of VD3 on OP9 cells was tested through cell counts of OP9 
samples after 48 hours and 72 hours of incubation with various VD3 levels. The results 
are presented in Figure 14 below. Values in the figure represent cell numbers for the 
control and samples with different VD3 concentrations (1 nM, 10 nM and 100 nM) after 
48 and 72 hours of incubation, as well as some statistic results. Data are representative of 
3 experiments with 3 measurements each. 
OP9 Cells 
 
Figure 14. The anti-proliferative effects of VD3 on OP9 cells 
Comparisons between the control and VD3-treated groups after 48-hour and 72-hour 
incubations show significant decreases in the number of OP9 cells in both 10 nM 
(p<0.01) and 100 nM (p<0.001) of VD3 whilst significant decrease in the sample with 
1 nm of VD3 only occurs after 72-hour incubation.  
N = 9. (+: p < 0.05; *: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
As shown in Figure 14 above, the p-values suggest that there was significant decrease in 
the numbers of OP9 cells after 48-hour incubation in the samples with two higher VD3 
concentrations, of 10 nM and 100 nM, respectively, compared with the control. The p-
value for the 1 nM treatment compared to the control was only marginally higher than the 
0.05 threshold. Similar results were obtained when the cells were incubated with VD3 at 
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the same concentrations for 72 hours. In this case, there was significant decrease in the 
numbers of OP9 cells in all three levels of VD3 concentrations compared to the control.  
The effect of VD3 on E14 cells in the proliferation phase 
An experiment similar to the one above was also done on E14 cells, and the results are 
presented in Figure 15 below. Values in the graph represent cell numbers after incubation 
for the control and VD3 at different concentrations (1 nM, 10 nM and 100 nM) for 48 and 
72 hours, as well as some statistic results. Data are representative of 3 experiments with 
3 measurements each.  
E14 Cells 
 
 
 
Figure 15. The anti-proliferative effects of VD3 on E14 cells  
Comparisons between the control and VD3-treated groups after 48-hour and 72-hour 
incubations show significant decreases in the number of E14 cells in both 10nM 
(p<0.01) and 100nM (p<0.001) of VD3.  
N = 9. (+: p < 0.05; *: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
As shown in Figure 15 above, the p-values suggest that there was significant decrease in 
the numbers of E14 cells after 48-hour incubation in the samples with two higher VD3 
concentrations, of 10 nM and 100 nM, respectively, compared with the control. Even the 
rounded p-value for the 1 nM treatment compared with the control was equal to the 
threshold. Same results were obtained when the cells were incubated in VD3 at the same 
concentrations for 72 hours.  
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Summary 
In both cell proliferation assays on OP9 and E14 cells, there were significant decreases in 
the numbers of respective cells in the samples with higher concentrations of VD3 
compared with the control, and the decrease was most prominent in the samples with 
100 nM of VD3. In other words, the higher the concentration of VD3 was, the more 
suppressed cell proliferation would be, and this applied to both cell lines. This showed 
that cell proliferation in both cell lines had been suppressed by the presence of VD3.  
2.3.2 Alkaline phosphatase staining for the determination 
of differentiation 
The effect of VD3 on OP9 cell differentiation 
The influence of VD3 on cellular proliferation and its extent, if any, were qualitatively 
investigated by the visual staining of alkaline phosphate. Cells were cultivated in a growth 
medium containing VD3 at various concentrations (1, 10 and 100 nM) for 48 or 72 hours. 
Alkaline phosphatase is associated with undifferentiated cells, and decreased expression 
of the enzyme is associated with differentiated cells. The specific localisation of the 
staining inside cells was considered to be indicative of the presence of undifferentiated 
cells (Macgregor et al., 1995). In contrast, in the absence of such a stain (i.e. colourless 
cells) it was assumed that these cells have differentiated into other types of cells 
(O'Connor et al., 2008).  
The results of alkaline phosphatase staining of OP9 cells are shown in Figure 16 and 
Figure 17 below. A reduction in the staining colour was manifest when comparing the 
effect of VD3 at 1 nM, 10 nM, and 100 nM concentration as compared to the control at 
both 48 and 72 hours. The large area of colourless cells demonstrated that VD3 may have 
inhibited cell proliferation and increased cell differentiation. This finding was associated 
with a morphological change in cells displaying reduced proliferation as cells were shown 
to be more rounded (Wolins et al., 2005). 
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OP9 with VD3 for 48 Hours 
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Figure 16. The result of alkaline phosphate staining assay showing the anti-proliferation effect 
of VD3 on OP9 cells after 48 hours of incubation  
A reduction in the staining colour was manifest when comparing the effect of VD3 
incubation at 1 nM (B), 10 nM (C) and 100 nM (D) concentrations with the control 
(A). The undifferentiated cells in (A) are shuttle-shaped whilst the differentiated ones 
in (D) are more rounded. N = 9. 
 
OP9 with VD3 for 72 Hours 
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Figure 17. The result of alkaline phosphate staining assay showing the anti-proliferation effect 
of VD3 on OP9 cells after 72 hours of incubation   
A reduction in the staining colour was manifest when comparing the effect of VD3 
incubation at 1 nM (B), 10 nM (C) and 100 nM (D) concentrations to the control (A). 
N = 9. 
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The effect of VD3 on E14 cell differentiation 
As shown in Figure 19 below, a similar trend of staining degree and density was also 
found in the experiments with E14 cells compared to the ones with OP9 cells described 
above. This finding was associated with a morphological change of cells displaying 
reduced proliferation.  
E14 with VD3 for 48 Hours 
 
   
 Control 1 nM  
   
 10 nM 100 nM  
Figure 18. The result of alkaline phosphate staining assay showing the anti-proliferation effect 
of VD3 on E14 cells after 48 hours of incubation  
A reduction in the staining colour was manifest when comparing the effect of VD3 
incubation at 1 nM (B), 10 nM (C) and 100 nM (D) concentrations to the control (A). 
N = 9. 
 
E14 with VD3 for 72 Hours 
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Figure 19. The result of alkaline phosphate staining assay showing the anti-proliferation effect 
of VD3 on E14 cells after 72 hours of incubation  
A reduction in the staining colour was manifest when comparing the effect of VD3 
incubation at 1 nM (B), 10 nM (C) and 100 nM (D) concentrations to the control (A). 
N = 9. 
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Summary 
In both experiment with OP9 and E14 cells using alkaline phosphate staining, there were 
reduction of staining with increased level of VD3. With the OP9 cell line, there was also 
decrease in shuttle-shaped cells and increase in more rounded and shortened cells. These 
effects were most prominent in samples with 100 nM of VD3. In other words, the higher 
the concentration of VD3 was, the more promoted cell differentiation would be, and this 
applied to both cell lines. This showed that cell differentiation in both cell lines had been 
promoted by the presence of VD3. 
2.3.3 Cell cycle examination by flow cytometric analysis 
The effect of VD3 on the cell cycle of OP9 cells  
To determine the specificity of cell counting and staining methods, and confirm the results 
obtained, cell-cycle analysis was performed using propidium iodide. As shown in Figure 
20 below, there was significant change in the percentage of OP9 cells in the G-phase 
compared to the control, at the respective concentrations of 1 nM, 10 nM and 100 nM 
after 48 or 72 hours of incubation as compared to the control. Moreover, the fact that there 
was a significant increase in the percentage in the G-phase with respect to the S-phase 
following VD3 incubation at the two higher concentrations of 10 nM and 100 nM as 
compared to control confirms that VD3 promotes cell differentiation rather than division.  
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% of G-phase OP9 
 
 
 
 
Figure 20. The effect of VD3 incubation on the percentage of OP9 cells displaying the G-phase 
of cell cycle using flow cytometric analysis after 48 and 72 hours of incubation.  
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
There were significant changes amongst several pairs of measurements with different 
levels of VD3 after 72 hours of incubation, i.e., the control vs. 10 nM of VD3, the control 
vs. 100 nM of VD3, 1 nM of VD3 vs. 100 nM of VD3, and 10 nM of VD3 vs. 100 nM of 
VD3. There was also significant difference between the samples with 100 nM after both 
48 and 72 hours of incubation. Data are derived from 3 experiments. 
Similarly, results were obtained when cells in the S-phase were incubated for 48 or 72 
hours, as shown in Figure 21 below.  
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Figure 21. The effect of VD3 incubation on the percentage of OP9 cells displaying the S-phase 
of cell cycle using flow cytometric analysis after 48 and 72 hours of incubation.  
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
There was significant change in the percentage of cells of the S-phase after 72 hours of 
incubation with 100 nM of VD3 as compared to the control and the treatments with 1 nM 
and 10 nM of VD3, respectively. There was also significant difference between the 
samples with 100nM after both 48 and 72 hours of incubation. Data are derived from 3 
experiments. 
The effect of VD3 on the cell cycle of E14 cells 
As shown in Figure 22, a similar trend was found in the cell cycle analysis of E14 cells 
to those with OP9 cells after 48 or 72 hours of incubation with 100nM of VD3. There was 
a significant increase in the percentage of cells in the G-phase with 100 nM of VD3 
comparing to the respective controls.  
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Figure 22. The effect of VD3 incubation on the percentage of E14 cells displaying the G-phase 
of cell cycle using flow cytometric analysis after 48 and 72 hours of incubation.  
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
There was significant change in the percentage of cells of the G-phase after 72 hours of 
incubation with 100 nM of VD3 as compared to the control and the treatments with 1 nM 
and 10 nM of VD3, respectively. Data are derived from 3 experiments. 
Again, as shown in Figure 23 below, a similar trend was found in the cell cycle analysis 
of E14 cells in the S-phase to the corresponding tests with OP9 cells.  
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Figure 23. The effect of VD3 incubation on the percentage of E14 cells displaying the S-phase 
of cell cycle using flow cytometric analysis after 48 and 72 hours of incubation.   
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
There was significant change in the percentage of cells of the S-phase after 72 hours of 
incubation with 100 nM of VD3 as compared to the control and the treatments with 1 nM 
and 10 nM of VD3, respectively. Data are derived from 3 experiments. 
Summary 
In both cell cycle examinations with the OP9 and E14 cell lines, there were significant 
increases in the percentage of cells in the G phase and significant decrease in the 
percentage of cells in the S phases with the presence of VD3 compared with the control 
after 72 hours of incubation, whilst similar trends of changes were not significant with 
only 48 hours of incubation. These changes were more prominent in the samples with 
higher concentrations of VD3.  
In other words, after 72 hours of incubation, the higher the VD3 concentration was, the 
higher percentage of cells in the G phase and the lower percentage of cells in the S phase 
there would be, and this applied to both cell lines. This showed that cell differentiation in 
both cell lines had been promoted by the presence of VD3  
*** 
** 
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2.4 Discussion 
This was the first study into the effects of VD3 on E14 embryonic stem cells and OP9 
stromal cells, respectively, in inhibiting proliferation and encouraging differentiation 
through cell cycle manipulation.  
In the cell proliferation assay, with the results of the separate OP9 and E14 cell counts, it 
was found that there was a correlation between the decrease of cell counts and the 
presence of higher level of VD3 concentration, suggesting that VD3 was related to the 
inhibition of the proliferation or the promotion of the differentiation of the OP9 cells. 
There was also a correlation between the decrease of cell counts and the presence of 
higher level of VD3 concentration, suggesting that VD3 was also related to the inhibition 
of the proliferation or the promotion of the differentiation of the E14 cells. Therefore, as 
shown in the results presented in Section 2.3, the statistically significant cell-number 
decreases for both OP9 and E14 cells suggested that VD3 promoted cellular 
differentiation and inhibits cellular proliferation. 
In the study on the determination of pluripotency by alkaline phosphatase staining, the 
level of staining was reduced with increased level of VD3 in E14 and OP9 cells, 
respectively. This suggested that the number of cells with pluripotency was reduced with 
increased level of VD3, meaning that many of these cells had differentiated into other 
cells. In other words, cell differentiation had been encouraged by the presence of VD3. 
The result from flow cytometric analysis further confirmed with the consistent findings 
about the role of VD3 in promoting cellular differentiation, i.e., the likelihood of cellular 
differentiation depends primarily on VD3 level and the period of incubation. This also 
suggested that VD3 might act directly or indirectly to elicit a cellular arrest in G-phase 
and drive cells to differentiation. 
Overall, these findings of the anti-proliferation and pro-differentiation effect of VD3 are 
in agreement with previous in vitro studies using squamous cell carcinoma (Hershberger 
et al., 1999), prostrate adenocarcinoma (Getzenberg et al., 1997), cancer of the ovary 
(Zhang et al., 2005), cancer of the breast (Colston et al., 1992) and cancer of the lung 
(Nakagawa et al., 2005), as well as with previous research in apoptosis (Simboli-
Campbell et al., 1996), angiogenesis (Mantell et al., 2000) and in the role of VD3 in cell 
cycle perturbation and anti-proliferation (Hiroshi et al., 2012). In line with the findings 
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of these researches, the findings from the study presented in this chapter demonstrated 
that the proliferation phases of both OP9 stromal cells and ESCs of the E14 cell line were 
inhibited by VD3.  
This is in agreement with the findings of previous studies showing that VD3 inhibits cell 
proliferation by mediating cell cycle arrest. The cell’s entry into the S phase is controlled 
by the activity of CDK2, cyclin E and cell division cycle 25A (CDC25A) phosphatase 
(Brenner et al., 2014; Santoni-Rugiu et al., 2000; Iavarone and Massague, 1997). VD3 
stops this from happening by preventing the activation of three related complexes, i.e., 
G1 phase complexes cyclin D1-CDK4 (Brookes et al., 2015; Asghar et al., 2015; Kliewer 
et al., 1992; Carlberg, 1996) and G1-S governing complexes of cyclin E-CDK2 and cyclin 
A-CDK2 (Tsai et al., 1993; Tsai et al., 1991). This is because VD3 reduces the activities 
of CDC25A phosphatase that regulates CDK2 and CDK4 activities (Busini et al., 2004).  
Studies so far have shown that there are three possible ways through which CDK2 
activation is reduced and entry to the S phase is prevented. In one scenario, VD3 
deregulates cyclin D1-CDK4 kinase activity. This prevents pRb phosphorylation, and 
pRb inaction then leads to E2F sequestration and inactivation. This prevents cyclin A and 
E protein expression (Narasimha et al., 2014; Jenson et al., 2000; Helin, 1998; Nevins, 
1998; Zhang et al., 1999), so CDK2 activation is consequently prevented.  
In another scenario, CDK2 activation can also be stopped by the induction of p21. VD3 
is known to induce the expression of p21 (Paydas et al., 2014; Cozzolino et al., 2001; Liu 
et al., 1996; Zhuang and Burnstein, 1998; Verlinden et al., 1998), which is a key molecule 
in blocking cellular proliferation (Fecteau et al., 2014; Liu, Hu and Chakrabarty, 2009). 
This is done through the induction of p21 transcript via a mechanism related to VDR 
(Milczarek et al., 2014; Liu et al., 1996). The increase in p21 protein prevents the 
activation of CDK2 (Bian and Li, 2012). Additionally, the increased p21 protein 
contributes to the failure of CDK2 activation and possibly prevents CAK (CDK activating 
kinase) activation of CDK2 (Mueller et al., 2015; Lolli and Johnson, 2005; Jenson et al., 
2000; Hitomi et al., 1998).  
Alternatively, CDK2 activity could also be stopped by the reduction in c-Myc gene 
expression because c-Myc induces CDK2 activity (Jackstadt and Hermeking, 2014; 
Dang, 1999). Activation of the ERK2 (extracellular-signal-regulated kinase 2) pathway 
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might cause down-regulation of c-Myc gene expression and thus stops CDK2 activation 
(Roskoski Jr, 2012; Busini et al., 2004).  
Moreover, a similar phenomenon was reported for p27 in inhibition of CDK4 (Kato et 
al., 1997) and CDK6 and subsequently CDK2 (Wang et al., 1997). This is because p27 
potently prevents Rb from being phosphorylation by cyclin E-CDK2, cyclin A-CDK2, 
and cyclin D2-CDK4 (Polyak et al., 1994). The increase in p27 protein level was 
dependent on the concentration of VD3 and was accompanied by an increase in cyclin D 
and E proteins, which normally peak in mid-G1 and at the G1 to S-phase transition, 
respectively (Wang et al., 1996). Thus, CDK6 and CDK2 activities are regulated by VD3 
(Wang et al., 1997). 
Therefore, exposure to VD3 induced cell cycle arrest, accompanied by upregulated protein 
expression of the cyclin-dependent kinase inhibitor (CDKI) p21 and p27 (Verlinden et 
al., 1998; Campbell et al., 1997). VD3 treatment leads to marked up-regulation of p21 
and p27 and marked down-regulation of cyclins, cyclin-dependent kinases and cyclin-
dependent kinase inhibitors. Thus, VD3 up-regulates p21 and p27 as an early event, which 
in turn could block the G1 phase to S phase transition (Kawa et al., 1997). This is because 
p21 and related p27 act as broad spectrum regulators of cyclin dependent kinase function 
by participating in ternary complexes by efficiently interacting with cyclins D1, D2, D3, 
E and A, and to a lesser extent with cyclin B (Hall et al., 1995). 
In summary, VD3 deregulates CDK2 and CDK4 activities. The up-regulation of VD3 level 
leads to the up-regulation of p27, which leads to the prevention of CDK4 activation and 
decreased phosphorylation of pRb. This causes sustained E2F sequestration that 
decreases cyclin A expression. Decrease in cyclin A expression and increase in p21 lead 
to repression of CDK2 activities. Without CDK2 activation, cell cycle will not transit 
from the G1 phase to the S phase, leading to a cell cycle block in the G1 phase. Low 
CDK2 protein level and decreased cyclin E-CDK2 association also contribute to the lack 
of CDK2 activation. It is through this mechanism that the anti-proliferation and pro-
differentiation properties of VD3 are manifested.  
In short, according to related researches, the mechanism of the anti-proliferation and pro-
differentiation effects of VD3 is understood as follows. VD3 bonds to VDR and promotes 
the production of p21 and p27 (Hiroshi et al., 2012). This promotes the production of 
CDK inhibitory protein (Harper et al., 1993; Toyoshima and Hunter, 1994). This inhibits 
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the phosphorylation of pRb (Kanatani et al., 1999) and reduces its amount. This in turn 
prohibits the binding of E2F-1 to its target gene, and compromised the production of 
cyclin E. Thus the cell cannot transit from the G1-phase to the S-phase (Hager et al., 
2001; Verlinden et al., 1998), so the cell differentiates rather than proliferates.  
 
Figure 24. Possible ways through which VD3 stops the entry to the S phase   
(Source: Adopted from Moore, Knight and Blann, 2010: 273 with modification) 
 
2.5 Conclusion 
As presented and discussed above, separate investigations had been carried out to find 
out the effects of VD3 on the proliferation phase of the E14 cell line and on stromal OP9 
cells, respectively, and it was found that optimal concentration, 100 nM in these cases, of 
VD3 was crucial in promoting differentiation and suppressing proliferation of both 
isolated E14 and OP9 cells in these in vitro studies. This was the first demonstration of 
the anabolic effect of VD3 on murine OP9 and E14 cells, respectively, in vitro. 
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Chapter 3 The Effects of VD3 on E14 / OP9 
Co-culture in Vitro 
 
3.1 Introduction 
The findings from the study presented in the previous chapter have demonstrated that 
VD3 has the effect of curtailing the proliferation and promoting the differentiation of E14 
and OP9 cells, respectively. Specifically, it was found that the optimal concentration of 
VD3 to reduce proliferation and promote differentiation was 100 nM.  
However, it remains to be determined whether this vitamin is able to influence both the 
early and the late phases of haematopoiesis of ESCs (E14) in the co-culture with OP9. 
Hence further studies need to be conducted to ascertain the validity of the hypothesis that, 
in the co-culture of ESCs and OP9 stromal cells, the presence of VD3 enhances the 
differentiation of ESCs into blood cells of erythroid, myeloid, and B cell lineages without 
adding exogenous growth factors.  
Hence, in this part of the research, the presence of early haematopoietic progenitors in 
ESC (E14) / OP9 co-culture in the presence of VD3 was monitored through the evaluation 
of CD-marker expressions, colony-forming cell (CFC) counts, haematopoiesis-associated 
gene and cytokine expressions on ESCs at key days between days 2 and 12 of 
differentiation. 
The materials and equipment used for the studies, the methods and protocols adopted for 
experimental preparation and analyses, the results obtained from the experiments, and the 
discussion based on the results are presented in this chapter.  
3.2 Principles and Methods 
3.2.1 Materials and general equipment used 
The sources of the cell culture, reagents, solvents, chemicals and plastic wares used in 
this study are the same as the ones mentioned in the first four parts of Section 2.2.5.  
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3.2.2 E14 / OP9 Co-culture Preparation 
The E14 / OP9 co-culture that was needed for clonogenic progenitor cell assay, flow 
cytometry and real time RT-PCR was prepared with the following procedures.  
Forming of a confluent monolayer of OP9 cells 
A confluent layer of OP9 cells was prepared before E14 cells were added to it. After the 
formation of confluent culture, half of the medium was changed on days 2 and 3, and cells 
were cultured for an additional 3 to 4 days to obtain the best results.  
Obtaining undifferentiated E14 cells 
Undifferentiated E14 cells were obtained by detaching them from the substrate and 
harvested by washing them twice with PBS and trypsinising them with pre-warmed 
0.25% trypsin-EDTA at 37ºC. Then the cells were re-suspended in the pre-warmed co-
culture differentiation medium composed of 385 mL of Alpha Modification Minimum 
Essential Medium (No nucleosides, αMEM), 50 mL of Foetal Bovine Serum, 250 µL of 
monothioglycerol,  5 mL of non-essential amino acid solution (NEAA), 5 mL of L-
glutamine (200mM final), 5ml of penicillin-streptomycin solution (10.000 units/mL 
penicillin and 10.000 mg/mL), 500 µL of 2-Mercaptoethanol, and 2.2 g/L of sodium 
bicarbonate (in at least 1:1 ratio of trypsin vs. GM) to deactivate the action of the trypsin. 
E14 cells were centrifuged at 750 rpm for 5-7 minutes at room temperature. The 
supernatant was discarded and cells were re-suspended in the aforementioned co-culture 
differentiation medium.  
Adding E14 cells to the confluent monolayer of OP9 cells 
The E14 cells were added to OP9 cultures at a density of 250 × 103 in the 5 mL co-culture 
differentiation medium in 25 mm plates with or without VD3.  Cells were incubated at 
37° C, in fully-humidified air, at 5% CO2, for up to 12 days. VD3 was added to the medium 
at the concentrations of 100 nM. This concentration was chosen because it is the optimum 
value found in healthy individuals, and it was found to have significant effect on the 
differentiation of the cells in the previous experiment.  
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Cells were harvested on after 2, 5, 8, 10 and 12 days of incubation, respectively, and 
single-cell suspension was prepared by washing the cells twice with PBS, followed by 
the treatment with 0.025% trypsin-0.5 mM EDTA for 5 minutes at room temperature. The 
cells were filtered through a 100 µM cell strainer (BD Biosciences) (Vodyanik et al., 
2005), centrifuged, and ready to be used as the control and treatment for clonogenic and 
flow-cytometric assays as well as gene-expression analysis.  
Additional procedures to remove cells of unknown origin 
In very unlikely events, adherent cells of unknown origin might appear on some 
occasions. These cells are disadvantageous for the maintenance of haematopoietic cells, 
because they cover the OP9 layer and inhibit haematopoiesis.  
To avoid this deleterious effect, the induced haematopoietic cells should be processed 
again on days 5, 8 and 10 (Kitajima et al., 2003) with the following procedures. On each 
of these days, after taking the sample designated for the experiments for the day, each of 
the remaining co-culture flasks (for harvesting on subsequent days) was aspirated and the 
aspirated medium was saved with the haematopoietic cells in suspension (Lynch et al., 
2011). The samples were washed twice with PBS, trypsinised with pre-warmed 0.25% 
trypsin-EDTA, and then the cells were re-suspended in the pre-warmed co-culture 
differentiation medium to stop trypdinisation, filtered with a 100 µM strainer, added to 
the differentiation medium saved from aspiration with the suspended haematopoietic cells 
(Lynch et al., 2011), and centrifuged at 750 rpm for 7 minutes at room temperature. The 
supernatant was discarded and the co-culture differentiation medium was added to the 
cells. A 21-gauge blunt-ended needle was used to re-suspend cells to ensure single-cell 
suspension. Then the cells were counted using a haemocytometer. The cell count is 
hypothesised to increase 100-150-fold from day 1 to day 5.  The cells were re-seeded onto 
a new layer of confluent OP9 cells in each flask for subsequent days.   
The co-culture was kept until day 12 to obtain the information on mature haematopoietic 
progenitors.  
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3.2.3 Immunofluorescence 
Principle 
Immunofluorescence is a specific example of immunochemistry. It uses antibodies 
labelled with a fluorescent dye, or fluorochrome, to detect target proteins, i.e., antigens. 
When the fluorescent antibody is combined with the corresponding antigen, the antigen-
antibody complex can be visualised using a fluorescent microscope. The commonly used 
fluorochrome in immunofluorescence is fluorescein isothiocyanate (FITC). It absorbs 
blue rays of wavelength of 488 nm and emits green light of wavelength of 520 nm.  
Sample preparation and fixation 
The objectives of the whole procedure described below are to determine the role of Oct4, 
Nanog and Sox2 as the master regulators of both pluripotency and differentiation of ESC 
(E14) in OP9 co-culture, and to evaluate the effect of VD3 as an accelerator and a 
promoter of early differentiation of E14 in the co-culture. After formation of the confluent 
culture of OP9 in T25 flask, 24-well plates were pre-coated with 0.5 mL of 0.1% gelatine 
and incubated overnight at room temperature. 
Excess gelatine was then aspirated. In order to prepare for cell-plating, adherent OP9 cells 
in the T75 flasks were harvested following trypsinisation with pre-warmed 0.25% trypsin-
EDTA at room temperature, centrifuged, and then counted using a haemocytometer. The 
harvested cells were then seeded in quantities of 1 × 104 cells in 1 mL growth medium 
per well. After formation of confluent cultures of OP9 cells on day 2, half of the medium 
was changed, and cells were cultured for an additional 2 days to obtain the best results.  
To detach cells adhered from the substrate, undifferentiated E14 cells were harvested by 
washing them twice with PBS, and then trypsinised. After that, the E14 cells were re-
suspended in the pre-warmed co-culture differentiation medium. Then the cells were 
centrifuged at 750 rpm for 5-7 minutes at room temperature. The supernatant was 
discarded, the cells were re-suspended in the co-culture differentiation medium and added 
to the OP9 cultures at a density of 1 × 104 cells in 1 mL co-culture differentiation medium 
in 24-well plates either without VD3 or with VD3 at 100 nM concentration. Then the cells 
were incubated in a fully humidified atmosphere with 5% CO2 at 37° C for up to 5 days. 
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Samples were taken from incubation at the end of days 1, 3 and 5. For each well 
containing these samples, the medium was aspirated and the cells were washed twice with 
PBS and fixed with 4% paraformaldehyde (Sigma, St. Lois, MO, USA) in 1× PBS for 10 
minutes. Excess paraformaldehyde was then aspirated. Cells were washed 3 times with 
PBS.  
Blocking 
Diluted blocking serum was prepared with 5% bovine serum albumin (BSA) in PBST, 
which was 500 µL Tween 20 in 1l PBS. Tween 20 was used to permeabilise the cells to 
help the antibodies to get into fixed cells. The prepared blocking buffer was added to 
cover the wells of 24-well plates and incubated for 30 minutes to minimise non-specific 
adsorption of the antibodies. The blocking serum was aspirated, and the plates were 
washed with PBST to remove the excess of BSA.  
Staining and Detection 
Two types of antibodies are used in secondary or indirect immunofluorescence. The 
primary antibodies are raised against an antigen of interest and are typically unconjugated 
(unlabelled), whilst the secondary antibodies are raised against immunoglobulins of the 
primary antibodies. The secondary antibodies are directly conjugated to the fluorochrome 
molecules. Antibodies can be raised in different species. This mechanism is depicted in 
the schematic diagram presented in Figure 25.  
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Figure 25. The schematic diagram of the mechanisms of the indirect and direct methods of 
immunochemical staining 
(Source: http://www.abcam.com/ps/CMS/Images/IndirectVsDirect_1200x615.jpg) 
The primary antibodies used in this study Oct3/4 (C-10), Nanog (A-11) mouse IgG and 
Sox2 (D-17) Goat IgG antibodies (Santa Cruz Biotechnology, UK). Appropriately diluted 
primary antibody solution (in 1:100 ratio of primary antibody vs. 5% BSA/TBST 
blocking buffer) was added to the samples collected on days 1, 3 and 5 of incubation and 
left to incubate overnight to allow the antibodies to attach to the corresponding antigens. 
Afterwards, the excess of primary antibody was aspirated, and the plates were washed 
with PBST 3 times for 3 minutes to remove unbound primary antibody.  
The secondary antibodies used in this study were Goat anti-mouse IgG-FITC and donkey 
anti-goat IgG-FITC (Santa Cruz Biotechnology, UK). Each of these secondary antibodies 
is species-specific to a portion of one of the primary antibodies and is conjugated to 
fluorescent substrate that produces a coloured signal for the identification of the position 
of the bound protein. For fluorescent secondary antibody binding, cells were incubated 
with secondary antibodies (in 1:100 ratio of secondary antibody vs. blocking buffer) for 
60 minutes in darkness before the plates were washed with PBST 3 times for 3 minutes.  
Undifferentiated ESCs, i.e., E14 strictly maintained in an undifferentiated state, were 
prepared alongside the tests and used as the control against which the results of the tests 
were evaluated. Images of both tests and controls were obtained using Leica DMI 6000B 
imaging system and a FITC-fluorescence L5 filter cube (excitation wavelength = 480/40 
nm). This microscope is equipped with an autoflow incubator, CO2 controller, heating 
unit and temperature controller, allowing maintenance of a fully humidified atmosphere 
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with 5% CO2 at 37 ºC. Videos were generated and exported using the Leica Application 
Suite software (Wetzlar, Germany). 
Counterstains  
To help the primary stain stand out, a second stain is often applied after immunochemical 
staining of the target proteins to provide visual contrast. Many of these dyes stain specific 
discrete cellular compartments or antigens, whilst other ones stain the whole cell. Both 
chromogenic and fluorescent dyes are available for immunochemical staining to provide 
a vast array of reagents to fit every experimental design. Commonly used dyes are 
haematoxylin, Hoechst stain and 4’,6-diamidino-2-phenylindole (DAPI). 
HardFSet™ Mounting Medium contains DAPI that binds strongly to AT-rich regions in 
DNA, i.e., a region where the sequence is highly rich in adenine (A) and thymine (T), 
forming a stable complex which fluoresces approximately 20 times greater than DAPI 
alone. This product is a substrate (reporter molecule) designed to be used for procedures 
requiring fluorescent labelling of DNA. DAPI excites at about 360 nm and emits at about 
460 nm when bound to DNA, producing a blue fluoresce through a blue/cyan filter of 
fluorescence microscopy. DAPI can pass through an intact cell membrane, so it can be 
used to stain both live and fixed cells. However, it passes through the membrane of live 
cells less efficiently and thus is less effective in staining live cells. In this study, DAPI 
was used to provide a contrasting background to the blue fluoresce stains of the 
differentiated cells to make the latter easily recognisable. 
An alternative approach of immunofluorescence using an optical 
microscope 
An alternative approach was also adopted for the preparation and detection of 
immunofluorescence. In this approach, to prepare and fix the samples of the tests and 
controls, the E14 cells were harvested after incubation of 24 hours, 3 days and 5 days, 
respectively, and single-cell suspension was prepared by washing the cells with PBS 
twice, trypsinised, filtered through a 100 µM cell strainer (BD Biosciences) and 
centrifuged. Then a pellet was obtained for the use of immunocytochemistry of 24-well 
plates with and without VD3. Cells from the pellet were placed and smeared on slides, 
utilising the common procedure of preparing a blood or bacteria smear for easy staining 
and observation, as shown in Figure 26. Then the slides were dried in the air, and the cells 
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were fixed with 4% paraformaldehyde (Sigma, St. Lois, MO, USA) in 1× PBS for 10 
minutes. Excess paraformaldehyde was then aspirated, and the cells were washed 3 times 
with PBS.   
 
 
Figure 26. Diagram showing the procedure of preparing a blood smear that was employed to 
prepare the plates for immunocytochemistry 
(Source: http://www.ruf.rice.edu/~bioslabs/bios318/smear.gif) 
Afterwards, the fixed samples were stained by dropping staining solutions unto the 
samples and then rinsing off excessive staining solutions in a jar with running water. The 
images of the stained samples were obtained using an optical microscope instead of the 
sophisticated imaging system used in the previous approach.  
3.2.4 Morphological detection of different colony-forming 
cells and CFC counting 
Principle 
May-Grunwald-Giemsa stains are universally employed for routine staining which are 
used to display morphological features and very satisfactory results can be obtained. It 
consists of Methylene Blue (methylthioninium chloride), Azure B (trimethylthionin) and 
Eosin Y (tetrabromo-fluorescein). The compound variations in binding of the dyes to 
chemical structures and interactions amongst themselves can influence the mechanism by 
which definite components of a cell’s composition stain only with particular dyes, and 
every component of the cell is stained in this method. The basic cellular components are 
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stained red-purple by azure. The acidic components of the cell are stained blue by 
methylene. The alkaline components of the cell are stained orange-red by eosin. Thus 
these dyes allow for distinction in shades of staining and for staining granules 
differentially, and this information is useful to distinguish amongst the various 
haemopoietic cells. 
Morphological detection of different colony-forming cells 
Method 
A clonogenic progenitor cell assay was performed to identify and confirm the cell content 
of particular colonies by using May-Grunwald-Giemsa staining. The cells from the 
ESC/OP9 co-culture (prepared according to the preparation method mentioned in Section 
3.2.1) were placed on slides, and the slides were dried in the air. The cells were fixed by 
immersion in a jar of methanol for 5-10 minutes before being transferred for 10-15 
minutes to a staining jar containing May-Grunwald stain that was freshly diluted with an 
equal volume of buffered water. Then the slides were transferred without washing to a jar 
containing Giemsa’s stain that was freshly diluted with 9 volumes of buffered water to 
pH6.8 for 10-15 minutes. The slides were then transferred to a jar containing buffered 
water of pH6.8, rapidly washed in three or four changes of water and finally allowed to 
stand undisturbed in water for a short time for staining differentiation. Samples were then 
thus ready for identification. The morphology of different CFC types was captured in 
images with a Zeiss Axio Imager M1 microscope using the Zen2012 software. 
Colony-forming cell counting 
Method 
To prepare for the sample to be observed after different days of incubation with or without 
VD3, cells from the ESC/OP9 co-culture (prepared according to the preparation method 
mentioned in Section 3.2.1) were seeded at different densities depending on the 
designated days of incubation before observation: 1 to 5 days, 2 × 105 cells/mL; 7 to 8 
days, 5 × 104 cells/mL; and 9 to 10 days, 2 × 104 cells/mL. Undifferentiated ESC cells 
were plated at densities up to 5 × 105 cells/mL, and no CFCs were found.  
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Clonogenic progenitor cell assay was performed to identify and confirm the cell content 
of appropriate colonies. To prepare the samples for counting after designated days of 
incubation, the culture medium was removed from the dishes and flasks containing E14 / 
OP9 co-culture with and without VD3. The remaining colonies were washed once with 
PBS to remove any residual culture media. Cells were fixed by adding 2 mL methanol 
for each plate, incubated for 15 minutes at room temperature before methanol was 
removed and the plate air dried at room temperature for 5 minutes. Then each plate was 
put in 2 mL of May-Grunwald stain freshly diluted with an equal volume of buffered 
water. After staining for 10 minutes at room temperature, 2 mL Giemsa staining freshly 
diluted with 9 volumes of buffered water of pH6.8 was also added, without washing, for 
10-15 minutes. Then the staining solution was removed and each plate was rinsed with 
running distilled water to remove unbound stain until water remains clear. Water was 
removed and the plate was allowed to dry at room temperature, and the sample was then 
ready for identification and counting using the Zeiss Axioimager M1 microscope. All 
clonogenic progenitor assays were performed in duplicate.  
CFCs were scored after incubation according to their colony morphology as erythroid (E-
CFC), granulocyte, erythroid, macrophage, megakaryocyte (GEMM-CFC), granulocyte-
macrophage (GM-CFC), and macrophage (M-CFC). The frequency of CFC was 
calculated per 106 total cells. 
3.2.5 Phenotype analysis by flow cytometry 
One of the major obstacles to the clinical use of ESCs is the difficulty of visually 
distinguishing them from other cell types. The discovery of molecule markers resulting 
from unique gene expression patterns in cells of different types of cells provided a 
valuable tool in the identification of undifferentiated and differentiated ESCs (Moore, et 
al., 2011; Zhao et al., 2012). 
Cell surface markers 
There are specialised proteins expressed on the surface of cells. These proteins have the 
property of being able to bind or adhere to other signal molecules (Zhao et al., 2012). 
Since each type of these membrane proteins has a different structure, its affinity for signal 
molecules is specific. Certain proteins are only present in or expressed by particular cell 
types, so particular proteins on the cell surface can be used as cell markers, and these cell 
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markers are the most important non-invasive and non-destructive tools for the 
identification of ESCs. 
CD antigens 
Cell surface marker antigens are commonly referred to as cluster of differentiation (CD) 
antigens. These are specific groups or cluster of epitopes of cell surface proteins 
belonging to several different classes, such as integrins, which are α/β heterodimeric cell 
surface receptors that mediate the attachment of a cell to its surrounding tissues, adhesion 
molecules, glycoproteins and receptors. Different types of cells have different CD 
antigens, so they can be used as effective tools for the identification and classification of 
different cell populations (Zhao et al., 2012) using anti-CD monoclonal antibody (mAb) 
or antibodies.  
CD antigens are named with their CD numbers. Some of the key CD markers related to 
murine haematopoietic studies and the corresponding monoclonal antibodies selected for 
this study (BD bioscience pharmingen™) are listed in Table 3 below. 
Table 3. The monoclonal antibodies used in this study and the corresponding CD markers 
(Source: BD Biosciences, 2010) 
 
Rat anti-mouse FLK1 FLK1 is monoclonal antibody specifically binds to foetal liver kinase 1, 
also known as VEGF receptor-2 (VEGF-2), a receptor for vascular 
endothelial growth factor (VEGF). It is expressed on distinct sets of 
mesoderm during gastrulation and on endothelial cells in embryonic 
and adult tissues. In vivo and in vitro studies indicate that FLK1 is 
required for the embryonic development of vascular endothelial and 
haematopoietic cells. 
Rat anti-mouse CD31 CD31 is integral membrane protein, a member of the immunoglobulin 
superfamily, which mediates cell-to-cell adhesion. It is expressed on 
the surface of adult and embryonic endothelia cells. 
Rat anti-mouse CD34 CD34 is a surface glycophosphoprotein expressed on committed and 
primitive hematopoietic progenitor cells. 
Rat anti-mouse CD41 CD41 is integral membrane protein expressed on platelets, 
megakaryocytes and early haematopoietic progenitors. 
Rat anti-mouse CD43 CD43 is a membrane protein expressed on granulocytes, monocytes, 
macrophages, platelets, natural killer cells, thymocytes and most T 
helper cells. 
Rat anti-mouse CD45 CD45 is a transmembrane glycoprotein expressed at high levels on the 
cell surface of leukocytes.  
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Principle 
The process of phenotyping involves the use of mAbs directed against extracellular CD 
antigens. The antibodies are labelled with fluorescent dyes called fluorochromes that will 
vary in their response to lasers of differing wavelengths. The fluorescence emission is 
then measured using flow cytometry, and this will indicate which of the labelled 
antibodies are attached to the cells. The data are electronically stored for analysis and can 
be displayed in the form of a graph or histogram. The total cells detected were displayed 
as a dot-plot of red fluorescence intensity vs. green fluorescence intensity, which can then 
be selectively gated to look at sub-populations in greater detail. 
Method 
Sets of cell samples incubated with respectively designated period of 2, 5, 8, 10, and 12 
days with or without VD3 were prepared according to the E14 / OP9 co-culture 
preparation method described in Section 3.2.1. When the supernatant was discarded, 
single-cell suspensions were prepared with cells from the pellet in 5 mL PBS containing 
0.05% sodium azide, 1 mM EDTA, 2% FBS, and 2% normal mouse serum (Sigma), or, 
alternatively, stain buffer (FBS) ready made-up (BD pharmingen™). This was then 
divided into 0.5 mL portions for testing against each CD marker under investigation. Each 
0.5 mL portion of this stain buffer solution with cells, which had been incubated either 
with or without VD3, was allocated to 15 mL tubes and then was incubated with 5 µL of 
a monoclonal antibody, which binds to any corresponding cell surface antigen that is 
present. After 30 minutes of incubation at room temperature and in darkness, the cells 
were then centrifuged at 750 rpm for 5 minutes at room temperature. The supernatant was 
discarded, single-cell suspensions were prepared in 0.5 mL of sheath fluid solution for 
each tube, and the samples were ready for flow cytometric analysis. For each monoclonal 
antibody, control staining with the appropriate isotype-matched control monoclonal 
antibody (BD pharmingen™) was included to establish thresholds for positive staining. 
Flow Cytometry was performed on BD FACSCalibur™ (Becton Dickinson, Franklin 
Lakes, NJ, USA) with Cell Quest Pro Software (Becton Dickinson, Franklin Lakes, NJ, 
USA).   
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Criteria for CD marker selection 
The monoclonal antibodies were tested for cross-reactivity with OP9, and only the ones 
without detectable cross-reactivity with OP9 cells were selected for this study. These 
we0re: PE rat anti-mouse FLK1, APC rat anti-mouse CD31, PE rat anti- mouse CD34, 
PE rat ant-mouse CD41, PE rat ant-mouse CD43, and FITC rat anti-mouse CD45 
(BD pharmingen™). The percentage of positive cells was calculated as the percentage of 
positive cells stained with specific antibody subtracted by the percentage of background 
staining with corresponding isotype control. 
3.2.6 RNA extraction 
A high purity of RNA solution is needed for Real-time Reverse Transcription Polymerase 
Chain Reaction (Real time RT-PCR) to be described in the next section. To achieve this, 
RNA was extracted from cells and isolated. RNA extraction was achieved using 
Guanidinium thiocyanate-phenol-chloroform extraction, with Trizol® reagent 
(Invitrogen, Life Technologies, Paisley, UK). Trizol contains phenol and Guanidinium 
thiocyanate, which have cell lysing and protein denaturing actions, so it also prevents the 
activity of RNAse and DNAse enzymes. Following cell treatments mentioned in Section 
3.2.1, 330 µL of Trizol® per well of a 6-well plate was added to the cell monolayers and 
plates were incubated for 5 minutes at room temperature. Cell lysates were collected and 
stored at -20 ºC until further analysis.  
For RNA isolation, a mixture of chloroform and Trizol® with the ratio of 1:5 was added 
to the lysate. The solution was mixed, incubated for 10 minutes at room temperature and 
centrifuged for 16 minutes at 12,000 × g. Chloroform, along with the phenol contained in 
the Trizol® reagent, causes the proteins to denature and precipitate, and thus separates 
the RNA into an aqueous supernatant. After the addition of chloroform and 
centrifugation, there was a visible separation of the solution into three phases, namely the 
aqueous phase, interphase and organic phase, as shown in Figure 27. The majority of the 
RNA was present in the aqueous phase, whilst DNA and proteins were in the interphase 
and organic phases, respectively. The aqueous phase was transferred to a new tube and 
equal volume of ice-cold isopropanol was added. Isopropanol precipitates and recovers 
the RNA from the aqueous phase, forming a visible pellet after 10 minutes of 
centrifugation at 12,000 × g. The RNA pellet was washed with 75% EtOH, centrifuged 
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at 8,000 × g for 10 minutes and air dried, and Tris-EDTA (TE) buffer (Applied 
Biosystems, Ambion, Cheshire, UK) was added to reconstitute the RNA.  
 
 
Figure 27. After the addition of chloroform to the Trizol® lysate and centrifugation, the solution 
is separated into 3 phases.  
RNA is isolated from the aqueous phase.  
(Source: www.openwetware.org) 
After reconstitution in TE buffer, RNA concentration and purity were assessed by UV 
spectroscopy, using a NanoDrop UV Spectrophotometer (NanoDrop, Wilmington, DE, 
USA). The absorbance of the diluted RNA sample was measured at 260 and 280 nm. 
Absorbance at 260 nm was used to determine the RNA concentration, as it is known that 
a 260 reading of 1.0 is equivalent of 40 µg/ml of RNA. A 260/280 ratio was used to assess 
the purity of RNA, as it is known that a 260/280 ratio of 1.8-2.1 indicates a good purity 
of RNA solution for the use of Real-time PCR. 
Method 
Sets of cell samples incubated with respectively designated period of 2, 5, 8, 10, and 12 
days with or without VD3 were prepared according to the E14 / OP9 co-culture 
preparation method described in Section 3.2.1. From each of these culture samples, total 
RNA was extracted and isolated following the procedure described in the previous 
section. These RNA samples were then used in running the TaqMan® PCR-based method 
by using the TaqMan® RNA-to-CT™ 1-Step Kit (Applied Biosystems, San Jose, CA, 
USA), as mentioned in the previous section. The workflow is illustrated in Figure 28:  
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 Control and treatment samples preparation 
 
 
Figure 28. The workflow for one-step RT-PCR using the TaqMan® RNA-to-CT™ 1-Step Kit 
(Source: Applied Biosystems, 2012: 6) 
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3.2.7 Real time RT-PCR 
Principle 
Gene expression can be altered in response to various conditions or by different stages of 
cell development and is a key step in knowing how many cellular processes, including 
differentiation, are accomplished. A commonly used method for investigating gene 
expression is Real-time Reverse Transcription Polymerase Chain Reaction (Real-time 
RT-PCR) or Quantitative Polymerase Chain Reaction (qPCR). It quantifies the amount 
of mRNA molecules produced by a specific gene after its transcription. This is achieved 
by producing complementary DNA (cDNA) through reverse transcribing the previously 
isolated mRNA (section) and amplifying the resulting cDNA, whilst detecting in real time 
the amount of amplified cDNA molecules (hence the emphasis of real-time in its name). 
The detection of amplified cDNA is performed by observing the fluorescence from the 
fluorescence-emitting molecules used for labelling the cDNA molecules. The intensity of 
fluorescence is proportionally increased with the amplification of the cDNA molecules 
with each cycle of the reaction. Two commonly used fluorescent tags in Real-time PCR 
are SYBR® Green I dye and TaqMan® probes. SYBR® Green I dye is the cheaper 
alternative. It binds to all double stranded DNA and enables the detection of all amplified 
double-stranded DNA molecules. However, it may also detect non-specific reaction 
products. TaqMan® probes are more expensive, but can be synthesised for each unique 
target sequence and are therefore emitting fluorescence only when the specific PCR 
product is amplified. A comparison between these two chemical products is presented in 
Figure 29.  
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Figure 29. A comparison between SYBR® Green and TaqMan® used in Real-time PCR.  
TaqMan® detection is more specific as it uses a specially designed probe for each 
target sequence and emits fluorescence only when the target sequence has been 
replicated. SYBR® Green dye is less specific, as it binds to any double stranded 
DNA present in the reaction.  
(Source: www.appliedbiosystems.com) 
The increase in fluorescence with each cycle is detected. This enables the estimation of 
the rate of amplification and the abundance of the cDNA molecules generated. The higher 
the gene expression, i.e., the starting concentration of cDNA, the fewer number of 
amplification cycles it would take for the levels of fluorescence to reach a certain 
threshold. Thus the first cycle at which the instrument can detect the amplification 
generated fluorescence to be above the ambient background signal is denoted as the 
threshold cycle Ct, or quantification cycle Cq by the new Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guideline, of the 
sample. The lower the value of Ct is, the higher the level of gene expression would be. 
Comparison of Ct values between different samples is therefore indicative of how gene 
expressions between these samples differ. Figure 30 shows an example of 3 samples with 
different gene expression levels and how this is represented by their Ct values. 
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Figure 30. Real-time PCR analysis demonstrates the number of cycles required for 3 different 
samples to reach a specific fluorescence threshold (represented by their Ct value).  
  
The lower the Ct value or the number of cycles required to reach the fluorescence 
threshold, the higher the expression of the gene. Thus, in the figure above, the sample 
represented by the green curve is the one with highest gene expression (Ct = 21.75), 
followed by the blue one (Ct = 26.5) and the red sample is the one with the lowest gene 
expression (Ct = 27.1).   
The TaqMan® method 
The TaqMan® PCR-based method was used in this study. This was done using the 
TaqMan® RNA-to-CT™ 1-Step Kit (Applied Biosystems, San Jose, CA, USA). The kit 
contains both AmpliTaq Gold® DNA polymerase and ArrayScript™ UP (Ultra-Pure) RT 
(Reverse Transcriptase). The former is the enzyme required for DNA amplification and 
the latter the reverse transcription of mRNA into cDNA.  
Final reaction volume was 20 µL per reaction, composed of 8.5 µL of RNA (5.5 ng/µL), 
10 µL master mix containing the DNA polymerase enzyme, 1 µL of probe TaqMan 
primers mix and 0.5 µL RT enzyme. Applied Biosystems StepOnePlus Real-time PCR 
system with StepOne Software v2.2.2 (Applied Biosystems, Life Technologies) was used. 
The housekeeping gene RNA polymerase GAPDH was used as a reference gene. The 
following program cycles were used:  
Ct 
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Table 4. The stages of the program cycles used in RT-PCR with the TaqMan© method 
(Source: Applied Biosystems, 2012: 10) 
 
Stage Step Temperature Time 
Holding Reverse Transcription 48 ºC 15 minutes 
Holding Activation of TAQ polymerase 95 ºC 10 minutes 
Cycling 
(40 cycles) 
Denaturation 95 ºC 15 second 
Annealing/Extension 60 ºC 1 minute 
The following predesigned dyes and primers (Applied Biosystems) were used in the 
TaqMan® detection method:  
Table 5. The dyes and primers used in RT-PCR with the TaqMan© method 
(Source: Applied Biosystems, 2012) 
 
Gene Dye or Primer / Assay ID 
FAM Reporter dye 
BHQ1 Quencher dye 
GAPDH mm99999915_m1 
Kdr/FLK1 mm01222421_m1 
Tall/SCL mm01187033_m1 
GATA1 mm01352636_m1 
GATA2 mm00492301_m1 
p21/CDKNA mm04205640_g1 
p27 mm00495994_m1 
 
The Livak method 
Comparative quantification of the target gene expression in the samples was performed 
based on Ct normalised to GAPDH for each time point with ΔCt = Ct (experiments) – Ct (GAPDH) 
and the Livak method or the 2−ΔΔCT method was used to ascertain the fold change using 
the Ct value for the vehicle as a reference. ΔΔCT = ΔCT (VD3) – ΔCT (vehicle). The fold 
change in mRNA expression for each time point was plotted in a graph using negative 
control as a reference as 2−ΔΔCT (vehicle) = 1. The formula for the calculation of the 
normalised expression ratio 2–ΔΔCT is 
ΔΔCT = ΔCt test – ΔCt calibrator 
ΔCt test = Mean Ct target gene, test – Mean Ct reference gene, test 
ΔCt calibrator = Mean Ct target gene, calibrator – Mean Ct reference gene, calibrator 
where  
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Mean Ct target gene, test is the average Ct value (sample and triplicate) of the targeted gene in 
the experimental condition;  
Mean Ct reference gene, test is the average Ct value (sample and triplicate) of reference 
house-keeping gene in the experimental condition; 
Mean Ct target gene, calibrator is the average Ct value (sample and triplicate) of targeted gene in 
the calibrator condition; and  
Mean Ct reference gene, test is the average Ct value (sample and duplicate) of reference house-
keeping gene in the calibrator condition. 
To compare the effect of the presence of VD3 on E14 in the E14 / OP9 co-culture, the 
experimental condition was E14 / OP9 co-culture with VD3 and the calibrator condition 
was E14 / OP9 co-culture without VD3. The RNAs isolated from E14 after different days 
of incubation were used for the calculation of ΔCttest and ΔCt calibrator. The targeted genes 
were FLK, P21, Gata1 and Gata2, etc. whilst GAPDH was used as the reference gene in 
all RT-PCR assays, and a pooled Ct value (22.31 ± 1.04) for the reference gene was taken 
from all RT-PCR runs (n = 9) as there was no significant difference in Ct values for the 
reference gene at different time points and between cell types.  
Analysis 
Relative quantification of gene expression was determined automatically by Opticon 
Monitor version 3.1.32 (MJ Geneworks Inc. and Bio-Rad Laboratories, Inc., Hercules, 
CA, USA) and StepOne Software v2.2 (Applied Biosystems, Life Technologies). The 
relative quantification is based on analysing changes in gene expression relative to a 
reference sample (control). One sample from the experiments was set as a 
calibrator/control and fold change to this calibrator was determined for every sample of 
the experiment. All samples were normalised to a house-keeping gene (GAPDH) as its 
expression is known to remain consistent in E14 cells regardless of the treatment 
(Tricarico et al., 2002).  
From this, the Ct values for all genes were tabulated and imported into an Excel spread 
sheet designed for the application of the Livak Method for determining normalised 
expression ratios using the 2-ΔΔCT formula. 
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3.2.8 Cytokine expression assay 
Better understanding of the growth control of hematopoietic cells during the in vitro 
differentiation of ES cells could be achieved through the investigation of the expression 
of a number of cytokine related genes involved in the haematopoiesis process. The point 
at which a particular factor begins to play a role corresponds to a detection of significant 
expression of the related gene. Conversely, the lack of expression is an indication that the 
corresponding factor is not critical at that point. As it is quite common for several 
cytokines to act simultaneously or collectively, it is important to be able to detect several 
expressions concurrently.  
There are several assays available for cytokine detection and analysis. For instance, 
cytokine bioassays measure biological activity by some sort of proliferation assay of 
primary cells or cell lines dependent or responsive to the cytokine of interest. 
Immunofluorescence staining and flow cytometry mentioned before use fluorescently 
labelled antibodies to detect intracellular cytokines and surface receptors at the single cell 
level. These and other assays have several drawbacks. It may take a long time to run some 
of these assays, whilst each analyte needs to be quantitated separately in some other 
assays.  
On the other hand, simultaneous detection of multiple analytes lasting only several hours 
could be achieved by conducting Luminex multiplex cytokine expression assays using 
the Luminex kits.  
Principle 
A specific antibody to the target protein is covalently coupled to microspheres (beads) 
that are dyed internally with two fluorescent dyes. Up to 100 distinctly colours could be 
achieved through using precise concentration ratios of the dyes. Beads with each distinct 
colour are coated with a specific capturing antibody. After an analyte from a test sample 
is captured by the bead, as illustrated in Figure 31, a biotinylated detection antibody is 
introduced. The reaction mixture is then incubated with the reporter molecule streptavidin 
PE conjugate to complete the reaction on the surface of each microsphere.  
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Figure 31. Schematic representation of the principle of the Luminex assay 
(Source: 
www.crcjussieu.fr/crc/upload/editor/image/Equipe09/multiplex%20Assay%20Desig
n2.JPG) 
 
As shown in Figure 32, the beads are passed rapidly through a first laser to excite the dyes 
inside the beads. A second laser excites PE, the fluorescent dye on the reporter molecule. 
The signals from individual beads are then identified using high-speed digital signal 
processors and the result quantified based on fluorescent reporter signals. 
 
 
Figure 32. Internal components of the Luminex system 
(Source: http://ifr125.timone.univ-mrs.fr/biopuces/LuminexPrinciple.jpg) 
Alternatively, as illustrated in Figure 33, superparamagnetic beads could be used, and the 
beads with the captured analyte can be pulled by a magnet to form a monolayer before it 
is illuminated by red and green LED light sources for the identification and quantification 
of the analytes.   
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Figure 33. Principle of magnetic bead based multiplex assay 
(Source: 
http://www.rndsystems.com/product_detail_objectname_versamap_magnetic_bead
_based_multiplex_assay_principle.aspx) 
 
Method 
The assays were conducted using the Luminex 200 system (Bio-Plex) running the 
xPONENT analytical software and the Milliplex MAP Kit of mouse cytokine / chemokine 
magnetic bead panel for 96-well plate assays (EMD Millipore). Cell samples were E14 / 
OP9 co-culture incubated for 2, 5, 8, 10 or 12 days with or without 100 nM of VD3 
prepared according to the procedures described previously. The superlative of each of the 
samples was used in the analysis using the Luminex 200 system. The cytokine of interest 
in this study are G-CSF, GM-CSF, IL-1α, IL-3, IL-4, IL-5, IL-6, TNF-α and VEGF 
because their known roles in haematopoiesis, which are briefly described in Table 6.  
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Table 6. The cytokines studied in this study and their roles in haematopoiesis 
(Source: Kurzrock, 2000; Gerber et al,. 2002; Gerber & Ferrara, 2003; Xu et al., 
2000) 
   
G-CSF Colony stimulating factors (CSFs) are soluble, membrane-bound substances of 
the hematopoietic microenvironment. It is secreted glycoproteins that bind to 
receptor proteins on the surfaces of hematopoietic stem cells, 
activating intracellular signalling pathways that can cause the cells 
to proliferate and differentiate into a specific kind of blood cell (usually white 
blood cells). They may be synthesised and administered exogenously. 
Granulocyte colony-stimulating factor (G-CSF) is a haematopoietic growth factor 
required for the proliferation and differentiation of haematopoietic precursors of 
neutrophil granulocytes. It increases the numbers of neutrophils and modulates 
neutrophil functions, as well as inducing the production of cytokines such as 
tumour necrosis factor alpha (TNF-alpha). 
GM-CSF  Granulocyte-macrophage colony-stimulating factor (GM-CSF) is 
a protein secreted by macrophages, T cells, mast cells, endothelial cells, 
and fibroblasts. It functions as a WBC growth factor, stimulating stem cells to 
produce granulocytes and monocytes.  
IL-1  Interleukin-1 has been associated with numerous activities. Some of these 
include the induction of the IL-2 receptor, the stimulation of pre-B cell 
differentiation, the augmentation of NK-cell cytotoxicity, the induction of adhesion 
molecules on endothelial cells, the induction of fever, the stimulation of 
thymocyte proliferation, the enhancement of collagen production, and the 
stimulation of the release of other cytokines involved in haematopoiesis.  
IL-3  The principle effects of Interleukin-3 haematopoietic growth factor are on early 
haematopoietic progenitors in which IL-3 induces haematopoiesis and cell 
differentiation. Administration of IL-3 produces an increase in erythrocytes, 
neutrophils, eosinophils, monocytes and platelets. It acts synergistically or 
additively with other haematopoietic growth factors.  
IL-4  Interleukin-4 is primarily derived from T cells and its principle site of action is the 
B cell. It stimulates B cell proliferation and activation. It induces IgG 1 & IgE 
expression from B cells and class II MHC expression. It also induces the 
differentiation of eosinophils and the involved in the activity of T cytotoxic cells.  
IL-5  The primary effect of Interleukin-5 is on the eosinophilic lineage. It stimulates 
eosinophil chemotaxis and eosinophil expansion.  
IL-6  Interleukin-6 is produced by lymphoid and non-lymphoid cells. It acts on T cells 
and B cells and stimulates multilineage haematopoiesis, including the maturation 
of megakaryocytes.  
TNF-α  Tumour necrosis factors (TNF) are a group of 19 cytokines which can cause cell 
death (apoptosis). These cytokines have similar sequences, functions and 
structures. One of the first members of the TNF family to be identified was 
Tumour necrosis factor alpha (TNF-α). It is a monocyte derived cytotoxin, 
implicated in tumour regression, septic shock and cachexia. It stimulates cell 
proliferation and induces cell differentiation under certain conditions. It is a potent 
pyrogen, causing fever by direct action or by stimulation of IL-1 secretion. It can 
cause cytolysis of certain tumour cell lines.  
VEGF Vascular endothelial growth factor (VEGF) is a chemical signal produced by cells 
that stimulates the growth of new blood vessels. VEGF is a sub-family of growth 
factors, specifically the platelet-derived growth factor family of cystine-knot 
growth factors. It acts as an endocrine-like hormone to induce extramedullary 
haematopoiesis, as well as promoting the formation of terminally differentiated 
red blood cells. 
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3.3 Statistical Analyses  
Statistical analyses and significance of data were determined using GraphPad Prism 
version 5.00 for Mac OS X and Microsoft Windows (GraphPad Software, San Diego 
California USA). As more than one factor was present, two-way ANOVA was performed 
to investigate the significances of factors or interactions. This was followed up by 
examining the statistical significance for interactions between more than two groups 
within the factor with Bonferroni post-hoc analysis. All results are presented as mean ± 
standard error of the mean (SEM). All values with p < 0.05 were considered as 
significant.  
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3.4 Results 
3.4.1 Immunofluorescence 
The purpose of this part of the experiment is to determine the role of Oct4, Sox2, Nanog 
as master regulators of stem cell pluripotency and differentiation of ESCs, and to evaluate 
the effect of VD3 as an accelerator and a promoter of early differentiation of ESCs as 
illustrated in Figure 8. 
These investigations were done by co-culturing E14 cells on OP9 cells in differentiated 
media with or without VD3 for up to 5 days. The extent, if any, of the roles of the 
aforementioned regulators was qualitatively investigated by immunocytochemistry.  
The results of immunofluorescence are shown in Figure 34. Compared to untreated co-
cultures, it was found that in up to 5 days’ incubation of VD3-treated co-cultures, there 
was visible reduction of fluorescence. This suggested the reduction of Oct4, Sox2 and 
Nanog expression. As mentioned before, Oct4, Sox2 and Nanog are associated with 
undifferentiated cells, and decreased expression of these transcription factors is 
associated with differentiated cells. Their heightened expression inside cells is therefore 
considered to be indicative of the presence of undifferentiated cells. On the other hand, 
reduced or lack of expression of these genes means that cells have differentiated.  
Summary 
Therefore, the results of immunofluorescence showed that VD3 was associated with the 
reduction of Oct4, Sox2 and Nanog expressions, the inhibition of cell proliferation, as 
well as the acceleration and promotion of cell differentiation. This result agrees with 
previous studies using other cell cultures that have linked VD3 to the acceleration and 
promotion of differentiation. 
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Day 1 
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Day 1 
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Day 3 
Control 
 
  
Day 3 
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Day 5 
Control 
   
Day 5 
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Figure 34. The results of immunofluorescence staining of E14 / OP9 co-culture with or without 
VD3 on days 1, 3 and 5.  
All cells are marked by the blue stain for easy identification whilst only 
undifferentiated cells are marked by the florescent green stain. The number of 
undifferentiated cells is reduced towards Day 5 and is consistently less in treatment 
than in control. N = 9.   
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3.4.2 CD-marker expressions on E14 cells in the presence 
of OP9 cells and VD3 
The data for the expressions of each CD markers of the sample were derived from the 
output charts of flow cytometry. Some of these examples are shown in Figure 35 below, 
with some brief explanation of how the data can be read from these charts.  
 
Day 2 
 
The amount of CD34+ progenitor cells 
in the sample with VD3 (the area 
between the yellow curve and the x-
axis within the region of M2) is greater 
than the amount of CD34+ progenitor 
cells in the sample without VD3 
(control) (the area between the top 
curve of the dark blue region and the 
x-axis within the region of M2). 
 
Day 5 
 
The amount of CD34+ progenitor cells 
in the sample with VD3 (the area 
between the green curve and the x-
axis within the region of M2) is greater 
than the amount of CD34+ progenitor 
cells in the sample without VD3 
(control) (the area between the white 
curve and the x-axis within the region 
of M2). 
 
Day 8 
 
The amount of CD34+ progenitor cells 
in the sample with VD3 (the area 
between the white curve and the x-axis 
within the region of M2) is greater than 
the amount of CD34+ progenitor cells 
in the sample without VD3 (control) (the 
area between the top curve of the 
green region and the x-axis within the 
region of M2). 
Figure 35. Some examples of flow cytometry results on the amount of CD34+ progenitor cells 
on set days 
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The expressions of different CD markers, FLK, CD31, CD34, CD41, CD43 and CD45, 
were assessed successively on days 2, 5, 8, 10 and 12, respectively. ESC (E14) cellular 
differentiation was dependent on the fluctuations in the levels of CD-marker expressions 
on the given days, starting from day 2, in the E14 / OP9 co-culture that were either 
untreated or treated with VD3. These fluctuations are described below and shown in 
graphical form. 
Each assessment procedure was done in triplicate to arrive at an average, given as 
percentage. Each pair of these averages was statistically analysed to determine if it was 
statistically significant. For the measurements of each CD marker, the significance of the 
presence of VD3 and the duration of incubation were evaluated using two-way ANOVA 
tests and Bonferroni post-hoc analysis.  
FLK Expression 
FLK1 is monoclonal antibody specifically binds to foetal liver kinase 1, also known as 
VEGF receptor-2 (VEGF-2), a receptor for vascular endothelial growth factor (VEGF). 
It is expressed on distinct sets of mesoderm during gastrulation and on endothelial cells 
in embryonic and adult tissues. In vivo and in vitro studies indicate that FLK1 is required 
for the embryonic development of vascular endothelial and haematopoietic cells (BD 
Biosciences, 2010). 
The mean magnitude of FLK expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 36 below.  
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FLK Expression 
 
Figure 36. Comparison of the percentages of FLK+ cells in the untreated and VD3-treated E14 
/ OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
The changes in the magnitude of FLK expression against time were visible in the bar 
chart above. The magnitude of FLK expression of untreated E14 cells increased after day 
2, to a peak on day 8, and then sharply decreased to the lowest value taken after day 12. 
The magnitude of FLK expression of treated E14 cells increased after day 2, to a peak on 
day 5, and only markedly decreased after day 8. The level of FLK expression of treated 
cells was superior to the magnitude of expression of untreated cells on days 2-8, but 
inferior after day 8 owing to its marked decrease. The greatest difference in the 
expressions between the treated and the untreated E14 cells was on day 5 and it was 
statistically significant (p < 0.05). The differences in the level of FLK expression between 
the treated and untreated cells were not statistically significant with the samples taken at 
the end of other days.  
This suggests that the FLK expression of E14 cells had been hastened by the presence of 
VD3 in the co-culture with OP9 cells. In other words, E14 cell differentiation had been 
encouraged and promoted by the presence of VD3 in the co-culture with OP9 cells.  
Both the presence of VD3 and the duration of incubation were significant factors to the 
FLK expression in the experiment, as indicated by the results of the two-way ANOVA 
test and confirmed by the Bonferroni post-hoc analysis.  
 115 
CD31 Expression 
CD31 is integral membrane protein, a member of the immunoglobulin superfamily, which 
mediates cell-to-cell adhesion. It is expressed on the surface of adult and embryonic 
endothelia cells (BD Biosciences, 2010). 
The mean magnitude of CD31 expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, together 
with the results of the two-way ANOVA test, are presented in Figure 37 below. 
CD31 Expression 
 
Figure 37. Comparison of the percentages of CD31+ cells in the untreated and VD3-treated E14 
/ OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
Again, the changes in the level of CD31 expression against time were visible in the bar 
chart above. The level of CD31 expression of untreated E14 cells reached its peak on day 
8, and then decreased afterwards. In comparison, the level of CD31 expression of treated 
E14 cells increased sharply after a small percentage on day 2 to a peak on day 5, and 
markedly decreased after day 5, whereupon the level remained relatively unvaried on 
days 8-12. The level of CD31 expression of treated cells was superior to the level of 
expression of untreated cells only on day 5, though it was not statistically significant. 
Again, the shift of maximum from day 8 to day 5 suggests that the CD31 expression of 
E14 cells had been hastened by the presence of VD3 in the co-culture with OP9 cells. In 
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other words, E14 cell differentiation had been encouraged and promoted by the presence 
of VD3 in the co-culture with OP9 cells.  
Both the presence of VD3 and the duration of incubation were significant factors to the 
CD31 expression in the experiment, as indicated by the results of the two-way ANOVA 
test and confirmed by the Bonferroni post-hoc analysis.  
CD34 Expression 
CD34 is a surface glycophosphoprotein expressed on committed and primitive 
hematopoietic progenitor cells (BD Biosciences, 2010). 
The mean magnitude of CD34 expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 38 below. 
CD34 Expression 
  
 
Figure 38. Comparison of the percentages of CD34+ progenitor cells in the untreated and VD3-
treated E14 / OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
As shown in the figure above, the level of CD34 expression of untreated E14 cells 
increased after day 2, then slightly decreased after day 5, slightly increasing again after 
day 8, to reach a peak on day 10, followed by a decrease after that. Similar to the results 
of FLK and CD31 expressions, the level of CD34 expression of VD3-treated E14 cells 
rapidly increased after day 2, to a peak on day 8, and then rapidly decreased afterwards. 
The level of CD34 expression of treated cells was superior to the level of expression of 
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untreated cells on days 2-8. The maximum difference between the expressions of the 
VD3-treated and untreated E14 cells was on day 8 and this is statistically significant 
(p < 0.05). Again, the differences between the VD3-treated and untreated cells were not 
statistically significant on other days. 
Once again, the shift of maximum from day 10 to day 8 suggests that the CD34 expression 
of E14 cells had been hastened by the presence of VD3 in the co-culture with OP9 cells. 
In other words, E14 cell differentiation had been encouraged and promoted by the 
presence of VD3 in the co-culture with OP9 cells.  
Both the presence of VD3 and the duration of incubation were significant factors to the 
CD34 expression in the experiment, as indicated by the results of the two-way ANOVA 
test and confirmed by the Bonferroni post-hoc analysis.  
CD41 Expression 
CD41 is integral membrane protein expressed on platelets, megakaryocytes and early 
haematopoietic progenitors (BD Biosciences, 2010). 
The expressions of CD41, CD43 and CD45 displayed transition patterns along time which 
were different from those of FLK, CD31 and CD34 in the E14 cells in untreated co-
culture with OP9 cells. 
The mean level of CD41 expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, and the 
results of the two-way ANOVA test, are presented in Figure 39 below. 
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CD41 Expression 
 
 
Figure 39. Comparison of the percentages of CD41+ cells in the untreated and VD3-treated E14 
/ OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
As shown in the bar chart above, the level of CD41 expression of untreated E14 cells 
increased after day 5 and reached the highest value after day 12. On the other hand, the 
level of CD41 expression of VD3-treated E14 cells slightly decreased after day 5 then 
rapidly increased after day 8 and peaked after day 10. The level of CD41 expression of 
VD3-treated cells was superior to the level of expression of untreated cells after days 8, 
10 and 12. The maximum difference between the CD41 expressions of the VD3-treated 
and untreated E14 cells occurred after day 10 (p < 0.05) and that was the only statistically 
significant difference.  
Once again, the shift of maximum from day 12 to day 10 suggests that the CD41 
expression of E14 cells had been hastened by the presence of VD3 in the co-culture with 
OP9 cells. In other words, E14 cell differentiation had been encouraged and promoted by 
the presence of VD3 in the co-culture with OP9 cells.  
Both the presence of VD3 and the duration of incubation were significant factors to the 
CD41 expression in the experiment, as indicated by the results of the two-way ANOVA 
test and confirmed by the Bonferroni post-hoc analysis.  
CD43 Expression 
CD43 is a membrane protein expressed on granulocytes, monocytes, macrophages, 
platelets, natural killer cells, thymocytes and most T helper cells (BD Biosciences, 2010). 
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The mean magnitude of CD43 expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, together 
with the results of the two-way ANOVA test, are presented in Figure 40 below. 
CD43 Expression 
 
 
Figure 40. Comparison of the percentages of CD43+ cells in the untreated and VD3-treated E14 
/ OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
As shown in the bar chart above, the level of CD43 expression of untreated E14 cells 
increased after day 2, to ultimately peak on day 10; whereas the level of CD43 expression 
of VD3-treated E14 cells rapidly increased after day 2, to a peak on day 5, then rapidly 
decreased after day 5, before virtually levelling out. The level of CD43 expression of 
VD3-treated cells was always superior to that of untreated cells. The greatest difference 
between the CD34 expressions of the VD3-treated and untreated E14 cells appeared after 
day 5 and it was statistically significant (p < 0.05). The difference was not statistically 
significant on the samples taken after other days of incubation. 
Unlike the results with other gene expressions, only the presence of VD3 was a significant 
factor to the CD43 expression in the experiment, as indicated by the results of the two-
way ANOVA test. The significance was confirmed by the Bonferroni post-hoc analysis.  
CD45 Expression 
CD45 is a transmembrane glycoprotein expressed at high levels on the cell surface of 
leukocytes (BD Biosciences, 2010).  
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The mean magnitude of CD45 expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 41 below. 
CD45 Expression 
 
 
Figure 41. Comparison of the percentages of CD45+ cells in the untreated and VD3-treated E14 
/ OP9 co-cultures after different days of incubation 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
Here, as shown in the bar chart above, the level of CD45 expression of untreated E14 
cells increased after day 2, to a peak on day 5, with minor fluctuations afterwards. The 
level of CD45 expression of VD3-treated E14 cells peaked first on day 5, but then again 
and much more pronouncedly on day 12. Again, the level of CD45 expression of VD3-
treated cells was superior to the level of expression of untreated cells on all days. The 
maximum difference between the expressions of CD45 of the VD3-treated and the 
untreated E14 cells was on day 12 and it was statistically significant (p < 0.01). The 
differences in the level of CD45 expressions between the VD3-treated and untreated cells 
were not statistically significant on other days.  
In this case, both the increase in gene expression in the VD3-treated samples and the shift 
of maximum from day 12 to day 10 suggest that the CD45 expression of E14 cells had 
been hastened by the presence of VD3 in the co-culture with OP9 cells. In other words, 
E14 cell differentiation had been encouraged and promoted by the presence of VD3 in the 
co-culture with OP9 cells.  
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Both the presence of VD3 and the duration of incubation were significant factors to the 
CD45 expression in the experiment, as indicated by the results of the two-way ANOVA 
test and confirmed by the Bonferroni post-hoc analysis.  
Summary 
In the control, FLK+ cells appeared from the beginning of the duration and the number of 
cells peaked on day 8 before dropping drastically on day 10. CD34+ cells appeared 
noticeably on days 5, 8 and 10. The temporal trend of the CD31+ cells closely followed 
that of CD34+ cells by 1 or 2 days. CD41+ cells appeared 3 days after the CD34+ 
population and gradually increased by day 10 of culture. CD43+ cells were present 
throughout the duration, gradually peaked on day 10. The number of CD45+ cells 
fluctuated around 5% after day 5.  
In the treatment, on the other hand, CD34+ cells appeared on day 2 and were more 
abundant until day 8. CD31+, CD41+ and CD43+ cells followed closely after the 
appearance CD34+ cells and peaked 2 to 4 days early. FLK+ cells appeared more 
prominently in the beginning of the duration between day 2 and day 8 and the peak moved 
from day 8 to day 5. CD45+ cells appeared more prominently throughout, with substantial 
peak on day 12.  
In other words, compared to the control, the peaks of the expression of the FLK, CD31, 
CD34 and CD43 markers had appeared earlier, whilst those of the CD41 and CD45 
markers had appeared later and greater in the treatment. The early decline of the 
expression of CD34 marker indicated that differentiation had occurred earlier. The greater 
expressions of the latter groups of CD markers towards the later days showed the greater 
build-up of several strands of differentiated cells. More of these cells had been produced 
because differentiation had started earlier. Thus, these temporal trends indicated that 
cellular differentiation had happened earlier with the presence of VD3. Additionally, on 
most days with every CD marker, there were greater expressions in the treatment than in 
the control. Both of these were indications that cell differentiation in haematopoiesis had 
been promoted by the presence of VD3.   
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3.4.3 Identification and counting of colony-forming cells 
The mode of E14 cell differentiation into different colony-forming cells, namely erythroid 
(E-CFC), granulocyte, erythroid, macrophage, megakaryocyte (GEMM-CFC), 
granulocyte-macrophage (GM-CFC), and macrophage (M-CFC), were assessed 
successively on days 2, 5, 8, 10 and 12, respectively, according to morphology and CD-
marker expression. In order to do this assessment, the cells were prepared on slides, and 
then stained by May-Grünwald Giemsa staining of the cytospins of different CFC types, 
and morphological examination and image-capture were attained with a Zeiss Axio 
Imager M1 Microscope using ZEN 2012 software. Each type of cells was identified and 
counted in the examination. Each assessment procedure was done in triplicate to arrive at 
an average. These averages were statistically analysed to determine whether or not there 
was statistical significance. For each set of measurements, the significance of the presence 
of VD3 and the duration of incubation were evaluated using two-way ANOVA tests.  
Cell count results of erythroid colony-forming cells (E-CFC) 
As shown in the microscopic photographs in Figure 42 below, individual E-CFCs can be 
identified in the cell smears of E14 / OP9 co-cultures after incubation.   
   
Figure 42. Individual cells of E-CFC identified in cell smears of differentiated E14 cells in co-
culture with OP9 cells.  
May–Grünwald Giemsa staining was used and images were captured with a Zeiss 
Axio Imager M1 microscope using ZEN 2012 software. N = 3. 
 
 
The identified E-CFCs were counted for each sample, and the overall result of cell counts 
of E-CFC per 106 E14 cells in the untreated and VD3-treated E14 / OP9 co-cultures after 
2, 5, 8, 10 and 12 days of incubation, as well as the results of the two-way ANOVA test, 
are presented in Figure 43 below. 
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E-CFC Cell Count 
 
 
Figure 43. Comparison of changes along time in the number of E-CFCs in untreated and VD3-
treated E14 cells with in co-culture with OP9 cells 
 
As shown in the bar chart above, the numbers of E-CFCs in both treated and untreated 
co-cultures increased after day 2 to a peak on day 5. The number of E-CFCs in treated 
co-cultures decreased markedly after day 5. On days 2 and 5, the numbers of E-CFCs in 
the VD3-treated samples were higher than that of the untreated controls. In contrast, after 
day 5, the number of E-CFCs in the treated samples was lower than that of the untreated 
controls. However, none of these differences in numbers were statistically significant. 
According to the result of the two-way ANOVA test, the presence of VD3 was not a 
statistically significant factor for the measurements, whilst the time of incubation was, 
though it is difficult to interpret the findings as there was statistically significant 
interaction between these two factors in this experiment.  
Cell count results of granulocyte, erythroid, macrophage and 
megakaryocyte colony-forming cells (GEMM-CFCs)    
As shown in the microscopic photographs in Figure 44 below, GEMM-CFCs can be 
identified in the cell smears of E14 / OP9 co-cultures after incubation.   
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Figure 44. GEMM-CFCs indicated by arrows identified in cell smears of differentiated E14 cells 
in co-culture with OP9 cells.  
May–Grünwald Giemsa staining was used and images were captured with a Zeiss 
Axio Imager M1 microscope using ZEN 2012 software. N = 3. 
 
The identified GEMM-CFCs were counted for each sample, and the overall result of cell 
counts of GEMM-CFC per 106 E14 cells in the untreated and VD3-treated E14 / OP9 co-
cultures after 2, 5, 8, 10 and 12 days of incubation, as well as the results of the two-way 
ANOVA test, are presented in Figure 45 below. 
GEMM-CFC Cell Count 
 
 
Figure 45. Comparison of changes along time in the number of GEMM-CFCs in untreated and 
VD3-treated E14 cells with in co-culture with OP9 cells  
N = 3. 
As shown in the bar chart above, between all pairs of measurements after the same days 
of incubation, the number of GEMM-CFCs of VD3-treated samples was virtually the 
same as that of untreated controls. The numbers in both treated and untreated cells 
increased slightly to day 5, then increased rapidly to a peak on day 8, and decreased 
afterwards. For all pairs of measurements, the differences in the numbers between the 
treated samples and the corresponding untreated controls were not statistically significant.  
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According to the result of the two-way ANOVA test, the presence of VD3 was not a 
statistically significant factor for the measurements, whilst the time of incubation was, 
and there was no statistically significant interaction between these two factors in this 
experiment.  
Cell count results of granulocyte-macrophage colony-forming cells 
(GM-CFCs)  
As shown in the microscopic photographs in Figure 46 below, GM-CFCs can be 
identified in the cell smears of E14 / OP9 co-cultures after incubation.   
  
Figure 46. GM-CFCs indicated by arrows identified in cell smears of differentiated E14 cells in 
co-culture with OP9 cells.  
May–Grünwald Giemsa staining was used and images were captured with a Zeiss 
Axio Imager M1 microscope using ZEN 2012 software. N = 3. 
The identified GM-CFCs were counted for each sample, and the overall result of cell 
counts of GM-CFC per 106 E14 cells in the untreated and VD3-treated E14 / OP9 co-
cultures after 2, 5, 8, 10 and 12 days of incubation, as well as the results of the two-way 
ANOVA test, are presented in Figure 47 below. 
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GM-CFC Cell Count 
 
 
Figure 47. Comparison of changes along time in the number of GM-CFCs in untreated and VD3-
treated E14 cells with in co-culture with OP9 cells  
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
As shown in the bar chart above, the number of GM-CFCs in untreated controls increased 
after day 5 to a peak on day 12.  The numbers of GM-CFCs in VD3-treated samples 
increased after day 5 to a peak on day 10. The numbers of GM-CFCs in VD3-treated 
samples were higher than those in untreated controls from day 5 onwards. The greatest 
difference between the treatment and control was on day 8 and this was statistically 
significant (p < 0.05), whereas the differences between the treatment and control for other 
days were not statistically significant.  
According to the result of the two-way ANOVA test, both the presence of VD3 and the 
time of incubation were statistically significant factors for the measurements, and there 
was no statistically significant interaction between these two factors in this experiment. 
The significance was confirmed by the Bonferroni post-hoc analysis.  
Cell count results of macrophage colony-forming cells (M-CFCs)  
As shown in the microscopic photographs in Figure 48 below, M-CFCs can be identified 
in the cell smears of E14 / OP9 co-cultures after incubation.   
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Figure 48. M-CFCs indicated by arrows identified in cell smears of differentiated E14 cells in 
co-culture with OP9 cells.  
May–Grünwald Giemsa staining was used and images were captured with a Zeiss 
Axio Imager M1 microscope using ZEN 2012 software. N = 3. 
The identified M-CFCs were counted for each sample, and the overall result of cell counts 
of M-CFC per 106 E14 cells in the untreated and VD3-treated E14 / OP9 co-cultures after 
2, 5, 8, 10 and 12 days of incubation, as well as the results of the two-way ANOVA test, 
are presented in Figure 49 below. 
M-CFC Cell Count 
 
 
Figure 49. Comparison of changes along time in the number of M-CFCs in untreated and VD3-
treated E14 cells with in co-culture with OP9 cells  
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
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As shown in the bar chart above, the number of M-CFCs in untreated controls increased 
after day 5 to a peak on day 8, whereas the numbers of M-CFCs in VD3-treated samples 
increased after day 5 to a peak on day 12. The numbers of M-CFCs in VD3-treated 
samples were higher than those of the corresponding untreated controls from day 5 
onwards. The difference between the VD3-treated sample and the corresponding control 
was statistically significant on day 8 (p < 0.05) and statistically extremely significant on 
days 10 and 12 (p < 0.001), whilst the maximum appeared on day 12. 
According to the result of the two-way ANOVA test, both the presence of VD3 and the 
time of incubation were statistically significant factors for the measurements. However, 
as there is extremely significant interaction between these two factors, it is difficult to 
interpret the P values of this test. The significance was confirmed by the Bonferroni post-
hoc analysis.  
Summary 
In the E14 / OP9 co-culture, E14 cells displayed a poly-dispersed cell morphology 
consisting of single cells and colonies. This differentiation of both untreated and VD3-
treated cells can be detected through monitoring the fluctuations in the levels of CD 
marker expressions on different days of incubation.  
The decreases in number in E-CFCs and GEMM-CFCs, and the contrasting increases in 
GM-CFCs and M-CFCs towards day 12 of E14 / OP9 co-culture is indicative of a shift in 
E14 cellular differentiation from haematopoietic cells to different cell lineages. 
Overall, from untreated E14 cells, the trends for E-CFCs and GEMM-CFCs showed 
gradual decreases, while, in contrast, the trends for GM-CFCs and M-CFCs showed 
gradual increases. 
In both untreated and VD3-treated E14 cells, kinetic analyses of the emergence of CFCs 
demonstrated that E-CFCs and GEMM-CFCs were induced on day 2 of culture. The 
former was accompanied by the appearance of CD34+ progenitor cells, whilst the latter 
was accompanied by the appearance of CD34+, CD41+ and CD43+ cells. GM-CFCs and 
M-CFCs appeared later, along with the induction of CD45+ cells. Generally, after day 5 
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of incubation, there was prominent expansion of GM-CFC and M-CFCs as well as 
gradual decrease of E-CFCs and GEMM-CFCs. 
With the presence of VD3, the measurement of all four types of CFCs had increased on 
almost all days of observation. This suggested that more cells were formed through cell 
differentiation.  
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3.4.4 Real-time quantitative PCR for gene expressions 
The expressions of different genes, FLK, GATA1, GATA2, SCL, p21 and p27, were 
assessed successively on days 2, 5, 8, 10 and 12, respectively. ESC (E14) cellular 
differentiation was dependent on the fluctuations in the levels of gene expressions on the 
given days, starting from day 2, in the E14 / OP9 co-culture that were either untreated or 
treated with VD3. These fluctuations are described below and shown in graphical form. 
Each assessment procedure was done independently trice and in triplicate to arrive at an 
average, given as relative quantification (fold change).  
FLK gene expression 
The mean level of FLK gene expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 50.  
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Figure 50. Comparison of the fold-change of FLK+ cells in the untreated and VD3-treated E14 / 
OP9 co-cultures after different days of incubation 
N = 9. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
The changes in the level of FLK expression against time and between the control and the 
treatment were visible in the bar chart above. According to the 2-way ANOVA test, both 
time and the presence of VD3 were significant factors. In the control group, the expression 
* 
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of FLK appeared towards the beginning of the duration. In comparison, the early peak of 
FLK in the treated co-cultures appeared higher, and the difference between the treatment 
and the control was significant. This significance was confirmed by the Bonferroni post-
hoc analysis.  
GATA1 gene expression 
The mean magnitude of GATA1 gene expression of both untreated control and VD3-
treated E14 cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of 
incubation, as well as the results of the two-way ANOVA test, are presented in Figure 51.  
GATA1 Expression 
 
 
Figure 51. Comparison of the fold-change of GATA1+ cells in the untreated and VD3-treated 
E14 / OP9 co-cultures after different days of incubation 
N = 9. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
In both treated and untreated groups, there was GATA1 gene expression from day 2, 
though this expression registered no time-dependent increase in its magnitude until after 
day 5. For the treated group, the peak of gene expression was not reached until at least 
day 12, whereas its counterpart in the untreated group appeared around day 9, with noted 
decrease towards zero afterwards. The most significant difference in gene expressions 
between the two groups was registered on day 12. This significance was confirmed by 
the Bonferroni post-hoc analysis.   
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GATA2 gene expression 
The mean magnitude of GATA2 gene expression of both untreated control and VD3-
treated E14 cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of 
incubation, as well as the results of the two-way ANOVA test, are presented in Figure 52.  
GATA2 Expression 
 
 
Figure 52. Comparison of the fold-change of GATA2+ cells in the untreated and VD3-treated 
E14 / OP9 co-cultures after different days of incubation 
N = 9. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
In the untreated control, the magnitude of GATA2 gene expression was small and slowly 
decreasing throughout the period. In the treated group, however, the expression was 
notably increased from virtually zero to a peak around day 5 before more slowly decreases 
to almost zero after day 12. In other words, the expression of GATA2 was more 
concentrated around day 5 in the treated group. The magnitude of GATA2 gene 
expression in treated cells was generally superior to that of untreated cells on days 5, 8 
and 12. The maximum GATA2 gene expression differential between the treated and the 
untreated E14 cells was on day 5. The significances of these were confirmed by the 
Bonferroni post-hoc analysis.   
*** *** 
 133 
SCL gene expression 
The mean magnitude of SCL gene expression of both untreated control and VD3-treated 
E14 cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation 
are presented in Figure 53.   
SCL Expression 
  
Figure 53. Comparison of the fold-change of SCL+ cells in the untreated and VD3-treated E14 / 
OP9 co-cultures after different days of incubation 
N = 9. 
The SCL gene expression was very low in the untreated control, increasing slowly from 
zero to a small peak around day 8 before gradually reduced to nearly zero again after day 
12. In contrast, the expression was much higher throughout the period in comparison, 
slowly increased to a peak around day 4 to a value slightly higher than the initial value. 
Afterwards, the expression slowly reduced to nearly zero after day 12. The strength of the 
peak expression for the treated group was about four times of that of the untreated control. 
The maximum difference between the SCL gene expressions of the two groups appeared 
on day 2. 
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p21 gene expression 
The mean magnitude of p21 gene expression of both untreated control and VD3-treated 
E14 cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation 
are presented in Figure 54.  
p21 Expression 
 
Figure 54. Comparison of the fold-change of p21+ cells in the untreated and VD3-treated E14 / 
OP9 co-cultures after different days of incubation 
N = 9. 
The level of p21 gene expression was small in both control and treated groups. However, 
the expression was generally decreasing for the untreated control throughout the duration 
of observation, whereas its counterpart in the treated group was constantly increasing in 
the same duration. The magnitudes of the p21 gene expression of these two groups were 
comparable at day 8. The maximum difference between the p21 gene expressions of the 
treated and the untreated E14 cells was on day 12.  
p27 gene expression 
The mean levels of p27 gene expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 55.  
 135 
p27 Expression 
 
Figure 55. Comparison of the fold-change of p27+ cells in the untreated and VD3-treated E14 / 
OP9 co-cultures after different days of incubation 
N = 9. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
 
In both the untreated control and the treated group, the magnitude of the p27 gene 
expression was small and constantly decreased notably throughout the duration, and the 
greatest difference between the measurements of both groups was observed in the 
beginning. The significance of this difference was confirmed by the Bonferroni post-hoc 
analysis. The initial magnitude was around seven times greater than the terminal 
measurement in both groups. Throughout the duration, the magnitude in the treated 
groups was roughly between 1.5 and 2 times of its counterpart in the untreated control.  
Summary 
In control, the expression of FLK appeared towards the beginning of the duration. 
GATA1, GATA2 and SCL expressions were detected about the same time as the CD34+ 
cells. GATA1 expression gradually increased up to day 10 of culture, whilst GATA2 and 
SCL expression peaked around the middle of the observed duration and then gradually 
decreased. In comparison, the peaks of FLK, GATA2 and SCL in the treated co-cultures 
appeared earlier and higher, and GATA1 expression in the treated co-cultures appeared 
higher and continued increasing till the end of the duration. The higher peaks for VD3-
treated E14 cells suggest that VD3 promotes cell differentiation. 
* 
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With the presence of VD3, the general expression of p21 gradually increased towards day 
12. This correlated with the fact that p21 played the role of stopping the cell progressing 
from the G2 phase to the M phase and thus it supressed proliferation. In other words, the 
up-regulation this expression indicated that proliferation had been hindered.  
On the other hand, compared with the control, the p27 gene expression was constantly 
greater and had peaked earlier. This correlated with the fact that p27 played the role of 
stopping the cell progressing from the G1 phase to the S phase and thus enabled 
differentiation. In other words, the early up-regulation of its expression indicated that 
differentiation had been encouraged.  
  
 137 
3.4.5 Cytokine multiplex assay 
G-CSF Expression 
The mean levels of G-CSF expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 56.  
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Figure 56. Comparison of the G-CSF expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis.  
GM-CSF Expression 
The mean levels of GM-CSF expression of both untreated control and VD3-treated E14 
cells in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well 
as the results of the two-way ANOVA test, are presented in Figure 57.  
*** *** *** *** *** 
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Figure 57. Comparison of the GM-CSF expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
IL-1α Expression 
The mean levels of IL-1α expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 58.  
*** *** *** *** *** 
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Figure 58. Comparison of the IL-1α expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
IL-3 Expression 
The mean levels of IL-3 expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 59.  
*** *** *** *** *** 
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Figure 59. Comparison of the IL-3 expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
IL-4 Expression 
The mean levels of IL-4 expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 60.  
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Figure 60. Comparison of the IL-4 expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
*** *** *** *** *** 
*** *** *** *** *** 
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According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
IL-5 Expression 
The mean levels of IL-5 expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 61.  
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Figure 61. Comparison of the IL-5 expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
IL-6 Expression 
The mean levels of IL-6 expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 62.  
*** *** *** *** *** 
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Figure 62. Comparison of the IL-6 expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
TNF-α Expression 
The mean levels of TNF-α expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 63.  
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Figure 63. Comparison of the TNF-α expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
*** *** *** *** *** 
*** *** *** *** *** 
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According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
VEGF Expression 
The mean levels of VEGF expression of both untreated control and VD3-treated E14 cells 
in co-culture with OP9 cells taken after days 2, 5, 8, 10 and 12 of incubation, as well as 
the results of the two-way ANOVA test, are presented in Figure 64.  
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Figure 64. Comparison of the VEGF expressions in both control and treatment 
N = 3. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001) 
According to the 2-way ANOVA test, both time and the presence of VD3 were significant 
factors of the measurement of expression. The significance was confirmed by the 
Bonferroni post-hoc analysis. 
Summary 
In the control, the measurements of IL-1α expression were constantly high throughout the 
duration. The temporal kinetic of the VEGF expression showed an early build-up to a 
minor peak around days 5 and 8 and sustained throughout the duration. The temporal 
kinetics of the TNF expression followed the initial trend of that of VEGF and remained 
constant after day 5.  
*** *** *** *** *** 
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This was followed by the temporal kinetics of both the GM-CSF and the G-CSF 
expressions, and these were subsequently followed by the temporal kinetics of both the 
IL-3 and the IL-5 expression. 
The temporal kinetics of both the IL-4 and the IL-6 expressions also followed that of the 
VEGF expression.  
On the other hand, compared with the control samples, the expression of each cytokine is 
statistically significantly higher in the treated samples overall. This suggests that the 
presence of VD3 encourages the expressions of these cytokine. As these cytokines are 
related to the presence of various blood cells, higher levels of these cytokines also 
suggests higher numbers of those blood cells, which are the products of differentiation 
from HSCs. Thus, these results suggest that VD3 encourages HSC differentiation.  
3.5 Discussion   
In this study, the E14 / OP9 co-culture has been used successfully for haematopoietic 
differentiation of mouse and non-human primate ESCs and to obtain multilineage 
haematopoietic progenitors, as well as mature haematopoietic cells, such as lymphocytes 
and megakaryocytes, which avoid the ethical challenge facing the alternative method 
using the embryoid body (Vodyanik et al., 2005). The onset of haematopoiesis and the 
appearance of early haematopoietic progenitors in the E14 / OP9 co-culture were 
investigated through the evaluation of CFCs and the expressions of haematopoiesis-
associated molecules, including CD markers, genes and cytokines, on both 
undifferentiated and differentiated ESCs during incubation up to 12 days.  
3.5.1 Haematopoiesis in the E14 / OP9 co-culture 
First, the study demonstrated that it was appropriate to use the E14 / OP9 co-culture for 
the study on haematopoiesis because signs of various cell differentiations associated with 
different stages of haematopoiesis had been observed. In the control, FLK+ cells appeared 
from the beginning of the duration and the number of cells peaked on day 8 before 
dropping drastically on day 10. CD34+ cells appeared noticeably on days 5, 8 and 10. The 
temporal trend of the CD31+ cells closely followed that of CD34+ cells by 1 or 2 days. 
CD41+ cells appeared 3 days after the CD34+ population and gradually increased by day 
10 of culture. CD43+ cells were present throughout the duration, gradually peaked on day 
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10. The number of CD45+ cells fluctuated around 5% after day 5. This showed that FLK+ 
mesoderm (Lynch et al., 2011) appeared first, followed by the appearance of CD34+ 
haematopoietic progenitor cells (Krause et al., 1994) and CD31+ endothelia cells (Choi 
et al., 1998), followed by the appearance of CD41+ early haematopoietic progenitors, 
platelets and megakaryocytes (Ferkowicz et al., 2003). The gradual increase of CD43+ 
cells suggested the accumulation of various differentiated cells, such as granulocytes, 
monocytes, macrophages, etc. (Vodyanik, 2005), whereas the presences of 
lymphohaematopoietic cells were shown by the measurement of CD45 (Saltini et al., 
1990). These temporal changes indicated the occurrences of various forms of cell 
differentiations at different stages of haematopoiesis.  
Likewise, in the findings regarding gene expressions, GATA1, GATA2 and SCL 
expressions in the control group were detected about the same time as the CD34+ cells. 
GATA1 expression gradually increased up to day 10 of culture, whilst GATA2 and SCL 
expression peaked around the middle of the observed duration and then gradually 
decreased. As SCL played an important role in haematopoietic differentiation (Lim et al., 
2013), its expression indicated the appearance of haematopoietic differentiation. This was 
accompanied by the expression of GATA2 as the protein encoded by GATA2 plays an 
essential role in regulating transcription of genes involved in the development of 
haematopoietic cell lineages (Gerber et al,. 2002). The gradual increase of GATA1 
expression was linked to the gradual appearances of various cell lines produced from the 
haematopoiesis process (Lim et al., 2013).  
These were supported by the findings with CFCs. E-CFCs and GEMM-CFCs were 
induced towards the beginning of the duration. The former coincided with the appearance 
of CD34+ progenitor cells, whilst the latter concurred with the appearance of CD41+ and 
CD43+ cells. GM-CFCs and M-CFCs appeared later, in accord with the induction of 
CD45+ cells. 
These were in agreement with the reduction of Oct4, Sox2 and Nanog expressions 
through the passage of time with immunofluorescence, and the temporal kinetics the 
appearance of various cells revealed by the expressions of various cytokines. All of these 
indicated progress in cellular differentiation from haematopoietic cells to different cell 
lineages.  
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As to the findings of the study of cytokines, the measurements of IL-1α expression were 
constantly high throughout the duration. This was in line of the role of IL-1 in helping the 
induction of the IL-2 receptor and stimulating the release of other cytokines involved in 
haematopoiesis (Gerber and Ferrara, 2003). 
The temporal kinetic of the VEGF expression showed an early build-up to a minor peak 
around days 5 and 8 and sustained throughout the duration. This early expression was in 
line with the role VEGF plays in helping the initiation of haematopoietic differentiation 
and promotes the formation of terminally differentiated red blood cells (Kurzrock, 2000).  
The temporal kinetics of the TNF expression followed the initial trend of that of VEGF 
and remained constant after day 5. This was in line of the role TNF plays in stimulates 
cell proliferation and induce cell differentiation under certain conditions (Gerber et al., 
2002).  
This was followed by the temporal kinetics of both the GM-CSF and the G-CSF 
expressions. This indicated the further differentiation from myeloid stem cells, as the 
GM-CSF is required for the differentiation of haematopoietic precursors of the 
granulocyte and monocyte lineages (Xu et al., 2000), and G-CSF is required for the 
differentiation of haematopoietic precursor of the granulocyte lineage (Kurzrock, 2000).  
This was also closely followed by the temporal kinetics of both the IL-3 and the IL-5 
expression, because IL-3 works in conjunction with other haematopoietic growth factors 
to increase the production of erythrocytes, neutrophils, eosinophils, monocytes and 
platelets, whilst IL-5 stimulates eosinophil expansion (Gerber et al,. 2002). 
The temporal kinetics of both the IL-4 and the IL-6 expressions followed that of the 
VEGF expression, but there were also build-up of IL-6 expression towards the end of the 
duration. This was primarily related to the cell differentiation from lymphoid stem cells, 
as IL-4 stimulates B cell proliferation and activation, and IL-6 acts on T cells and B cells 
and stimulates multilineage haematopoiesis, including the maturation of megakaryocytes 
(Rodak et al., 2008).  
Thus, the temporal relations of these findings indicate the process of haematopoiesis was 
in progression in the E14 / OP9 co-culture throughout the duration of the study.  
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Therefore, all these observations showed that, in the E14 / OP9 co-culture, E14 cells had 
not only differentiated, but also differentiated into cells of various haematopoietic 
lineages. In other words, haematopoiesis had happened. Moreover, the differentiation into 
myeloid, lymphoid, erythroid, and megakaryocytic lineage cells had all occurred in the 
co-culture, so it is an appropriate means to study all lineages of haematopoiesis.  
These findings confirm with the findings of several prior researches. Nakano et al. (1994) 
showed that ESCs can be induced in vitro to differentiate into myeloid, lymphoid, 
erythroid, and megakaryocytic lineage cells by co-culturing with OP9. Maureen et al. 
(2001) found that, when cultured on OP9 stromal cells, ESCs differentiate into FLK1+ 
haemangioblasts, hematopoietic progenitors, and finally mature, terminally differentiated 
lineages. Vodyanik et al. (2006) showed that it was possible to observe the 
haematopoietic differentiation of ESCs, CD34+ cells and CFCs in OP9 co-culture. It was 
also found that another benefit of OP9 co-culture was that CD34+ cells could be generated 
in large quantity without the addition of cytokines. These studies and others (Lynch et al., 
2011; Lim, et al., 2013) showed that the in vitro ESC/OP9 co-culture system can be used 
to recapitulate the early stages of hematopoietic development and support both 
haemogenic precursors and their primitive haematopoietic progeny. 
3.5.2 The effects of VD3 on haematopoiesis 
Secondly, the effects of VD3 in promoting cell differentiation and suppressing cell 
proliferation in the haematopoietic process were studied through the comparison of 
treatment with control. With immunofluorescence, the more visible reduction of Oct4, 
Sox2 and Nanog expressions showed that a greater percentage of the cells had 
differentiated with VD3 than without, i.e., cell differentiation had been enhanced by the 
presence of VD3.  
Compared with the control, FLK expression appeared earlier and the expression was 
greater in the treatment. This meant that the FLK+ mesoderm (Lynch et al., 2011) had 
appeared earlier and in greater quantity. The peak of CD34 expression was earlier and 
significantly higher, shifting from day 10 to day 8. This suggested that the CD34+ 
haematopoietic progenitor cells (Krause et al., 1994) appeared earlier and in greater 
quantity. The peak of CD31 expression shifted from day 8 to day 5, suggesting the CD31+ 
endothelia cells (Choi et al., 1998) appeared earlier. The expression of CD41 was greater 
and had a significantly great peak on day 10. This meant that CD41+ early haematopoietic 
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progenitors (Ferkowicz et al., 2003) appeared earlier and in greater quantity. The 
measurements of CD43 expression were greater on all days and had a significantly greater 
peak on day 5 shifted early from day 10. This indicated an earlier build-up of various 
CD43+ differentiated cells (Vodyanik, 2005). The expression of CD45 was greater on all 
days and had a significant peak on day 12. This showed that greater quantities of 
lymphohaematopoietic cells (Saltini et al., 1990) were produced through cell 
differentiation. Thus, these temporal trends indicated that cellular differentiation had 
happened earlier with the presence of VD3. The greater measurements suggested that the 
activity of cell differentiation had been intensified. Both of these were indications that 
cell differentiation in haematopoiesis had been promoted by the presence of VD3. 
This was supported by the findings with CFCs in which, compared with the control, the 
quantities of all four types of CFCs were higher in the treatment in general. This suggested 
that more cells were formed through cell differentiation.  
In the findings regarding gene expressions, in comparison with the control, the peaks of 
FLK, GATA2 and SCL in the treated co-cultures appeared earlier and higher, and GATA1 
expression in the treated co-cultures appeared higher and continued increasing till the end 
of the duration. The higher peaks for VD3-treated E14 cells suggest that VD3 promotes 
and accelerates cell differentiation. 
With the presence of VD3, the general expression of p21 gradually increased towards day 
12. This correlated with the fact that p21 played the role of stopping the cell transiting 
from the G1 phase to the S phase (Fecteau et al., 2014). With the up-regulation of p21, 
CDK2 activation was reduced. This actuated G1/S cell cycle arrest, so cells could not 
proliferate.  
On the other hand, compared with the control, the p27 gene expression was constantly 
greater and had peaked earlier. This correlated with the fact that p27 played the role of 
stopping the cell progressing from the G1 phase to the S phase and thus enabled 
differentiation (Galderisi et al., 2003). In other words, the early up-regulation of its 
expression indicated that differentiation had been encouraged.  
Thus, the findings on all gene expressions studied indicated that, in haematopoiesis, VD3 
promotes and accelerates cell differentiation and supresses proliferation.  
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As to the findings of the study of cytokines, overall, the expression of each cytokine is 
statistically significantly higher in the treated sample than in the control sample. This 
suggests that the presence of VD3 encourages the expressions of these cytokine. As these 
cytokines are related to the presence of various blood cells, higher levels of these 
cytokines also suggests higher numbers of those blood cells, which are the products of 
differentiation from HSCs. Thus, these results suggest that VD3 encourages HSC 
differentiation.  
Therefore, all these comparisons between the treatment and the control showed that, in 
the E14 / OP9 co-culture, with the presence of VD3, haematopoietic differentiations in all 
related cell lineages had been promoted and accelerated, whilst proliferation had been 
supressed. In other words, it was found in this study that VD3 promotes and at times 
accelerates cellular differentiation, as shown by higher and sometimes earlier peaks in 
CFC numbers, CD-marker expressions, gene expressions and cytokine expressions. 
These findings with E14 / OP9 co-culture is in agreement with those of the related prior 
in vitro studies using other cell lines, in spite of the major difference that this study was 
conducted on non- cancer embryonic stem cells whilst the others were on cancer cells. 
Significant anti-cancer effects with the addition of VD3 or its analogues have been shown 
in these studies using squamous cell carcinoma (Hershberger et al., 1999), prostrate 
adenocarcinoma (Getzenberg et al., 1997), ovary cancer cells (Zhang et al., 2005), breast 
cancer cells (Colston et al., 1992) and lung cancer cells (Nakagawa et al., 2005).  
3.5.3 Correlation with researches on cell-cycle 
perturbation by VD3 
Through various related researches, aspects of the mechanism with which VD3 affects 
cell proliferation and differentiation had been discovered. It is understood that the anti-
proliferation and pro-differentiation activity of VD3 is through cell-cycle perturbation. It 
has been demonstrated that the effects of VD3 and its derivatives operate by means of the 
VDR to regulate proliferation, apoptosis (Simboli-Campbell et al., 1996) and 
angiogenesis (Mantell et al., 2000). VDR encodes the proteins p21 and p27 involved in 
blocking cell cycle progression (Liu et al., 1995). It was found that VD3-induced cell-
cycle arrest by means of the VDR in the proliferating C2C12 cells is indicated by the 
dose-dependent increase of the VDR mRNA level (Hiroshi et al., 2012).  
 150 
On the other hand, genes mediating G1 arrest are induced by hormonal agents like 
1,25(OH)2D3 to initiate an induction that leads to terminal differentiation. The 
differentiation pathway can be activated by merely arresting these cells in G1 with p21 
and p27 (Liu et al., 1996), which are proteins encoded by the VDR, and the process can 
be induced by VD3 (Hiroshi et al., 2012). 
Additionally, cyclins and their associations with CDKs and CDK inhibitors (CKIs) all 
regulate cell cycle progression, in which p21 and p27 (Toyoshima et al., 1994) have been 
found to be inhibitors of G1 cyclin-dependent kinase. VD3 treatment inducing a G0 / G1 
phase arrest in squamous cell carcinoma cell lines (Hager et al., 2001) and, also, breast-
cancer MCF-7 cells (Verlinden et al., 1998) reportedly increased expressions of p21 and 
p27. The gene expressions of p21 and p27 were up-regulated by VD3 treatment in the 
C2C12 myoblast cell line (Hiroshi et al., 2012). 
Furthermore, VD3 inhibits the phosphorylation of retinoblastoma (pRb) and blocks 
progression of the cell cycle from G1 to S phase. Significant decreases in the amount of 
pRb and significant increased expression of p21 and p27 were also observed in monocytes 
leukaemia, which preceded the appearance of dephosphorylated pRb (Kanatani et al., 
1999). Therefore, the findings from the studies mentioned above suggest that VD3 
treatment up-regulates p21 and p27 gene expressions, through which CKIs influence cell-
phase arrest.  
The findings of this study as discussed so far suggested that these processes had occurred 
in haematopoiesis.  
3.6 Conclusion 
With optimal dosage, VD3 was found to inhibit the proliferation of E14 and OP9 cells. 
This inhibition was evident in terms of decreased cell number. Visually, alkaline-
phosphatase staining revealed significant differences between VD3-treated and untreated 
cells, characterised by decreased enzyme expression (resulting in colourless cells). Cell-
cycle analyses using propidium-iodide showed no significant percentage change in VD3-
treated E14 and OP9 cells compared to the untreated controls within their G and S-phases.  
With optimal dosage, VD3 was also found to promote and accelerate the differentiation 
of the cells in the treated E14 / OP9 co-cultures, whereby GM-CFC number, in 
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concurrence with FLK, CD31, CD34 and CD43 markers, together with FLK, GATA2 
and SCL gene expressions, manifested earlier (accelerated) and higher (promoted) peak 
values, which then markedly decreased. In contrast, M-CFC number, in concurrence with 
CD45 marker, together with GATA1 and p21 gene expressions, peaked with later and 
higher values towards day 12, compared with the untreated co-cultures.  
Thus, the findings demonstrated that VD3 enhanced cellular differentiation in E14 / OP9 
co-cultures, in which ESC-derived CD34+ progenitor cells became highly enriched in 
colony-forming cells that expressed haematopoiesis-associated genes GATA1, GATA2, 
SCL, and FLK, such that the phenotype of primitive haematopoietic progenitors and 
definitive hematopoietic stem cells were displayed.  
The findings of the research on separate E14 and OP9 cultures as well as on the E14 / 
OP9 co-culture indicate that VD3 treatment up-regulates p21 and p27 gene expressions. 
Although cyclin-dependent kinase inhibitor protein (CDK-CDI) through p21 and p27 is 
thought to influence cell-phase arrest, adequate VD3 concentration could still enhance 
cellular differentiation and inhibits proliferation. Furthermore, this is supported by the 
fact that the expressions of various cytokines associated with various blood cells are also 
higher when VD3 is present. 
This was the first demonstration of the anabolic effect of VD3 on mouse embryonic stem 
cells (E14 cell line) co-cultured on OP9 stromal cells in vitro, confirming similar 
researches using other cells suggesting potential clinical effects of VD3 treatment. In other 
words, this research demonstrates that OP9 cells support both haemogenic precursors and 
their primitive hematopoietic progeny, making it possible to generate hematopoietic stem 
cells from ESC lines.  
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Chapter 4 A Pilot Study into the Effects of VD3 
on Human Haematopoiesis in Vivo  
 
4.1 Introduction 
It is found through the studies described in the previous two chapters that VD3 is crucial 
in promoting the differentiation and suppressing the proliferation of both E14 and OP9 
cells, and accelerates and promotes haematopoiesis of E14 cells in the presence of OP9 
cells in vitro. Previous researches by others also reveal that VD3 regulates bone health 
and many features of the immune system, and it has been shown to be a powerful 
differentiation inducer for a wide variety of neoplastic cells. Therefore, the next step in 
the study would be to ascertain whether a lower level of VD3 hinders haematopoiesis. To 
achieve this, in vivo studies have been done with human participants during winter when 
the chance of exposure to sunlight for VD3 synthesis is limited.  
The objective of this part of the research is to establish the effect of VD3 level on the stem 
cell count and the numbers of three major types of blood cells. It is hypothesised that the 
stem-cell count and the numbers of three major types of blood cells decline over time as 
the VD3 level diminishes. The null hypothesis will be that VD3 level will have no effect 
on the number of stem cell and the total number of blood cells.  
Thus, to achieve this objective, it is necessary to accomplish the following three tasks 
first:  
1. Recruit normal healthy participants; 
2. Collect blood samples from the participants monthly over the period of study;   
3. Measure the VD3 level of blood samples;  
4. Measure the stem-cell count by determining circulating CD34+ haematopoietic 
progenitor cells;  
5. Measure the total number of blood cells and the various differentiated cells. 
Once these tasks are accomplished, the results would be analysed and compared with one 
another to test the hypothesis.  
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The materials, equipment, principles and methods used for the experiments to obtain these 
measurements, the results obtained from the experiments, and the finding from the 
analysis of these obtained results are presented in the subsequent sections of this chapter.   
4.2 Principles and Methods 
4.2.1 Ethical approval 
Before the commencement of the study, the standard ethics procedure of the university 
(Appendix A.2) was followed and the ethical approval for the study was obtained 
(Appendix A.3).  
4.2.2 Demographics of the participants 
Initially, sixteen healthy participants of aged between 35 and 45, eight men and eight 
women, were recruited amongst the research students of the university to take part in this 
study. Eventually, four of the original eight men did not stay with the study through to 
the end, so only the samples of twelve of these participants, four men and eight women, 
were used for this study. None of the participants were VD deficient at the beginning of 
the experiment or throughout its duration according to the US national guideline as serum 
25(OH)D levels greater than 20 ng/mL were generally considered adequate for healthy 
individuals (IOM, 2011). The demographic characteristics of the participants are shown 
in Table 7.  
Table 7. Demographic characteristics of the participants 
 
Participant Code Sample Code Age Gender Baseline VD Status Comments 
    25(OH)D 1,25(OH)2D  
    (ng/mL) (pg/mL)  
PN_001 MMU_001 43 F 21.1 31  
PN_002 MMU_002 45 M 27.0 49  
PN_003      withdrawn 
PN_004      withdrawn 
PN_005 MMU_003 36 F 23.5 48  
PN_006 MMU_004 35 F 21.5 24  
PN_007      withdrawn 
PN_008 MMU_005 41 F 29.8 41  
PN_009 MMU_006 40 F 22.2 52  
PN_010 MMU_007 43 M 31.4 34  
PN_011 MMU_008 43 M 21.1 77  
PN_012 MMU_009 45 M 20.6 46  
PN_013 MMU_010 43 F 24.7 47  
PN_014 MMU_011 35 F 31.4 52  
PN_015 MMU_012 43 F 24.3 48  
PN_016      withdrawn 
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4.2.3 Recruitment of participants 
Advertisements (Appendix A.4) had been put up in the university campus for recruitment. 
During the recruitment process, potential participants were provided with the details of 
this study. Information of this study was provided in verbal and written formats 
(Appendix A.5) in order for potential participants to make an informed decision on 
whether or not to participate. Participants were encouraged to understand this information 
and make a considered decision on their own, away from the researchers. Each participant 
was asked to sign a copy of the consent form to give their consent (Appendix A.6), whilst 
they had the right to withdraw from the experiment at any time, too. They were also asked 
to complete a medical questionnaire (Appendix A.7) with which they needed to answer 
several questions about their general health as well as any medication or supplement that 
they took regularly. All recorded details from these questionnaires were completely 
anonymous (free from any potential identification). This was achieved by allocating each 
participant with a non-identifiable participant number (PN). Based on these details, only 
the ones stated negatively to all of these questions were included in the study.  
4.2.4 Sample collection and management 
Each of the participants contributed blood samples in a procedure taking no more than 15 
minutes each time. The samples were taken by a phlebotomist by inserting a needle into 
an antecubital vein. Each time, three baseline blood samples of 5 mL each were taken. 
After obtaining the blood, the needle was removed and gauze applied at the site of 
venepuncture. The participants were then free to leave the laboratory.  
Two of these three samples collected were kept in 5 mL serum tubes (without anti-
coagulant) and the other in a 5 mL EDTA tube (with anticoagulant). These two types of 
tubes are shown in Figure 65. The samples in the serum tubes were for Vitamin D 
measurements, and the samples in the EDTA tubes were for the various blood cell counts.  
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 (a)  (b)  
Figure 65. (a) 5 mL Serum tube (without anti-coagulant) and (b) 5 mL EDTA tube (with anti-
coagulant) used for blood sample collection 
All raw samples and data were stored anonymously under a participant number (PN) 
rather than by name. Data storage was complied with the Data Protection Act (1998). If 
a participant had decided to withdraw from the study at any time after the experimental 
procedure commenced, all that participant’s samples and data stored in whatever format 
would be destroyed. 
The blood samples thus collected were then used in the three experiments described in 
the following sections.  
4.2.5 Tests for Vitamin D measurement  
Serum Preparation  
After collection, the blood samples kept in serum tubes were allowed to clot by leaving it 
undisturbed at room temperature. This usually took 15-30 minutes. The clot was removed 
by centrifuging at 1000-2000 × g for 10 minutes in a refrigerated centrifuge. Following 
centrifugation, the liquid component (serum) was transferred into a clean polypropylene 
tube using a Pasteur pipette. Serum is the blood extract which contains all the proteins 
not used in blood clotting (coagulation) and all the electrolytes, antibodies, antigens and 
hormones. The samples were maintained at -80° C whilst in transit to the NHS. Special 
couriers were used to transfer the serum samples to the NHS laboratories at the 
Manchester Central Hospitals.  
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Liquid chromatography 
At the NHS, examination was done by means of liquid chromatography mass 
spectroscopy (LCMS). It is liquid chromatography used in conjunction with tandem mass 
spectrometry. This is a potent technique in providing selectivity, sensitivity and reliability 
in results. It is used to separate and measure the concentration of VD3 from the midst of 
other hormones and protein.  
Chromatography refers to the use of any analytical technique with which components of 
mixtures of molecules could be separated out for identification, and possibly for their 
concentrations in the original mixture to be estimated. A substance for investigation in a 
sample is known as an analyte. However, other substances in a biological or clinical 
sample may interfere or be confused with the analyte, making it necessary to separate and 
isolate it. Chromatography techniques are mainly used to remove contaminants from the 
analyte under investigation, to make it possible to identify unknown analytes, and to 
determine analyte concentration. 
Generally, the fundamental principle of all chromatography techniques is that of the 
differences between the relative affinities of the polar molecules in a mixture of two 
distinct and immiscible phases, with one mobile and the other stationary. Irrespective of 
the particular type of chromatography, each substance in a mixture can be separated out 
from the rest by its different affinities to the two phases (Glencross et al., 2011; James 
2009). This is demonstrated schematically in Figure 66.  
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Figure 66. Schematic representation of chromatography in which two substances separated out 
using differences in their relative affinities to two phases 
(Source: Glencross, Ahmed & Wang, 2011) 
The way a substance distributes at equilibrium between the immiscible mobile and 
stationary phases is described by the partition coefficient (Kd). As shown in Figure 67, 
for a substance X distributing between the mobile and stationary phases, denoted as A 
and B, respectively, at respective concentrations of X[A] and X[B], Kd is defined as   
Kd = X[A] / X[B] 
 
 
Figure 67. Schematic illustration of a substance distributing at equilibrium between two 
immiscible phases in chromatography 
 
 
High-performance liquid chromatography (HPLC) 
Adsorption and partition effects are generally involved in the methods of high-
performance liquid chromatography. Partition chromatography works by using the 
differences in solubility and partition coefficients of polar substances to separate them 
 
X[A] 
A 
B 
X[B] 
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between the mobile and stationary phases. The two partition-chromatography techniques 
that tend to be used are the normal-phase and reverse-phase liquid chromatography, and 
the latter is the commonest type of HPLC. In the normal phase, the stationary phase is a 
polar substance and the mobile phase a non-polar solvent in the normal phase. On the 
other hand, the contrary occurs in reverse phase liquid chromatography, where the 
stationary phase is a non-polar substance, and the mobile phase a polar solvent. The major 
components of a high performance liquid chromatography system are shown in Figure 
68. 
 
Figure 68. The major components of a high-performance liquid chromatography system 
(Source: Glencross et al., 2011) 
 
Mass spectrometry 
Mass spectrometry in general involves a spectrometer consisting of an ioniser or source 
region, a mass analyser, and a detector, as shown in Figure 69.  
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Figure 69. The general organisation of a mass spectrometer  
(Source: Glencross et al., 2011) 
Each of these three parts is kept at high vacuum so as to minimise collisions between 
analyte and residual air molecules, which could diminish accuracy in analysis. For atoms 
or molecules in a sample, it is necessary to add or remove a H+ ion to ionise them, giving 
a positive ([M-H]+) or a negative ([M-H]-) ion, respectively. The site of ionisation is the 
source region.  
Once ionisation has taken place, a potential difference is applied to transfer the sample 
into the analyser. The ions produced are separated from the different components of the 
initial sample by using static or dynamic electric or magnetic fields in the analyser. Since 
each ion has a characteristic movement through the analyser, dependent on its mass, 
separation of the ions takes place (Glencross et al., 2011), as shown in Figure 70. 
 
Figure 70. The overview of the operation of a mass spectrometer.  
An electric potential difference is used to accelerate ions through the system.  
(Source: Glencross et al., 2011) 
 
Tandem mass spectrometry 
Tandem mass spectrometry, used to separate mixtures, involves a spectrometer consisting 
of an ioniser or source region, two mass analysers in sequence with a collision-induced 
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dissociation (CID) cell between them, and a detector. This is illustrated in Figure 71. After 
introducing the sample into the ioniser, separation one from another of the individual 
components of the mixture occurs in the first analyser and a selected ion is transmitted 
into the CID cell. The ion is fragmented in the CID cell. The second analyser analyses 
fragments of ions from an individual component to yield an MS / MS spectrum that 
represents the specific compound. Fragmentation of ions from any given compound of 
the sample tends to occur in a predictable way. Therefore, fragment sizes produced can 
be pieced together like a jigsaw puzzle to reveal information about the structure of the 
component (Glencross et al., 2011).  
 
Figure 71. The general organisation of a tandem mass spectrometer  
(Source: Glencross et al., 2011) 
 
4.2.6 Phenotype analysis by flow cytometry 
As mentioned above, a major difficulty in using ESCs is the problem of identifying them 
amongst other types of cells. One of the means of distinguishing the identity of a 
particular cell type is by molecular cell markers. These markers result from unique gene 
expression patterns within cells. In this way, such markers can be most useful in 
identifying undifferentiated and differentiated ESCs (Zhao et al., 2012; Moore, et al., 
2011).  
Cell Surface Markers 
Specialised proteins expressed on the surface of cells. These proteins are able to bind or 
adhere to other signal molecules (Zhao et al., 2012). Since each type of membrane protein 
has a different structure, the affinity for signal molecules is specific. Some proteins are 
only found or secrete in specific cell types, so the presence of specific proteins on the cell 
surface can act as cell markers. Cell-membrane proteins are the most important type of 
marker for identifying ESCs with the membrane remained intact. 
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Cluster of Differentiation (CD) Antigens 
Cell-surface marker antigens are surface proteins, known as cluster of differentiation 
molecules or CD molecules. This refers to specific cluster of epitopes on cell-surface 
antigens. The CD number indicates the cell-surface antigen and anti-CD monoclonal 
antibodies used to determine cell expression of individual CDs. 
CD antigens belong to various different classes. One class of these are integrins, which 
are α/β heterodimeric cell surface receptors that mediate the attachment of a cell to 
surrounding tissues. Some other classes are adhesion molecules, glycoproteins, and 
receptors. Since CD antigens vary according to cell types, they can be used as effective 
tools to identify and characterise different cell populations (Zhao et al., 2012). 
Principle 
The phenotyping process involves using a monoclonal antibody or antibodies (mAbs) 
directed against extracellular CD antigens. Fluorescent dyes, known as fluorochromes, 
are used to label the antibodies. The fluorochromes will vary in their response to lasers at 
different wavelengths.  By forcing a diluted cell suspension through a fine tube, the cells 
go through the laser beam in a flow-cytometer. The extent of light scattering is detected 
by sensitive photomultiplier tubes. Cell size can be obtained from the extent of forward 
scattering and cell granularity from side scattering. By measuring the fluorescence 
emission, those fluorochrome-labelled antibodies attached to the cells are indicated. The 
electronically stored data can be displayed as a graph or a histogram for analysis. A dot-
plot can display the total cell detected. In order to analyse sub-populations in greater 
detail, the dot-plot can be selectively gated.  
 
Figure 72. The BD FACSVerse™ flow cytometer 
(Source: www.bd.com) 
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The BD stem cell enumeration kit 
Using the BD Stem Cell Enumeration Kit (BD Biosciences, Oxford Science Park, Oxford, 
UK), assays are carried out with the samples being stained with suitable reagents in 
separate BD Trucount™ tubes. Fluorochrome-labelled antibodies attach themselves to 
specific cell-surface antigens when a blood sample is added to the reagent, whilst the 
DNA and RNA of all nucleated cells are stained by the nucleic-acid dye. A particular 
number of fluorescent beads are released when the lyophilised (frozen) pellet is dissolved 
in the BD Trucount™ tube. The overall procedure is illustrated in Figure 73.  
 
Figure 73. Overview of the procedure of phenotype analysis by flow cytometry 
(Source: 
www.bdbiosciences.com/wcmimages/facscalibur_features_beadsflowchart_lrg.jpg) 
The extent of non-specific binding is assessed by means of the control agent. Amongst 
such bindings, especial attention is given to the ones brought about by fragment 
crystallisable (Fc) receptors, which are the proteins on the surface of particular cells, such 
as lymphocytes, natural killer cells, macrophages and neutrophils. Before the sample is 
obtained on flow cytometry, erythrocytes are lysed using BD FACS™ lysing solution. 
During analysis, the respective absolute numbers of CD34+ and CD45+ progenitor cells 
in the sample can be determined by dividing the respective numbers of CD34 and CD45 
cellular events by the number of fluorescent bead events, then multiplying by the bead 
concentration. 
The reagents (BD Biosciences, Oxford Science Park, Oxford, UK) supplied with the BD 
stem cell enumeration kit are listed in Table 8 below.  
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Table 8. The reagents supplied with the BD stem cell enumeration kit 
(Source: BD Sciences, 2011) 
 
BD stem cells reagent 
(CD45/CD34) 
This is prepared in phosphate-buffered saline (PBS) 
containing bovine serum albumin (BSA) and 0.1% sodium 
azide. The reagent contains FITC and PE. 
CD45 fluorescein 
isothiocyanate (FITC) 
CD45 recognises human leucocyte antigen that is a member 
of the leucocyte common antigen (LCA) family, which is 
present on all human leucocytes and is weakly expressed 
on haematopoietic progenitor cells. 
CD34 phycoerythrin (PE) CD34 recognises the class III human progenitor cell antigen 
(HPCA). The CD34 antigen is present on immature 
haematopoietic precursor cells and all haematopoietic 
colony-forming cells in blood, including unipotent and 
pluripotent progenitor cells. 
7-aminoactinomycin-D 
(7-AAD) 
This is a nucleic-acid dye used to identify dead cells  
10x ammonium chloride 
lysing solution 
This is a fixative-free solution for red blood cell lysis 
50 BD Trucount™ tubes Each single-use tube contains a freeze-dried pellet of 
fluorescent beads. 
 
Method 
Circulating blood stem cells measurements   
The BD stem cell enumeration kit was used to determine the absolute counts of circulating 
CD34+ and CD45+ haematopoietic progenitor cells. This kit made it possible to enumerate 
CD34+ and CD45+ haematopoietic progenitor cells accurately and reproducibly. CD34 
and CD45 marker expressions were measured by means of a flow cytometer. To 100 μL 
of whole blood, 20 μL of CD45 FITC/CD34 PE reagent and 20 μL of 7-AAD reagent 
were added to a Trucount™ tube. Tubes of the samples were vortexed and then kept in 
the dark at room temperature for 20 minutes before 2 mL of 1x ammonium chloride lysing 
solution was added. Then the tubes containing the samples were vortexed and kept in the 
dark at room temperature for 10 minutes. Thus the samples were ready within 1 hour after 
lysis, and measurements were made using the BD FACSVerse™ flow cytometer. 
4.2.7 Blood cells counting  
Blood cell counts were obtained using the XS-1000i/XS-800i Sysmex blood-counting 
machine, as explained in the sections below. 
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Principle  
There are three broad types of blood cells, namely white blood cells, red blood cells and 
platelets. They range in diameter from about 15 μm (micrometres) in the case of white 
blood cells to about 2 μm for platelets. The basic form of measuring blood-cell number, 
and distinguishing their types according to size, is by sheath-flow DC detection using the 
XS-1000i/XS-800i Sysmex blood-counting machine. There are twee processes in this 
method, namely achieving accurate dilution, passing cell one by one through the detection 
aperture, and counting cells by the electric signals, as highlighted in Figure 74. These are 
described in the sections below.  
 
Accurate  
dilution 
Passing cells one by one  
through the detection aperture 
Counting cells  
by the electric signals 
 
  Stream of fluid that form a sheath 
Figure 74. Three processes in counting blood cells   
(Source: Sysmex, www.sysmex.co.jp) 
 
Achieving accurate dilution 
In order to reduce errors, it is necessary to achieve accurate dilution of the blood samples 
to avoid blood cells piling up together. The measuring chamber must exhibit micro-level 
precision. Degradation and abrasion are kept to a minimum by the apparatus used.   
Passing cells one by one through the detection aperture 
The process of counting the cells is aided by prior alignment. As illustrated in Figure 75, 
there is a stream of fluid forming a sheath around the flowing blood cells to keep them 
aligned and guided through the centre of the detection aperture to be counted. Backward 
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flow through the aperture is avoided by the flow of the sheath solution to ensure the flow 
of blood cells is unidirectional so that each cell will not be counted more than once.  
 
Figure 75. Passing cells one by one through the detection aperture  
(Source: Sysmex, www.sysmex.co.jp) 
 
Counting cells by the electric signals 
Electric current does not pass through blood cells easily. This means there is resistance 
when electric current is passed through a cell. Alternatively, as presented in Figure 76, an 
electric field (voltage) and its measurement (current) are set to go through a solution. 
When a cell goes through this current solution, the measurement of current is changed. 
Resistance is defined by the ratio between voltage and current. Because voltage is kept 
constant, resistance changes according to the change in current. In this way, cells can be 
counted according to how many times an electric resistance spike is read. Additionally, 
the larger the cell is, the greater the resistance will be, so cell types may be distinguished 
by the measurement of resistance.  
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Figure 76. Counting cells by the electric signals 
(Source: Sysmex, www.sysmex.co.jp) 
 
Acquiring more information using flow cytometry 
Flow cytometry can be used to reveal more information about blood cell counts because 
it can be used to measure the sizes of the cells, to examine the internal structures of the 
cells, and to analyse the chemicals within these cells.  
To do so, the red blood cells and platelets in the sample are first shrunk using a surfactant, 
and the white blood cells undergo nucleic-acid staining before being used in the flow 
cytometer. Once inside the flow cytometer, the cells in the sample are irradiated with a 
laser diode to produce forward-scattered light, side-scattered light and side-fluorescence.  
Analysis of the light signals enables the categorisation of the cells, as illustrated in Figure 
77. Cell size is indicated by forward-scattered light, internal cellular structure is shown 
by side-scattered light, and some information about the chemicals inside the cells is 
revealed by side-fluorescence. With the ability to obtain these additional details, 
therefore, this technique can be used to not only distinguish amongst the three main types 
of blood cells, but also classify the five different types of white blood cell, namely 
neutrophil, lymphocyte, monocyte, eosinophil and basophil. 
 167 
 
Figure 77. Information captured through flow cytometry  
(Source: Sysmex, www.sysmex.co.jp) 
 
Method 
From each of the blood samples collected from the participants, 2 mL of fresh blood was 
placed in an EDTA tube to stop it from clotting and was placed in a Sysmex XS-
1000i/XS-800i blood-counting machine shown in Figure 78 to ascertain the total blood-
cell count and the counts of the various differentiated cells.  
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Figure 78. General components of Sysmex XS-1000i/XS-800i blood-counting machine  
(Source: www.dotmed.com) 
Reagents for Sysmex blood-counting machine (Sysmex, UK) are listed in Table 9. 
Table 9. Sysmex blood-counting machine reagents   
(Source: Sysmex, www.sysmex.co.jp) 
 
Cell-pack isotonic diluent 
Stromatolyser 4DL lyse reagent in differential analysis 
Stromatolyser 2DS dye used in differential analysis 
Sulfolyser cyanid free haemoglobin reagent 
 
This same procedure for each participant, initially carried out in September, was repeated 
successively in the months of October, November and December. 
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4.3 Statistical Analyses 
Statistical analyses and significance of data were determined using GraphPad Prism 
version 5.00 for Mac OS X and Microsoft Windows (GraphPad Software, San Diego 
California USA).  
One-way ANOVA was used to analyse the data as the factors of time and VD3 level were 
considered in separately analyses. All results are presented as mean ± standard error of 
the mean (SEM). All values with p < 0.05 were considered as significant.  
The results of one-way ANOVA were further evaluated with various post-hoc tests. In 
the study of the correlation between time and other measurements, Tukey’s and 
Bonferroni’s multiple comparisons tests were used to perform pair-wise comparison to 
see if the differences between subsets of data were statistically significant. The former is 
more powerful with larger number of means whilst the latter is more powerful with 
smaller number of means, but it is recommended that both tests should be performed and 
the smaller of the two intervals be taken.  
Tukey’s and Bonferroni's multiple comparisons tests assume that variances are equal 
across groups or samples. The Bartlett test was used to verify that assumption. ANOVA 
assumes normality, i.e., samples are taken from a population with Gaussian distribution. 
As the Bartlett test is sensible to deviation from normality, it could also be used to test 
non-normality.  
In the study of the correlation between VD3 level and other measurements, Deming 
(1943) linear regression was applied to the data pairs to take into account of the 
measurement errors in both quantities. Pearson correlation and Spearman’s correlation 
were used to ascertain the correlation between the independent and dependent variables. 
The former makes the assumption that data are taken from a population with normal 
distribution, whilst the latter does not make that assumption and is considered to be more 
suitable when the sample size is small.  
To decide the result of which of these two is more relevant, normality tests were done on 
each sample data set to assess the probability that the random varialbe underlying the data 
set is normally distributed. If the data set passes the normality tests, the result of the 
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parametric Pearson correlation is used, otherwise that of the nonparametric Spearson’s 
correlation is used instead.  
There are three normality tests provided by GraphPad Prism. These are the D'Agostino-
Pearson omnibus test, the Shapiro-Wilk test and the Kolmogorov-Smirnov test, with the 
Dallal-Wilkinson-Lilliefor corrected P value. All three normality tests were used for these 
analyses. The D'Agostino-Pearson omnibus test is recommended by GraphPad Prism as 
it works well even if there are duplicated data and the mathematics basis is simpler, 
whereas the Shapiro-Wilk test works very well only if every value is unique and the 
mathematical basis is complex. The Kolmogorov-Smirnov test is weaker than the other 
two but can still be useful in situations where the performances of the other two are 
conpromised.  
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4.4 Results 
4.4.1 Correlations with time 
VD3 level vs. time 
The statistics of monthly measurements of VD3 levels from all participants, including the 
results of one-way ANOVA, was well as Tukey’s and Bonferroni multiple comparisons 
tests, are presented in Figure 79.  
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Figure 79. VD3 level vs. month for all participants 
N = 12. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001; ****: p < 0.00001) 
The monthly average of 25(OH)D level rose from 57.667 pg/mL in September to 
45.167 pg/mL in October, rising slightly to 49.350 pg/mL in November before dropping 
to 35.333 pg/mL in December. The result of one-way ANOVA indicated that the 
differences amongst these measurements were significant. This was supported by both 
Tukey’s and Bonferroni’s multiple comparisons tests except October vs. November.  
25(OH)D level vs. time 
The statistics of monthly measurements of 25(OH)D levels from all participants, 
including the results of one-way ANOVA, was well as Tukey’s and Bonferroni multiple 
comparisons tests, are presented in Figure 79.  
**** 
** 
**** 
**** 
*** 
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Figure 80. 25(OH)D level vs. month for all participants 
N = 12.  
The monthly average of 25(OH)D level dropped from 24.896 ng/mL in September to 
24.604 ng/mL in October, rising slightly to 24.858 ng/mL in November before dropping 
to 24.636 ng/mL in December. The result of one-way ANOVA indicated that the 
differences amongst these measurements were not significant. This was confirmed by 
both Tukey’s and Bonferroni’s multiple comparisons tests.  
White blood cell count vs. time 
The statistics of monthly measurements of white blood cell counts from all participants, 
including the results of one-way ANOVA, was well as Tukey’s and Bonferroni multiple 
comparisons tests, are presented in Figure 81.  
)D Level 
 173 
White Blood Cell Count
S
ep
.
O
ct
.
N
ov
.
D
ec
.
0
2
4
6
8
Month
W
h
it
e
 B
lo
o
d
  
C
e
ll
 C
o
u
n
t 
(1
0
9
 C
e
ll
s
/L
)
 
Figure 81. White blood cell count vs. month for all participants 
N = 12. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001; ****: p < 0.00001) 
The monthly average of white blood cell count dropped from 6.969 × 109 cells/L in 
September to 6.060 × 109 cells/L in October and further to 5.113 × 109 cells/L in 
November before rising slightly to 5.459 × 109 cells/L in December. The result of one-
way ANOVA indicated that the differences amongst these measurements were significant. 
This was confirmed by both Tukey’s and Bonferroni’s multiple comparisons tests except 
October vs. December and November vs. December.  
Red blood cell count vs. time 
The statistics of monthly measurements of red blood cell counts from all participants, 
including the results of one-way ANOVA, was well as Tukey’s and Bonferroni multiple 
comparisons tests, are presented in Figure 82.  
*** 
*** 
*** 
*** 
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Figure 82. Red blood cell count vs. month for all participants 
N = 12. 
The monthly average of red blood cell count was 4.837 × 1012 cells/L in September, rising 
slightly to 5.121 × 1012 cells/L in October and dropping back to 4.850 × 1012 cells/L in 
November and 4.901 × 1012 cells/L in December. The result of one-way ANOVA 
indicated that the differences amongst these measurements were not significant. This was 
confirmed by both Tukey’s and Bonferroni’s multiple comparisons tests.  
Platelet count vs. time 
The statistics of monthly measurements of red platelet counts from all participants, 
including the results of one-way ANOVA, was well as Tukey’s and Bonferroni multiple 
comparisons tests, are presented in Figure 82.  
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Figure 83. Platelet count vs. month for all participants 
N = 12. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001; ****: p < 0.00001) 
The monthly average of platelet count dropped from 239.917 × 109 cells/L in September 
to 192.075 × 109 cells/L in October, rising to 204.567 × 109 cells/L in November before 
dropping to 170.933 × 109 cells/L in December. The result of one-way ANOVA indicated 
that the differences amongst these measurements were significant. This was confirmed 
by both Tukey’s and Bonferroni’s multiple comparisons tests except October vs. 
November and October vs. December.  
CD34+ progenitor cell count vs. time 
The statistics of monthly measurements of CD34+ progenitor cell counts from all 
participants, including the results of one-way ANOVA, was well as Tukey’s and 
Bonferroni multiple comparisons tests, are presented in Figure 84.  
**** 
**** 
**** 
*** 
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Figure 84. CD34+ progenitor cell count vs. month for all participants 
N = 12. (*: p < 0.01; **: p < 0.001; ***: p < 0.0001; ****: p < 0.00001) 
The monthly average of CD34+ progenitor cell count dropped from 249.417 × 106 cells/L 
in September to 176.833 × 106 cells/L in October and further to 96.833 × 106 cells/L in 
November and 82.333 × 106 cells/L in December. The result of one-way ANOVA 
indicated that the differences amongst these measurements were significant. This was 
confirmed by both Tukey’s and Bonferroni’s multiple comparisons tests except 
November vs. December.  
Summary 
In the study of the correlations between various observations and time, the results of one-
way ANOVA indicated that the temporal variations of VD3 level, white cell count, 
platelet count and CD34+ progenitor cell count were all statistically significant, whereas 
the temporal variations of 25(OH)D level and red blood cell count were statistically 
insignificant. All these findings were generally confirmed by both Tukey’s and 
Bonferroni’s multiple comparisons tests.  
*** 
**** 
**** 
**** 
**** 
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4.4.2 Correlations with VD3 level 
25(OH)D level vs. VD3 level 
The relation between 25(OH)D level (ng/mL) and VD3 level (pg/mL) for all participants 
are shown in Figure 87, together with the best-fit line according to Deming linear 
regression. The equation of the best-fit line is   
y = 0.1020 x + 19.97 
Its slope (0.1020  0.04858) was positive but was not to be considered significantly non-
zero (p = 0.0412).  
The sample data of VD3 passed all three normality tests (for the D’Agostino and Pearson 
test, p = 0.4015; for the Shapiro-Wilk test, p = 0.2325; for the Kolmogorov-Smirnov test, 
p > 0.10). The sample data of 25(OH)D passed the D’Agostino and Pearson test 
(p = 0.1141) and the Kolmogorov-Smirnov test (p > 0.10) but did not pass the Shapiro-
Wilk test (p = 0.0198). Therefore, it is justified to rely on the result of Pearson correlation 
rather than that of the Spearson’s correlation, and the correlation between 25(OH)D level 
and VD3 level was significant according to Pearson correlation (r = 0.2958, p = 0.0412). 
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Figure 85. 25(OH)D level (ng/mL) vs. VD3 level (pg/mL) for all participants and the best-fit line 
according to Deming linear regression 
N = 48. 
 
White blood cell count vs. VD3 level 
The relation between the white blood cell count (109 cells/L) and VD3 level (pg/mL) for 
all participants are shown in Figure 86, together with the best-fit line according to Deming 
linear regression. The equation of the best-fit line is   
y = 0.03727 x + 4.153 
Its slope (0.03727  0.01356) was positive and was great enough to be considered 
significantly non-zero (p = 0.0085).  
The sample data of VD3 passed all three normality tests (for the D’Agostino and Pearson 
test, p = 0.4015; for the Shapiro-Wilk test, p = 0.2325; for the Kolmogorov-Smirnov test, 
p > 0.10). The sample data of white blood cell count also passed all three normality tests 
(for the D’Agostino and Pearson test, p = 0.2305; for the Shapiro-Wilk test, p = 0.0827; 
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for the Kolmogorov-Smirnov test, p > 0.10). Therefore, it is justified to rely on the result 
of Pearson correlation rather than that of the Spearson’s correlation, and the correlation 
between white blood cell count and VD3 level was significance according to Pearson 
correlation (r = 0.3756, p = 0.0085). 
 
 
Figure 86. Total white blood cell count (109 cells/L) vs. VD3 level (pg/mL) for all participants and 
the best-fit line according to Deming linear regression 
N = 48. 
Red blood cell count vs. VD3 level 
The relation between the red blood cell count (109 cells/L) and VD3 level (pg/mL) for all 
participants are shown in Figure 87, together with the best-fit line according to Deming 
linear regression. The equation of the best-fit line is   
y = 0.005886 x + 5.203 
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Its slope (0.005886  0.09266) was marginally smaller than zero and was not to be 
considered significantly non-zero (p = 0.5285).  
The sample data of VD3 passed all three normality tests (for the D’Agostino and Pearson 
test, p = 0.4015; for the Shapiro-Wilk test, p = 0.2325; for the Kolmogorov-Smirnov test, 
p > 0.10). However, the sample data of red blood cell count did not pass any of the three 
normality tests (for the D’Agostino and Pearson test, p = 0.0255; for the Shapiro-Wilk 
test, p = 0.0003; for the Kolmogorov-Smirnov test, p = 0.0002). Therefore, it is justified 
to rely on the result of Spearman’s correlation rather than that of the Pearson correlation, 
and the correlation between red blood cell count and VD3 level was not significant 
according to Spearman’s correlation (r = 0.01393, p = 0.9251). 
 
 
Figure 87. Total red blood cell count (109 cells/L) vs. VD3 level (pg/mL) for all participants and 
the best-fit line according to Deming linear regression 
N = 48. 
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Platelet count vs. VD3 level 
The relation between the platelet count (109 cells/L) and VD3 level (pg/mL) for all 
participants are shown in Figure 88, together with the best-fit line according to Deming 
linear regression. The equation of the best-fit line is   
y = 6.806 x  117.2 
Its slope (6.806  1.977) was positive and was great enough to be considered significantly 
non-zero (p = 0.0012).  
The sample data of VD3 passed all three normality tests (for the D’Agostino and Pearson 
test, p = 0.4015; for the Shapiro-Wilk test, p = 0.2325; for the Kolmogorov-Smirnov test, 
p > 0.10). The sample data of platelet count also passed all three normality tests (for the 
D’Agostino and Pearson test, p = 0.6641; for the Shapiro-Wilk test, p = 0.6393; for the 
Kolmogorov-Smirnov test, p > 0.10). Therefore, it is justified to rely on the result of 
Pearson correlation rather than that of the Spearson’s correlation, and the correlation 
between platelet count and VD3 level was significant according to Pearson correlation (r 
= 0.4527, p = 0.0012). 
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Figure 88. Total platelet count (109 cells/L) vs. VD3 level (pg/mL) for all participants and the 
best-fit line according to Deming linear regression 
N = 48. 
 
CD34+ progenitor cell count vs. VD3 level 
The relation between the CD34+ progenitor cell count (106 cells/L) and VD3 level (pg/mL) 
for all participants are shown in Figure 89, together with the best-fit line according to 
Deming linear regression. The equation of the best-fit line is   
y = 16.71 x  631.9 
Its slope (16.71  5.021) was positive and was great enough to be considered significantly 
non-zero (p = 0.0017).  
The sample data of VD3 passed all three normality tests (for the D’Agostino and Pearson 
test, p = 0.4015; for the Shapiro-Wilk test, p = 0.2325; for the Kolmogorov-Smirnov test, 
p > 0.10). However, the sample data of CD34+ progenitor cell count did not pass any of 
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the three normality tests (for the D’Agostino and Pearson test, p = 0.0216; for the 
Shapiro-Wilk test, p = 0.0007; for the Kolmogorov-Smirnov test, p = 0.0078). Therefore, 
it is justified to rely on the result of Spearman’s correlation rather than that of the Pearson 
correlation, and the correlation between CD34+ progenitor call count and VD3 level was 
significant according to Spearman’s correlation (r = 0.4440, p = 0.0016). 
 
 
Figure 89. Total CD34+ progenitor cell count (106 cells/L) vs. VD3 level (pg/mL) for all 
participants and the best-fit line according to Deming linear regression 
N = 48. 
 
Summary 
In the study of the correlations between various observations and VD3 level, the results 
of Deming linear regression indicates that there was statistically significant positive 
correlation between VD3 level and each of 25(OH)D, white blood cell count, platelet 
count and  CD34+ progenitor cell count. The only exception was that there was no 
statistically significant correlation between red blood cell count and VD3 level. These 
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results were confirmed by the results of both Pearson correlation and Spearman’s 
correlation.  
4.5 Discussion 
There are two stages in the analysis of the findings. It is necessary to ascertain that the 
temporal changes to the measurements are statistically significant before it is possible to 
check if there are positive correlations between the various cell counts, etc. and VD3 level. 
4.5.1 Correlation with time 
The first task in interpreting the findings was to establish if there were significant non-
random changes in the measurement along time. In the study of the correlations between 
various observations and time, the results of one-way ANOVA indicated that the temporal 
variations of VD3 level, white cell count, platelet count and CD34
+ progenitor cell count 
were all statistically significant, whereas the temporal variations of 25(OH)D level and 
red blood cell count were statistically insignificant. All these findings were generally 
confirmed by both Tukey’s and Bonferroni’s multiple comparisons tests. This meant that 
there were significant non-random changes in the measurements along time. On the other 
hand, the 25(OH)D level and red blood cell count remained virtually constant.  
The small sample size did not seem to cause much problem as both Tukey’s and 
Bonferroni’s multiple comparisons tests confirmed the significance found. 
Because the duration of this pilot study did not cover the four seasons of a year, it was 
not possible to conclusively ascertain the seasonal variation of these measurements, 
though it did indicate non-random variation in most of these measurements. Nevertheless, 
it was not surprising to note that recent researches had found seasonal variation of VD3 
status, particularly in colder climates with reduced sunlight exposure during autumn and 
winter (Bose et al., 2013), and it was not surprising, either, to note that recent researches 
had identified this to be responsible for the high prevalence of VD3 insufficiency amongst 
populations residing at higher latitudes (Lips, 2010).  
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4.5.2 Correlation with VD3 level 
As mentioned in Section 4.2.2, none of the participants were VD deficient at the 
beginning or during the course of the experiment according to the US national guideline 
as serum 25(OH)D levels greater than 20 ng/mL were generally considered adequate for 
healthy individuals (IOM, 2011).  
Once it was established that there were significant correlations between the measurements 
and time, which meant that there were significantly non-random changes in the 
measurements along time, the next focus was on finding if there were positive correlations 
between the various cell counts and VD3 level.  
In the study of the correlations between various observations and VD3 level, the results 
of Deming linear regression indicates that there was statistically significant positive 
correlation between VD3 level and each of 25(OH)D, white blood cell count, platelet 
count and  CD34+ progenitor cell count. The only exception was that there was no 
statistically significant correlation between red blood cell count and VD3 level. These 
results were confirmed by the results of both Pearson correlation and Spearman’s 
correlation.  
There was positive correlation between 25(OH)D and VD3 level. That meant the more 
plasma 25(OH)D there was, the more VD3 could be synthesised. Conversely, the less 
plasma 25(OH)D there was, the less VD3 could be synthesised. 
There were positive correlation between VD3 level and each of white blood cell count, 
platelet count and CD34+ progenitor cell count. That meant the more VD3 there was, the 
more each of these types of cells there would be. Conversely, the less VD3 there was, the 
less each of these types of cells there would be. 
On the other hand, there was no significant correlation between red blood cell count and 
VD3 level. In other words, red blood cell count was independent of VD3 level. 
The small sample size did not seem to cause much problem as both Pearman’s correlation 
and Spearman’s correlation confirmed the significance of correlation found. 
Most of the research into the effects of VD3 on the growth and differentiation of blood 
cells concentrated on the cells related to immunology and its potential in treating 
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autoimmune or inflammatory diseases. Recent studies had shown that VD3 could 
influence the growth and differentiation of immune cells and their functions (Wang et al., 
2014; Bikle, 2009; Adams and Hewison, 2008; Mora et al., 2008). Moreover, correlation 
had been found between the seasonal variation of VD3 level and the variation of human 
T cells (Khoo et al., 2012). Furthermore, the seasonal variation of VD3 level had also 
been found to be linked to the occurrence or the risk of developing various diseases. It 
had been found that low VD3 levels in winter contributed to the seasonal peak in the 
occurrences of influenza and upper respiratory tract infection (Sabetta et al., 2010; Cinde 
et al., 2009; Cannell et al., 2006), and the risk of developing autoimmune diseases such 
as multiple sclerosis and insulin-dependent diabetes mellitus (Ascherio et al., 2014; 
Simpson et al., 2011; Zold, Barta and Bodolay, 2011; Moltchanova, Schreier, Lammi and 
Karvonen, 2009; Correale, Ysrraelit and Gaitan, 2009; de Abreu et al., 2009; Willer et 
al., 2005).  
Thus, the pilot study was unique in being the first attempt to investigate the possible 
correlation between VD3 level and a wider range of measurements including 25(OH)D 
level, white blood cell count, red blood cell count, platelet count and CD34+ progenitor 
cell count. Its findings further our understanding on the anti-proliferative and pro-
differentiative effects of VD3 in the human body, and support the basis for conducting 
larger population-based studies to investigate the benefits of VD3 supplementation at 
higher latitudes during autumn and winter.  
4.5.3 The limitation of short experiment duration 
Ideally, the experiment should have been conducted over a longer period such as one 
whole year to investigate the seasonal variations. For instance, the general downward 
trends of the measurements might have been shown clearer if data had been collected 
over a longer period. There were also concerns that the data collected in autumn and 
winter would be too poor for the study due to limited exposure to sunlight during this 
period. However, this did not seem to be too problematic as significant temporal 
variations in most of the measurements had been detected.  
One instance where the short period of investigation might have caused problem was the 
insignificant results related to red blood cell count. VD3 lasts only for hours after being 
converted from the inactive form by the body (Bowen, 2011), but red blood cells last 100 
to 120 days (Thomé and Petz, 2002: 90), whereas the duration of the experiment from the 
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first measurements in September to the last ones in December was less than 120 days. 
This meant that all the red blood cell counts had included the effects of VD3 before the 
experiment started, and the full result of the VD3 level during the experiment on red blood 
cell count could not be detected before the experiment was over. Thus, the recorded red 
blood cell counts could not truly be paired with the recorded VD3 levels and thus could 
not have truly reflected the outcome of the effect of the recorded VD3 levels. Therefore, 
the effect of changing VD3 level on red blood cell count might have been delayed for 
three or four months and thus not fully recorded in the four-month experiment, so 
correlation could not be detected.  
Alternatively, due to the relative long-lasting of red blood cells, it might be intrinsically 
difficult to detect any effect of VD3 on red blood cell count unless it was kept under the 
same condition for a long time, and this might be the reason behind the relatively constant 
measurement of red blood cell count and its lack of correlation with VD3 level.  
Similarly, the seemly constant 25(OH)D level might have been due to the fact that it lasts 
for weeks in the body (Bowen, 2011). Hence, unless the body was deprived of any dietary 
VD or exposure to sunlight for a prolonged period, the detrimental effect on plasma 
25(OH)D level might not have shown.  
The short duration of experiment might have also reduced the correlation between the 
measurements of white blood cell count and VD3 level. White blood cells generally last 
for 5.4 days (Pillay et al., 2010). Most types of white blood cells and platelet lasts no 
more than a few weeks. Amongst the different types of white blood cells, for neutrophil, 
it is 6 hours to a few days; for eosinophil, it is 8–12 days, but it circulates for 4–5 hours; 
for basophil, it is a few hours to a few days; lymphocyte lasts for weeks, except memory 
cells which last for years; whilst monocyte lasts for hours to days (Daniels et al., 1979). 
Because some white blood cell could last for weeks, each month’s measurement was not 
independent of the ones in the adjacent months, e.g., the effect of VD3 on white blood 
cell count in September could affect the white blood cell count in October as some of the 
white blood cells generated in September were still present in October.  
In comparison, Platelet (thrombocyte) lasts for 8 to 9 days (Harker et al., 2000). Thus, 
assuming that there was no great fluctuation in VD3 level, even though there might be a 
delay of a few days or weeks between the change in VD3 level and the corresponding 
change in white blood cell count, platelet count and CD34+ progenitor cell count, these 
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data were still likely detectable in the data recorded in the same month, and the 
correlations were still detectable.  
4.5.4 The limitation of small sample size 
Ideally, more data should have been collected by recruiting more participants, but there 
are difficulties in recruitment to clinical research in general, and ways to improve such 
recruitment remain elusive (Newington and Metcalfe, 2014). There was concern that the 
sample size was too small for any meaningful analysis. Nevertheless, this concern was at 
least partially relieved by the results of both Tukey’s and Bonferroni’s multiple 
comparisons tests in the investigation of correlation with time, and by the results of both 
Pearson correlation and Spearman’s correlation in the investigation of the correlation with 
VD3 level. Amongst these tests, Bonferroni’s multiple comparisons test and Spearman’s 
correlation were designed to work with small sample sizes.  
4.5.5 Difference between in vitro and in vivo studies 
In the in vitro experiment, the level of VD3 in each sample was given, and was fixed 
initially. This was an independent variable in the experiment. Whatever other data 
recorded after the experiment were the dependent variables. In other words, the level of 
VD3 set at the beginning of the experiment was the cause of whatever other data observed 
and collected. Furthermore, these data were the results of some reactions related to VD3 
and, even though it was not recorded at the end of the experiment, at least some of the 
VD3 in the sample would have been used by these reactions and the level of VD3 in each 
sample would have been reduced at the end of the experiment.  
In contrast, in the in vivo experiment, the amount of VD3 in each of the blood sample was 
not given or fixed. It was up to the body to convert some of the available 25(OH)D into 
VD3.  
Finally, it was worth noting that there were other factors in the body that could influence 
the cell counts and VD level measurements. For instance, blood cell counts could have 
been affected by vitamin B6, B12 or foliate (vitamin B9) deficiency, as well as internal 
bleeding, kidney disease or malnutrition (Weiss, 2013); whilst VD3 could be consumed 
by calcium metabolism (Easttel et al., 1991; Lappe et al., 2007; Pittas et al., 2007). The 
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consequences of these factors could potentially obscure in vivo the effects of VD3 in 
experiments such as this.  
4.6 Conclusion 
This is the first attempt at conducting studies of this kind. Despite its limitations, the 
findings of this study do confirm those of the aforementioned in vitro studies that VD3 
suppresses the proliferation of haematopoietic progenitor cells and encourages the latter 
to differentiate into various blood cells. Additionally, in this in vivo study, it was found 
that there were statistically significant correlations between VD3 level and CD34
+ 
progenitor cell count, white blood cell count and platelet count, whereas it was not 
successful in finding significant correlation with red blood cell count.  
There was correlation between the amount of serum 25(OH)D and serum VD3, but only 
a small amount of the former is converted to the latter. The exact mechanism that dictates 
the occurrence of this conversion has not been revealed by this study. Nevertheless, it did 
suggest the existence of some mechanism to keep the level of storage of the inactive form 
of VD3 when it was not deemed necessary to be used.   
In view of these findings, it is worth extending this study to investigate the effects of VD3 
on these cell counts with more extensive investigations involving more participants and 
for a longer duration. Taking into considerations of the half-lives of VD3 and various 
blood cells under study, as well as the seasonal variation of sunlight, it would be more 
appropriate to collect weekly samples in a period of at least one year / 52 weeks in order 
to obtain more conclusive findings and gain better insight into this subject.  
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Chapter 5 Conclusion 
 
5.1 Summary of Findings  
In the first part of the research, it is found that:  
 The presence of VD3 in vitro suppresses the proliferation of murine E14 ESCs in 
isolation.  
 The presence of VD3 in vitro promotes the differentiation of murine E14 ESCs in 
isolation.  
 The presence of VD3 in vitro suppresses the proliferation of murine OP9 stromal 
cells in isolation.  
 The presence of VD3 in vitro promotes the differentiation of murine OP9 stromal 
cells in isolation.  
 The effects are most significant in the samples with 100 nM of VD3  in vitro 
In the second part of the research, it is found that:  
 The presence of VD3 in vitro suppresses the proliferation of murine E14 ESCs in 
haematopoiesis in the proximity of murine OP9 stromal cells.  
 The presence of VD3 in vitro promotes the differentiation of murine E14 ESCs in 
haematopoiesis in the proximity of murine OP9 stromal cells.  
In the third part of the research, it is found that:  
 The presence of VD3 in vivo could encourage haematopoiesis by suppressing the 
proliferation and promoting the differentiation of adult human HSCs, though there 
are complex mechanisms and other influential factors in the human body that would 
also compete with this process for the VD3 available in the body.  
5.2 Validation of Hypotheses 
The mouse study in the first part of the research ascertained in vitro that VD3 was crucial 
in suppressing proliferation and promoting differentiation. This was done by investigating 
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separately the effects of VD3 on the proliferation phase of the E14 cell line and on stromal 
OP9 cells. In both studies, VD3-treated cells were compared to untreated ones. The results 
showed that VD3 inhibited the proliferation of the cells in a dose-dependent manner, 
quantitatively by decreased VD3-treated cell number, and qualitatively by alkaline-
phosphatase staining that revealed colourless VD3-treated cells indicating decreased 
enzyme expression. Propidium-iodide cell-cycle analyses showed that by directly 
comparing VD3-treated E14 cells with untreated E14, and, likewise, VD3-treated OP9 
cells with untreated OP9 cells, there were significant increase in percentage of cells in the 
G-phase and significant decrease in percentage of cells in the S-phase in a dose-dependent 
manner. This meant that there was significant G/S cell cycle arrest that resulted in 
suppressed proliferation and promoted differentiation.  
Thus, the results from separate E14 and OP9 cell cultures indicated that adequate VD3 
level inhibited proliferation and enhanced differentiation. In other words, the first 
hypothesis of the research had been validated.  
The study then went on to ascertain in vitro whether VD3 accelerates and promotes 
haematopoiesis in mouse ESC co-cultured on OP9 stromal cells (E14 / OP9 co-culture). 
The E14 / OP9 co-cultures were tested for colony-forming-cell (CFC) numbers, as well 
as concurrent CD markers, gene expressions, and cytokine expressions on days 2, 5, 8, 
10 and 12, respectively, and some general trends were observed. In co-cultures treated 
with an optimal 100nM VD3 level, earlier (accelerated) and higher (promoted) peak 
values had shown with E-CFC and GEMM-CFC numbers, FLK, CD31 and CD34 
markers, and FLK, SCL, GATA1 and GATA2 gene expressions. These values then 
markedly decreased. On the other hand, later and higher peaks had shown with GM-CFC 
and M-CFC numbers, CD41, CD43 and CD45 markers, and GATA1 gene expressions. 
These peaks had shifted towards day 12 compared with measurements of the untreated 
co-cultures.  
Hence, the results from E14 / OP9 co-cultures showed that treatment with optimal VD3 
accelerates and promotes differentiation of ESCs towards haematopoiesis, i.e., into 
haematopoietic stem cells and then into blood cells. This was shown in observation that  
ESC–derived CD34+ progenitor cells become more enriched in colony-forming cells 
expressing the haematopoiesis-associated genes GATA1, GATA2, SCL and FLK, as well 
as expressions of related cytokines, so that the phenotypes of primitive haematopoietic 
progenitors and definitive hematopoietic stem cells were displayed. These suggested that 
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greater quantities of various differentiated cells had appeared earlier, which meant cell 
differentiation had been accelerated and promoted. Likewise, p21 and p27 expressions 
had been up-regulated by the presence of VD3, resulting in G/S cell cycle arrest whereby 
proliferation was suppressed and differentiation was accelerated and promoted.  
In other words, it was found that VD3 played a key role in suppressing proliferation and 
promoting differentiation of cells in haematopoiesis and, in the co-culture of E14 
embryonic stem cells and OP9 stromal cells, VD3 enhances the differentiation of E14 
cells into blood cells of erythroid, myeloid, and B cell lineages without adding exogenous 
growth factors or complex embryoid structures. Hence, the second hypotheses of the 
research had also been validated.  
In the pilot study that was the third part of the research, it was shown that, first, the 
numbers of white blood cells, platelets and CD34+ progenitor cells, as well as plasma 
VD3 levels, had significant non-random variation along time during the observation 
period. Secondly, it showed that there was statistically significant positive correlation 
between plasma VD3 level and plasma 25(OH)D level, white blood cell count, platelet 
count and CD34+ cell count.  
Thus, these findings largely support the hypothesis, despite its limitation on small sample 
size due to the small number of participants stayed with the study and the short 
observation duration. Hence, it indicated that it would be worth to further conduct more 
extensive research to investigate.  
Hence, all three hypotheses of the research had been validated, and all three objectives 
had been met. Therefore, the overall objective was also met and the aim of the research 
achieved.  
5.3 Novelty 
Previously, the effects of VD3 on suppressing proliferation and promoting differentiation 
had been studied using mainly cancer cells. On the other hand, instead of using cancer 
cells, this research was conducted to study first the similar effects of VD3 on ESCs and 
stromal cells, using the E14 and OP9 cell lines in the in vitro studies, and then its effects 
on the haematopoiesis process using the E14 / OP9 co-culture in the in vitro studies and 
live participants in the in vivo study.  
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In this respect, the first two parts of the research was collectively the first study to 
investigate in vitro the anti-proliferation and pro-differentiation effects of VD3, especially 
in haematopoiesis, using E14 and OP9 cells and the E14 / OP9 co-culture. Through its 
findings, this was the first demonstration of the anabolic effect of VD3 on murine E14 
and OP9 cells in vitro. 
The third part of the research was also the first attempt at in vivo human studies of the 
effects of VD3 in enhancing cell differentiation in haematopoiesis that provided useful 
information to inform further studies. 
5.4 Contributions 
The findings of the in vitro researches on E14 / OP9 co-culture indicate that VD3 
treatment inhibits cellular proliferation and enhances cellular differentiation through cell 
cycle regulation by up-regulating p21 and p27 gene expressions. These suggest potential 
clinical applications of VD3 treatment through cell cycle regulation.  
The capacity of ESCs to undergo unlimited self-renewal and differentiation into many 
different cell types in the body has unveiled widespread application potentials in the fields 
of biomedical research and regenerative medicine. Furthermore, ESCs have been used for 
therapeutic intervention in the treatment of a wide number of disease conditions. In 
particular, the most important potential application of ESCs is the generation of cells that 
could be used for cell-based therapies, such as transplanting HSCs in leukaemia treatment 
entailing the use of high-quality sources of tissue-matched bone marrow, mobilised 
peripheral blood or umbilical cord blood. Appropriate bone marrow is often in short 
supply and cord blood, though bankable, contains fewer HSCs, which makes it less 
suitable for adult transplantation. Directed differentiation of ESCs towards HSCs offers 
a potentially attractive alternative to these conventional sources.  
Since this research showed that VD3 could be used to promote cell differentiation in 
haematopoiesis, it could be used to improve the success rate of these cell-based therapies, 
by either increase in vitro the quantity of the blood cells needed for later transplantation, 
or enhancing the differentiation of ESCs towards HSCs and haematopoiesis in vivo.  
Overall, this thesis furthers the advancement in knowledge of the function of VD3 in 
suppressing cell proliferation and enhancing differentiation, specifically in stem cells and 
 194 
related to haematopoiesis. The effect of VD3 in accelerating and promoting differentiation 
of stem cells into blood cells has been established, revealing the importance of VD3 in 
human health. This study paves the way for future research into the development of 
therapeutic strategies for the treatment of leukaemia, in particular. More widely, it 
indicates that VD3 plays a crucial role in disease prevention related to cancers and other 
chronic illnesses. To maintain a healthy state, it is necessary to acquire adequate amount 
of vitamin D by synthesis through sufficient exposure to sunlight, normal dietary intake, 
and/or supplementation to achieve an optimal vitamin D level.  
5.5 Study Limitations 
As mentioned in the discussions of the in vivo study, it was not possible to undertake 
further statistical analyses that were meaningful and more detailed owing to the scarcity 
of the data, which partly was the result of limited resources and funding. Despite this, as 
well as the complex nature of the living body, the study did yield some encouraging 
findings and new contribution to the body of knowledge in this field that could provide 
directions for further investigation.  
Furthermore, one third of the participants of the study were men and the rest women, 
despite the initial design of having equal number of participants of either gender. Again, 
due to the limited number of participants and the varied personal health conditions and 
histories amongst them, it was not possible to investigate any possible gender variations 
in the in vivo study.  
One of the reasons of having only limited number of participants was due to the difficulty 
in recruitments. It might be beneficial to explore in different settings new and diverse 
strategies to ensure that all potentially eligible patients are invited to participate. It might 
also be help to establish integrated clinical and academic teams with shared 
responsibilities for recruitment. Recruitment might have also been hindered by language 
barriers and long journey times. 
Finally, this study does serve as a reminder the extent of complexity such an in vivo study 
would entail and should be taken into consideration in the design of the experiments.  
Since the focus of this study was on the changes in proliferation and differentiation, the 
study of apoptosis was not included. The reduction of undifferentiated cells was assumed 
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to be due to differentiation. Some of these were supported by the appearance of 
differentiated cells, but it might be possible that some of the reductions were the result of 
cell death. Steps had been taken to retain and identify dead cells in some of the procedures, 
including the retention and inclusion of aspirated media and identification by trypan blue 
staining. However, this could still be enhanced in further researches by including 
apoptosis assays to address this issue.  
5.6 Possible Further Research Directions 
On the basis of the finding of this research, it would be useful to conduct in vivo mouse 
experiments in a condition where the level of VD3 and other measurements are more 
constantly controlled and monitored. This might reveal a more detailed mechanism and 
the temporal and casual relations between different parameters could be established.  
This could be followed by in vitro study on human cells, though it would be subject to 
more stringent ethical check.  
Afterwards, the study could be furthered by conducting in vivo human tests, such as more 
extensive researches based on the pilot study presented here, running through a longer 
duration covering a whole year and recruiting more participants. 
Alternatively, longer term clinical trials of VD3 treatments on VD3 deficient patients 
could also be conducted, as it is possible that more directed casual relations between 
certain parameters could be more clearly revealed in the studies of abnormal or extreme 
circumstances.  
5.7 Conclusion 
In summary, the findings of this research point out that VD3 can indeed suppress the 
proliferation and promote the differentiation of haematopoietic stem and progenitor cells. 
This suggests potential benefit from the using VD in the prevention and treatment of 
haematological disorders and diseases, as well as in immune modulation, although the 
importance of this in various disease states remains poorly understood. Continued 
scientific investigations and well-controlled trials will likely be necessary to advance the 
understanding of the mechanisms underneath these physiological effects of VD and 
confirm any clinical benefit of VD therapy.  
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A.1 Overview of Research 
Table 10. Overview of the design of the studies included in this research, together with the 
experiments conducted, the results obtained and the key findings from these 
experiments 
 
in vitro 
/ in 
vivo 
Part Subject Tests 
Results 
Key Findings 
E14 alone OP9 alone 
in vitro 
1 
Mouse 
E14 alone 
OP9 alone 
Cell proliferation assay by 
cell counting 
The number of E14 cells decreases 
significantly with more than 10 nM of 
VD3 compared with the control (due 
to promoted differentiation).  
The number of OP9 cells decreases 
significantly with more than 10 nM of 
VD3 compared with the control (due 
to promoted differentiation).  
The presence of VD3 
promotes the differentiation 
and suppresses the 
proliferation of E14 without 
the presence of OP9. 
 
The presence of VD3 
promotes the differentiation 
and suppresses the 
proliferation of OP9 without 
the presence of E14. 
 
The effect is most significant 
in the samples with 100 nM 
of VD3   
Alkaline phosphatase 
staining for the 
determination of 
differentiation 
Fewer cells are stained with VD3 
(due to differentiation). 
Fewer cells are stained and more are 
rounded with VD3 (due to 
differentiation). 
Cell cycle examination by 
flow cytometric analysis 
The percentage of cells in the G 
phase is significantly higher with VD3 
compared to the control (due to 
differentiation).  
The percentage of cells in the S 
phase is significantly lower with VD3 
compared to the control (due to 
differentiation). 
The percentage of cells in the G 
phase is significantly higher with VD3 
compared to the control (due to 
differentiation).  
The percentage of cells in the S 
phase is significantly lower with VD3 
compared to the control (due to 
differentiation). 
2 
Mouse 
E14/OP9 
co-culture 
Immunofluorescence 
The expressions of the growth factors Oct4, Sox2 and Nanog are reduced 
after incubation due to differentiation, and this reduction is enhanced by the 
presence of VD3. These growth factors regulate the pluripotency of the 
embryonic stem cells.  
The presence of VD3 
promotes haematopoiesis by 
suppressing proliferation and 
promoting differentiation in 
the E14/OP9 co-culture. 
 
CD-marker expressions on 
E14 cells in the presence of 
OP9 cells and VD3 
The expressions of the CD-markers are generally earlier and with higher 
peaks with the presence of VD3 compared with the controls (due to promoted 
differentiation). 
Identification and counting 
of colony-forming cells 
The numbers of most colony-forming cells are increased with VD3. This 
indicates that VD3 promotes differentiation.   
Real-time quantitative PCR 
for gene expressions 
Overall, the gene expressions indicate the presence of VD3 affects the 
composition of the culture. This indicates that various differentiated 
haematopoietic cells appear earlier and are increased in number in treatment 
than in control. This shows that the presence of VD3 promotes differentiation.   
Cytokine multiplex assay 
The expressions of selected cytokines are significantly higher in the treatment 
with VD3 than in the control. This indicates the higher numbers of the 
differentiated blood cells in treatment. This means VD3 promotes the 
differentiation of stem cells.   
in vivo 3 Human 
Tests for Vitamin D3 
measurement 
The non-bioactive VD concentration is affected by the degree of exposure to 
sunlight.   
VD3 promotes differentiation 
and suppresses proliferation 
in human haematopoiesis. 
Phenotype analysis by flow 
cytometry 
Deming regression is used to take into account the observational variations in 
both the VD3 level and the cell counts.  
There is significant correlation between the VD3 level and the numbers of 
white blood cells, platelets and CD34+ (stem) cells.  
Blood cells counting 
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A.2 MMU Ethics Procedure 
 
 
 
 
 
 
(http://www2.mmu.ac.uk/research/ethics/ethics-forms-and-guidance/) 
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A.3 Ethical Approval of the in vivo Study 
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A.4 Advertisement for Participant Recruitment 
 
Participants wanted 
The effect of 1,25-dihydroxyvitamin D3 (VD3) on the total 
blood-cell count and on the counts of circulating stem cells. 
Healthy volunteers, (young 35-45 years) are needed to participate in a study which will 
investigate the effect of VD3 levels on total blood count and circulating haematopoietic 
progenitor cells. We need in this study to get 15 mL of whole blood from each participant once 
every month for four months. The process will take up to 10 minutes each time then you will 
be free to leave the room.  The purpose of taking blood samples is to measure VD3 level, total 
blood count and circulating haematopoietic progenitor cells. VD3 is able to mobilise stem cells 
from bone marrow into blood circulation which may differentiate into blood cells (blood cells 
renewal) and increase repair of vascular lesions of heart muscle.   
The blood will be taken by a Dr AL-SHANTI at a phlebotomy room on the first floor of John 
Dalton Tower.   
For more information, please contact: Mayada Al Qaisi:  09989750@stu.mmu.ac.uk 
All information will be confidential and securely stored in password-protected folder. The 
name of participants will be coded in compliance with the Data Protection Act 1998.  
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A.5 Information about the in vivo Study  
Manchester Metropolitan University 
School of Healthcare Science 
Volunteer Information 
 
 
Project title: The effect of 1,25-dihydroxyvitamin D3 (VD3) on the total blood-
cell count and on the counts of circulating haematopoietic progenitor cells  
 
This information pack is compiled to provide you with details of this study to help you make an informed 
decision on whether or not to participate. You are encouraged to understand this information and make a 
considered decision on your own, away from the researchers, but you can ask the researchers for further 
clarification and explanation if you have any question.  
 
If you decide to participate, you will need to sign the consent form given to you by the researchers. Please 
read this information pack and the consent form carefully before signing. You will also need to complete 
a medical questionnaire in which all recorded details are completely anonymous (free from any potential 
identification). This will be achieved by allocating each participant with a non-identifiable participant 
number (PN).  
 
Once you are selected to participate in this study, you are free to withdraw at any time without giving any 
reason.  
 
Background 
 
The capacity of embryonic stem cells (ESCs) to undergo unlimited self-renewal and differentiation into 
many different cell types in the body has unveiled widespread application potentials in the fields of 
biomedical research and regenerative medicine. Embryonic stem cells (ESCs) are being used for 
therapeutic intervention in the treatment of a wide number of disease conditions. In particular, the most 
important potential application of ESCs is the generation of cells that could be used for cell-based therapies, 
such as transplanting haematopoietic stem cells (HSCs) in leukaemia treatment, entailing the use of high-
quality sources of tissue-matched bone marrow, mobilised peripheral blood or umbilical cord blood. 
Appropriate bone marrow is often in short supply and cord blood, although bankable, contains fewer HSCs, 
which makes it less suitable for adult transplantation. Directed differentiation of ESCs towards HSCs offers 
a potentially attractive alternative to these conventional sources. Vitamin D3 was demonstrated to be a 
powerful differentiation inducer for a wide variety of neoplastic cells. Thus, 1α, 25-Dihydroxyvitamin D3 
could enhance differentiation of embryonic stem cells into blood cells of erythroid, myeloid, and B cell 
lineages. Exposure to VD3 is thought to increase the blood-cell counts of differentiated cells. The 
implications of using VD3 in cancer prevention and treatment are exciting.   
 
Study protocol 
 
Sixteen healthy participants will be recruited to take part in this study. The same procedure mentioned 
below will be repeated with each participant once every month between September and December. 
 
Sample collection and management 
 
If you are selected as one of the participants, you will be asked to give blood samples once every month 
for four months. The blood samples will be taken by a phlebotomist. A needle will be inserted in an 
antecubital vein to obtain 3 tubes of 5 mL baseline blood samples. After the blood samples are taken, the 
needle will be removed and gauze applied at the site of venepuncture. This method of blood sampling is 
routinely used in clinical and research settings. You will then be free to leave the laboratory. This procedure 
will take no more than 15 minutes.  
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As mentioned above, all raw data will be stored anonymously and referred to by participant numbers rather 
than by names. Data storage will comply with the Data Protection Act (1998). If you decide to withdraw 
from the study at any time after the experimental procedure commences, all your samples and data stored 
in any form will be destroyed. 
 
Vitamin D3 measurement test  
 
To prepare the serum for VD3 measurement, one of the collected blood samples will be allowed to clot by 
leaving it undisturbed at room temperature. This usually takes 15-30 minutes.  The clot will be removed 
by centrifuging at 1,000-2,000  g for 10 minutes in a refrigerated centrifuge. Following centrifugation, 
the liquid component (serum) will be transferred into a clean polypropylene tube using a Pasteur pipette. 
The samples will be maintained at 2-8°C while handling. Then, the samples will be sent to the NHS for 
examination of the level of VD3. 
 
Circulating CD34+ haematopoietic progenitor cells measurements   
 
The BD stem cell enumeration kit will be used to determine the amount of circulating CD34+ 
haematopoietic progenitor cells. This kit will enable us to enumerate CD34+ haematopoietic progenitor 
cells accurately and reproducibly. CD34 and CD45 marker expressions will be measured by means of a 
flow-cytometer machine. To 100 μL of whole blood, 20 μL of CD45 FITC/CD34 PE reagent and 20 μL of 
7-AAD reagent will be added to a Trucount tube. The tubes of the samples will be vortexed and then kept 
in the dark at room temperature for 20 minutes. 2 mL of 1× ammonium chloride lysing solution will be 
added. After that, the tubes of the samples will be vortexed and kept in the dark at room temperature for 
10 minutes. The samples will be ready for analysis within 1 hour after lysis. 
 
Count Blood Cells 
 
2mL fresh blood in an EDTA tube will be placed in an XS-1000i/XS-800i (Sysmex) blood-counting 
machine in order to ascertain the total blood-cell count and the counts of the various differentiated cells.  
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A.6 Participant Consent Form  
 
Participant Consent Form 
 
 
 
Project  Title: ‘The effect of 1,25-dihydroxyvitamin D3 (VD3) on the total blood-cell 
count and on the counts of circulating haematopoietic progenitor 
cells’  
Principal Investigator: Mayada Alqaisi 
 
 
NAME OF PARTICIPANT:_____________________________________ 
 
1. I agree to take part in the above research.  I have read the Participant Information Sheet.  I 
understand what my role will be in this research, and all my questions have been answered to 
my satisfaction. 
 
2. I understand that I am free to withdraw from the research at any time, for any reason and 
without prejudice. 
 
3. I have been informed that the confidentiality of the information I provide will be safeguarded. 
 
4. I am free to ask any questions at any time before and during the study. 
 
5. I agree to the Manchester Metropolitan University processing personal data which I have 
supplied. I agree to the processing of my supplied data for any purposes connected with the 
research project as outlined to me 
 
6. I agree that the tissue donation(s) I have given can be stored after completion of this research 
study/project and can be used in any future, as yet undetermined, study /project. 
(I have the right to ask for these donated tissue(s) to be destroyed or returned to me at any 
time). 
 
7. I agree that the tissue donation(s) I have given can be stored after completion of this research 
study/ project and can be used on any future research project/study that is related to the 
study/project in which I have taken part. 
 
8. (I have the right to ask for these donated tissue(s) to be destroyed or returned to me at any 
time). 
 
Name of participant (print) __________________________________________________________ 
 
Signed_______________________________________________  Date______________________ 
 
 
- - - - - - - - - - - - - - - - - - - -- - - - - - - - - -- - - - - - - - - -- - - - - - - - - -- - - - - - - - - -- - - - - - - - - -- - - - - -  
 
 
If you wish to withdraw from the research, please complete the form below and return to the 
principal investigator named above. 
 
 
Project  Title: 
 
 
I WISH TO WITHDRAW FROM THIS STUDY 
 
Signed_______________________________________________  Date______________________ 
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A.7 Medical Screening Questionnaire 
‘The effect of 1,25-dihydroxyvitamin D3 (VD3) on the total blood-cell 
count and on the counts of circulating haematopoietic progenitor cells’  
 
Participant number: 
 
 
 
Medical Screening Questionnaire 
 
It is important that the investigators are aware of any health conditions before participation in this 
research study. This is to ensure that the study protocol will not exacerbate any existing conditions of 
the participant. Please answer the following questions as accurately as possible. 
 
Are you currently taking any prescribed medication? YES/NO 
 
Are you currently attending your GP? YES/NO 
 
Have you ever suffered from a cardiovascular problem?  
for example: high blood pressure, anaemia, heart attack etc.  YES/NO 
 
Have you ever suffered from a neurological disorder?  
for example: epilepsy, convulsions etc.  YES/NO 
 
Have you ever suffered from an endocrine disorder?  
for example: diabetes etc.  YES/NO 
 
Have you ever suffered from a chronic gastrointestinal disorder?  
for example: Crohn’s disease, irritable bowel syndrome etc.  YES/NO 
 
Have you ever suffered from a skin disorder?  
for example: eczema etc.   YES/NO 
 
Do you suffer from any allergies?  
for example: medications, foods etc.  YES/NO 
 
Are you aware of any other medical condition that may prevent you from participating in 
this investigation?  
for example: immunological disorders, numbness in extremities, asthma etc.  YES/NO 
 
Are you currently taking any supplements  
for example: creatine  YES/NO 
 
If you have answered “yes” to any of these questions, please provide details below: 
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